BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072-2077. [PMID: 12086760 DOI: 10.1016/s0140-6736(02)08905-5] [Cited by in Crossref: 1789] [Cited by in F6Publishing: 1337] [Article Influence: 89.5] [Reference Citation Analysis]
Number Citing Articles
1 Li H, Chang G, Jiang Y, Xu L, Shen L, Gu Z, Lin H, Shi F. System Dynamic Model Simulates the Growth Trend of Diabetes Mellitus in Chinese Population: Implications for Future Urban Public Health Governance. Int J Public Health 2022;67. [DOI: 10.3389/ijph.2022.1605064] [Reference Citation Analysis]
2 Taylor J. Implications of Elevated Postprandial Glucose and Nutritional Approaches for Postprandial Glucose Management with a Focus on Whey Proteins. EMJ Diabet 2022. [DOI: 10.33590//emjdiabet/10047523] [Reference Citation Analysis]
3 Morelli R, Conidi C, Tundis R, Loizzo MR, D’avella M, Timpone R, Cassano A. Production of High-Quality Red Fruit Juices by Athermal Membrane Processes. Molecules 2022;27:7435. [DOI: 10.3390/molecules27217435] [Reference Citation Analysis]
4 Fan M, Bao Z, Li T, Zhao J, Li Y, Qian H, Zhang H, Rao Z, Wang L. New insights into the interactions between dark blue pigment from Vaccinium bracteatum Thunb leaves and digestive enzymes. Food Bioscience 2022. [DOI: 10.1016/j.fbio.2022.102184] [Reference Citation Analysis]
5 Hameed S, Babatunde O, Salar U, Jabbar A, Chigurupati S, Solangi M, Atta L, Ul-Haq Z, Saleem F, Bhatia S, Al-Harrasi A, Taha M, Khan KM. Efficient one-pot synthesis of arylated pyrazole-fused pyran analogs: as leads to treating diabetes and Alzheimer's disease. Future Med Chem 2022. [PMID: 36268762 DOI: 10.4155/fmc-2022-0103] [Reference Citation Analysis]
6 Hussain R, Iqbal S, Shah M, Rehman W, Khan S, Rasheed L, Rahim F, Dera AA, Kehili S, Elkaeed EB, Awwad NS, Bajaber MA, Alahmdi MI, Alrbyawi H, Alsaab HO. Synthesis of Novel Benzimidazole-Based Thiazole Derivatives as Multipotent Inhibitors of α-Amylase and α-Glucosidase: In Vitro Evaluation along with Molecular Docking Study. Molecules 2022;27:6457. [PMID: 36234994 DOI: 10.3390/molecules27196457] [Reference Citation Analysis]
7 Zhang X, Zhang L, Zhang B, Liu K, Sun J, Li Q, Zhao L. Herbal tea, a novel adjuvant therapy for treating type 2 diabetes mellitus: A review. Front Pharmacol 2022;13:982387. [DOI: 10.3389/fphar.2022.982387] [Reference Citation Analysis]
8 Yin S, Niu L, Shibata M, Liu Y, Hagiwara T. Optimization of fucoxanthin extraction obtained from natural by-products from Undaria pinnatifida stem using supercritical CO2 extraction method. Front Nutr 2022;9. [DOI: 10.3389/fnut.2022.981176] [Reference Citation Analysis]
9 Ren X, Sun Y, Guo Q, Liu H, Jiang H, He X, Li X, Shi X, Xiu Z, Dong Y. Ameliorating Effect of the Total Flavonoids of Morus nigra L. on Prediabetic Mice Based on Regulation of Inflammation and Insulin Sensitization. J Agric Food Chem 2022. [PMID: 36150176 DOI: 10.1021/acs.jafc.2c04970] [Reference Citation Analysis]
10 Jiang W. Inactivation of the antidiabetic drug acarbose by human intestinal microbial-mediated degradation.. [DOI: 10.21203/rs.3.rs-2086719/v1] [Reference Citation Analysis]
11 Nwosu BU. The Progression of Prediabetes to Type 2 Diabetes in Children and Adolescents in the United States: Current Challenges and Solutions. Endocrines 2022;3:545-551. [DOI: 10.3390/endocrines3030045] [Reference Citation Analysis]
12 Chen V, Zurbau A, Ahmed A, Khan TA, Au-yeung F, Chiavaroli L, Blanco Mejia S, Leiter LA, Jenkins DJA, Kendall CWC, Sievenpiper JL. Effect of oats and oat ß-glucan on glycemic control in diabetes: a systematic review and meta-analysis of randomized controlled trials. BMJ Open Diab Res Care 2022;10:e002784. [DOI: 10.1136/bmjdrc-2022-002784] [Reference Citation Analysis]
13 Padmaja P, Reddy PN, Reddy BS, Tiwari AK, Ugale VG, Komati A, Sridhar B. Design, synthesis, in vitro α-glucosidase inhibitory, antioxidant activity and molecular docking studies of novel pyridine linked imidazo[1,2-a]pyridine derivatives. Journal of Molecular Structure 2022. [DOI: 10.1016/j.molstruc.2022.134238] [Reference Citation Analysis]
14 Samigullin A, Humpert PM, Östman E. Continuous glucose monitoring as a close to real life alternative to meal studies – a pilot study with a functional drink containing amino acids and chromium. Front Med Technol 2022;4. [DOI: 10.3389/fmedt.2022.931837] [Reference Citation Analysis]
15 Seghieri G, Franconi F, Campesi I. Why We Need Sex-Gender Medicine: The Striking Example of Type 2 Diabetes. Diabetology 2022;3:460-469. [DOI: 10.3390/diabetology3030034] [Reference Citation Analysis]
16 Feng J, Kong F. Enzyme inhibitory activities of phenolic compounds in pecan and the effect on starch digestion. Int J Biol Macromol 2022;220:117-23. [PMID: 35963356 DOI: 10.1016/j.ijbiomac.2022.08.045] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Kok K, Kuo CL, Katzy RE, Lelieveld LT, Wu L, Roig-Zamboni V, van der Marel GA, Codée JDC, Sulzenbacher G, Davies GJ, Overkleeft HS, Aerts JMFG, Artola M. 1,6-epi-Cyclophellitol Cyclosulfamidate Is a Bona Fide Lysosomal α-Glucosidase Stabilizer for the Treatment of Pompe Disease. J Am Chem Soc 2022. [PMID: 35917590 DOI: 10.1021/jacs.2c05666] [Reference Citation Analysis]
18 Blonde L, Umpierrez GE, Reddy SS, Mcgill JB, Berga SL, Bush M, Chandrasekaran S, Defronzo RA, Einhorn D, Galindo RJ, Gardner TW, Garg R, Garvey WT, Hirsch IB, Hurley DL, Izuora K, Kosiborod M, Olson D, Patel SB, Pop-busui R, Sadhu AR, Samson SL, Stec C, Tamborlane WV, Tuttle KR, Twining C, Vella A, Vellanki P, Weber SL. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update. Endocrine Practice 2022. [DOI: 10.1016/j.eprac.2022.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Koh YQ, Sin YAD, Rong HJ, Chua THS, Ho SS, Ho HK. Evaluation of anthoxanthins and their actions on digestive enzyme inhibition when used independently and in combination. Heliyon 2022;8:e10131. [PMID: 35991985 DOI: 10.1016/j.heliyon.2022.e10131] [Reference Citation Analysis]
20 Yuldasheva N, Acikyildiz N, Akyuz M, Yabo-dambagi L, Aydin T, Cakir A, Kazaz C. The Synthesis of Schiff bases and new secondary amine derivatives of p-vanillin and evaluation of their neuroprotective, antidiabetic, antidepressant and antioxidant potentials. Journal of Molecular Structure 2022. [DOI: 10.1016/j.molstruc.2022.133883] [Reference Citation Analysis]
21 Yan Y, Sun Y, Wang X, Zhu L, Chen Y, Liu Z. Acupuncture for Impaired Glucose Tolerance in People With Obesity: A Protocol for a Multicenter Randomized Controlled Trial. Front Med 2022;9. [DOI: 10.3389/fmed.2022.932102] [Reference Citation Analysis]
22 Lee Y, Nakano A, Nagasato Y, Ichinose T, Matsui T. In Vitro and in Silico Analyses of the Adiponectin Receptor Agonistic Action of Soybean Tripeptides. J Agric Food Chem 2022;70:7695-703. [PMID: 35704463 DOI: 10.1021/acs.jafc.2c02115] [Reference Citation Analysis]
23 Fisher M. Acarbose and Alpha Glucosidase Inhibitors. Diabetes Drug Notes 2022. [DOI: 10.1002/9781119785033.ch11] [Reference Citation Analysis]
24 Mishra A. Cardiovascular complications of diabetes mellitus. InnovAiT 2022;15:354-361. [DOI: 10.1177/17557380221086012] [Reference Citation Analysis]
25 Díaz-rizzolo DA, Acar-denizli N, Kostov B, Roura E, Sisó-almirall A, Delicado P, Gomis R. Glycaemia Fluctuations Improvement in Old-Age Prediabetic Subjects Consuming a Quinoa-Based Diet: A Pilot Study. Nutrients 2022;14:2331. [DOI: 10.3390/nu14112331] [Reference Citation Analysis]
26 Yagyu H, Shimano H. Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease. J Diabetes Investig 2022. [PMID: 35638331 DOI: 10.1111/jdi.13859] [Reference Citation Analysis]
27 Liu X, Song Y, Liu A, Zhou Y, Zhu Q, Lin Y, Sun H, Zhu K, Liu W, Ding N, Xie W, Sun H, Yu B, Xu P, Li W. More than a Leaving Group: N-Phenyltrifluoroacetimidate as a Remote Directing Group for Highly α-Selective 1,2-cis Glycosylation. Angew Chem Int Ed Engl 2022;61:e202201510. [PMID: 35266604 DOI: 10.1002/anie.202201510] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
28 Ke C, Narayan KMV, Chan JCN, Jha P, Shah BR. Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations. Nat Rev Endocrinol 2022. [PMID: 35508700 DOI: 10.1038/s41574-022-00669-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
29 Kamble RP, Ghosh P, Kulkarni AA. Identification of α-amylase inhibitory compounds from leaves of Careya arborea Roxb. and in silico docking studies. South African Journal of Botany 2022. [DOI: 10.1016/j.sajb.2022.05.018] [Reference Citation Analysis]
30 Fallah Z, Tajbakhsh M, Alikhani M, Larijani B, Faramarzi MA, Hamedifar H, Mohammadi-khanaposhtani M, Mahdavi M. A review on synthesis, mechanism of action, and structure-activity relationships of 1,2,3-triazole-based α-glucosidase inhibitors as promising anti-diabetic agents. Journal of Molecular Structure 2022;1255:132469. [DOI: 10.1016/j.molstruc.2022.132469] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
31 Nguyen HT, Nguyen TT, Duong TH, Tran NM, Nguyen CH, Nguyen TH, Sichaem J. α-Glucosidase Inhibitory and Antimicrobial Benzoylphloroglucinols from Garcinia schomburgakiana Fruits: In Vitro and In Silico Studies. Molecules 2022;27:2574. [PMID: 35458771 DOI: 10.3390/molecules27082574] [Reference Citation Analysis]
32 Kulkarni AS, Aleksic S, Berger DM, Sierra F, Kuchel GA, Barzilai N. Geroscience-guided repurposing of FDA-approved drugs to target aging: A proposed process and prioritization. Aging Cell 2022;21:e13596. [PMID: 35343051 DOI: 10.1111/acel.13596] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
33 Srichaikul K, Jenkins DJA. The Glycemic Index, Rate of Digestion of Carbohydrate Foods, and Their Potential Link with Cardiovascular Disease. J Nutr 2022;152:920-1. [PMID: 35174392 DOI: 10.1093/jn/nxab427] [Reference Citation Analysis]
34 Kamar AKDBA, Yin LJ, Liang CT, Fung GT, Avupati VR. Rhodanine scaffold: A review of antidiabetic potential and structure-activity relationships (SAR). Medicine in Drug Discovery 2022. [DOI: 10.1016/j.medidd.2022.100131] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Miao R, Fang X, Wei J, Wu H, Wang X, Tian J. Akt: A Potential Drug Target for Metabolic Syndrome. Front Physiol 2022;13:822333. [PMID: 35330934 DOI: 10.3389/fphys.2022.822333] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
36 Yadav RN, Hossain MF, Das A, Srivastava AK, Banik BK. Organocatalysis: A recent development on stereoselective synthesis of o-glycosides. Catalysis Reviews. [DOI: 10.1080/01614940.2022.2041303] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
37 Daou M, Elnaker NA, Ochsenkühn MA, Amin SA, Yousef AF, Yousef LF. In vitro α-glucosidase inhibitory activity of Tamarix nilotica shoot extracts and fractions. PLoS ONE 2022;17:e0264969. [DOI: 10.1371/journal.pone.0264969] [Reference Citation Analysis]
38 Mela DJ, Cao X, Govindaiah S, Hiemstra H, Kalathil R, Lin L, Manoj J, Mi T, Verhoeven C. Dose–response efficacy of mulberry fruit extract for reducing post-prandial blood glucose and insulin responses: randomised trial evidence in healthy adults. Br J Nutr 2022. [DOI: 10.1017/s0007114522000824] [Reference Citation Analysis]
39 Pang B, Zhang YY, Hu HJ, Sun Y, Cao AM, Lu CQ, Zhang WH, Ni Q. Prevention of Diabetes in Overweight/Obese Adults through Traditional Chinese Patent Medicine: Study Protocol for a Prospective Cohort Study. Evid Based Complement Alternat Med 2021;2021:6006802. [PMID: 35265141 DOI: 10.1155/2021/6006802] [Reference Citation Analysis]
40 Das J, Mahammad FS, Krishnamurthy RG. An integrated chemo-informatics and in vitro experimental approach repurposes acarbose as a post-ischemic neuro-protectant. 3 Biotech 2022;12:71. [PMID: 35223357 DOI: 10.1007/s13205-022-03130-5] [Reference Citation Analysis]
41 Wang Z, Zhang Y, Yan H. In situ net fishing of α-glucosidase inhibitors from evening primrose (Oenothera biennis) defatted seeds by combination of LC-MS/MS, molecular networking, affinity-based ultrafiltration, and molecular docking. Food Funct 2022. [PMID: 35165681 DOI: 10.1039/d1fo03975j] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
42 Moghaddam FM, Daneshfar M, Daneshfar Z, Iraji A, Samandari-najafabad A, Faramarzi MA, Mahdavi M. Synthesis and characterization of 1-amidino-O-alkylureas metal complexes as α- glucosidase Inhibitors: Structure-activity relationship, molecular docking, and kinetic studies. Journal of Molecular Structure 2022;1250:131726. [DOI: 10.1016/j.molstruc.2021.131726] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
43 Wang J, Yu L, Zeng X, Zheng J, Wang B, Pan L. Screening of probiotics with efficient α-glucosidase inhibitory ability and study on the structure and function of its extracellular polysaccharide. Food Bioscience 2022;45:101452. [DOI: 10.1016/j.fbio.2021.101452] [Reference Citation Analysis]
44 Ren X, Xing Y, He L, Xiu Z, Yang L, Han A, Jia Q, Dong Y. Effect of 1-Deoxynojirimycin on insulin resistance in prediabetic mice based on next-generation sequencing and intestinal microbiota study. J Ethnopharmacol 2022;:115029. [PMID: 35077826 DOI: 10.1016/j.jep.2022.115029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
45 Luo Y, Wang H, Zhou X, Chang C, Chen W, Guo X, Yang J, Ji L, Paul SK. A Randomized Controlled Clinical Trial of Lifestyle Intervention and Pioglitazone for Normalization of Glucose Status in Chinese with Prediabetes. J Diabetes Res 2022;2022:2971382. [PMID: 35036447 DOI: 10.1155/2022/2971382] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Altay M. Acarbose is again on the stage. World J Diabetes 2022; 13(1): 1-4 [DOI: 10.4239/wjd.v13.i1.1] [Reference Citation Analysis]
47 Le J, Jang C. Genetic Variation in Sugar Metabolism Confers a Protective Metabolic Profile. Gastroenterology 2022;162:1033-5. [PMID: 35007516 DOI: 10.1053/j.gastro.2022.01.006] [Reference Citation Analysis]
48 Akmeşe ÖF. DIAGNOSING DIABETES WITH MACHINE LEARNING TECHNIQUES. Hittite Journal of Science and Engineering 2022. [DOI: 10.17350/hjse19030000250] [Reference Citation Analysis]
49 Pol K, Puhlmann ML, Mars M. Efficacy of L-Arabinose in Lowering Glycemic and Insulinemic Responses: The Modifying Effect of Starch and Fat. Foods 2022;11:157. [PMID: 35053889 DOI: 10.3390/foods11020157] [Reference Citation Analysis]
50 Kassa SB, Taslimi P, Özel Ş, Gür B, Gülçin İ, Onganer Y. Effects of some phenolic compounds on the inhibition of α-glycosidase enzyme-immobilized on Pluronic®F127 micelles: An in vitro and in silico study. Colloids and Surfaces A: Physicochemical and Engineering Aspects 2022;632:127839. [DOI: 10.1016/j.colsurfa.2021.127839] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
51 Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R, Green J, Huang E, Isaacs D, Kahan S, Leon J, Lyons SK, Peters AL, Prahalad P, Reusch JEB, Young-Hyman D, Das S, Kosiborod M; American Diabetes Association Professional Practice Committee., American Diabetes Association Professional Practice Committee:. 3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Medical Care in Diabetes-2022. Diabetes Care 2022;45:S39-45. [PMID: 34964876 DOI: 10.2337/dc22-S003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 21] [Article Influence: 14.0] [Reference Citation Analysis]
52 Pham N, Tran N, Truong Nguyen H, Pham D, Nguyen T, Nguyen T, Nguyen H, Do T, Nguyen N, Duong T. Design, modification, and bio-evaluation of salazinic acid derivatives. Arabian Journal of Chemistry 2022;15:103535. [DOI: 10.1016/j.arabjc.2021.103535] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
53 Kim H, Antonisamy P, Kim Y, Lee G, Ham H, Kwon K. Inhibitory effect of Amomum villosum water extracts on α-glucosidase activity. Physiological and Molecular Plant Pathology 2022;117:101779. [DOI: 10.1016/j.pmpp.2021.101779] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
54 Rossing P, Inzucchi SE, Vart P, Jongs N, Docherty KF, Jhund PS, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, Demets DL, Bengtsson O, Lindberg M, Langkilde AM, Sjöstrand M, Stefansson BV, Karlsson C, Chertow GM, Hou FF, Correa-rotter R, Toto RD, Wheeler DC, Mcmurray JJV, Heerspink HJL. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. The Lancet Diabetes & Endocrinology 2022;10:24-34. [DOI: 10.1016/s2213-8587(21)00295-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
55 Jothibas M, Srinivasan S, Kannan KS, Elayaraja M, Kumar BA. Facile synthesis of rock candy shaped silver doped zinc oxide and its anti-diabetic activity. RECENT TRENDS IN SCIENCE AND ENGINEERING 2022. [DOI: 10.1063/5.0074617] [Reference Citation Analysis]
56 Cheng AYY. SGLT-2 inhibitors: does it matter if they prevent type 2 diabetes. The Lancet Diabetes & Endocrinology 2022;10:2-3. [DOI: 10.1016/s2213-8587(21)00310-7] [Reference Citation Analysis]
57 Usman M, Patil PJ, Patil DN, Mehmood A, Shah H, Zahra SM, Ali Z, Nasreen S. Low Glycaemic Index Cereal Grain Functional Foods. Functional Cereals and Cereal Foods 2022. [DOI: 10.1007/978-3-031-05611-6_12] [Reference Citation Analysis]
58 Trout KK, Dolin CD. Diabetes in pregnancy. Clinical Pharmacology During Pregnancy 2022. [DOI: 10.1016/b978-0-12-818902-3.00005-1] [Reference Citation Analysis]
59 Ramos FMM, Salgaço MK, Cesar T, Sivieri K. Impact of Probiotic and Prebiotic on Gut Microbiota in Pre-diabetes and Type 2 Diabetes. Natural Products in Obesity and Diabetes 2022. [DOI: 10.1007/978-3-030-92196-5_3] [Reference Citation Analysis]
60 Kawa LB. Evidence in Primary Prevention of Type 2 Diabetes Mellitus—What It Means for Primary Prevention of Type 2 Diabetes Mellitus Epidemic in Papua New Guinea. JDM 2022;12:87-97. [DOI: 10.4236/jdm.2022.122009] [Reference Citation Analysis]
61 Sim R, Chong CW, Loganadan NK, Fong AYY, Navaravong L, Hussein Z, Khunti K, Lee SWH. Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials. Diabet Med 2021;:e14780. [PMID: 34962662 DOI: 10.1111/dme.14780] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
62 Kohlenberg J, Vella A. “Is Prediabetes a Risk Factor or Is It a Disease?”. Clinical Dilemmas in Diabetes 2021. [DOI: 10.1002/9781119603207.ch1] [Reference Citation Analysis]
63 Echouffo-Tcheugui JB, Selvin E. Prediabetes and What It Means: The Epidemiological Evidence. Annu Rev Public Health 2021;42:59-77. [PMID: 33355476 DOI: 10.1146/annurev-publhealth-090419-102644] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 24.0] [Reference Citation Analysis]
64 Xie L, Zhang T, Karrar E, Zheng L, Xie D, Jin J, Chang M, Wang X, Jin Q. Insights into an α-Glucosidase Inhibitory Profile of 4,4-Dimethylsterols by Multispectral Techniques and Molecular Docking. J Agric Food Chem 2021;69:15252-60. [PMID: 34898206 DOI: 10.1021/acs.jafc.1c06347] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
65 Guha MK. PREDIABETES – RISKS AND APPROACH FOR MANAGEMENT. PIJR 2021. [DOI: 10.36106/paripex/3500371] [Reference Citation Analysis]
66 Handelsman Y, Anderson JE, Bakris GL, Ballantyne CM, Beckman JA, Bhatt DL, Bloomgarden ZT, Bozkurt B, Budoff MJ, Butler J, Dagogo-Jack S, de Boer IH, DeFronzo RA, Eckel RH, Einhorn D, Fonseca VA, Green JB, Grunberger G, Guerin C, Inzucchi SE, Jellinger PS, Kosiborod MN, Kushner P, Lepor N, Mende CW, Michos ED, Plutzky J, Taub PR, Umpierrez GE, Vaduganathan M, Weir MR. DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications 2021;:108101. [PMID: 34922811 DOI: 10.1016/j.jdiacomp.2021.108101] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
67 Ishiyama S, Kimura M, Nakagawa T, Fujimoto Y, Uchimura K, Kishigami S, Mochizuki K. Development of the Diabetic Kidney Disease Mouse Model Culturing Embryos in α-Minimum Essential Medium In Vitro, and Feeding Barley Diet Attenuated the Pathology. Front Endocrinol (Lausanne) 2021;12:746838. [PMID: 34867790 DOI: 10.3389/fendo.2021.746838] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Lim J, Ferruzzi MG, Hamaker BR. Dietary starch is weight reducing when distally digested in the small intestine. Carbohydr Polym 2021;273:118599. [PMID: 34560999 DOI: 10.1016/j.carbpol.2021.118599] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Balaich J, Estrella M, Wu G, Jeffrey PD, Biswas A, Zhao L, Korennykh A, Donia MS. The human microbiome encodes resistance to the antidiabetic drug acarbose. Nature 2021;600:110-5. [PMID: 34819672 DOI: 10.1038/s41586-021-04091-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
70 Skwiersky S, Iwuala S, Chillumuntala S, Osafehinti D, Karam J. Renin Angiotensin Aldosterone System, Glucose Homeostasis, and Prevention of Type 2 Diabetes: Mechanistic Insights and Evidence from Major Clinical Trials. Renin-Angiotensin Aldosterone System 2021. [DOI: 10.5772/intechopen.97737] [Reference Citation Analysis]
71 Lee Y, Nakano A, Nakamura S, Sakai K, Tanaka M, Sanematsu K, Shigemura N, Matsui T. In vitro and in silico characterization of adiponectin-receptor agonist dipeptides. NPJ Sci Food 2021;5:29. [PMID: 34772952 DOI: 10.1038/s41538-021-00114-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
72 Duong TH, Nguyen HT, Nguyen CH, Tran NM, Danova A, Tran TM, Vu-Huynh KL, Musa V, Jutakanoke R, Nguyen NH, Sichaem J. Identification of Highly Potent α-Glucosidase Inhibitors from Artocarpus integer and Molecular Docking Studies. Chem Biodivers 2021;:e2100499. [PMID: 34761862 DOI: 10.1002/cbdv.202100499] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
73 Pavan Phani Kumar M, Anuradha V, Subramanyam C, Hari Babu VV. In silico molecular docking study, synthesis and α-amylase inhibitory activity evaluation of phosphorylated derivatives of purine. Phosphorus, Sulfur, and Silicon and the Related Elements 2021;196:1010-1017. [DOI: 10.1080/10426507.2021.1960833] [Reference Citation Analysis]
74 Mannucci E, Gallo M, Pintaudi B, Targher G, Candido R, Giaccari A, Monami M; SID-AMD joint panel for Italian Guidelines on Treatment of Type 2 Diabetes. All-cause mortality and cardiovascular events in patients with type 2 diabetes treated with alpha-glucosidase inhibitors: A meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis 2021:S0939-4753(21)00508-1. [PMID: 34893404 DOI: 10.1016/j.numecd.2021.10.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Al-Thani MH, Al-Mutawa KA, Alyafei SA, Ijaz MA, Khalifa SAH, Kokku SB, Mishra ACM, Poovelil BV, Soussi MB, Toumi AA, Dargham SR, Awad SF, Abu-Raddad LJ. Characterizing epidemiology of prediabetes, diabetes, and hypertension in Qataris: A cross-sectional study. PLoS One 2021;16:e0259152. [PMID: 34699571 DOI: 10.1371/journal.pone.0259152] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Wolf AM. Rodent diet aids and the fallacy of caloric restriction. Mech Ageing Dev 2021;200:111584. [PMID: 34673082 DOI: 10.1016/j.mad.2021.111584] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
77 Seetharaman R, Pawar S, Advani M. One hundred years since insulin discovery: An update on current and future perspectives for pharmacotherapy of diabetes mellitus. Br J Clin Pharmacol 2021. [PMID: 34608666 DOI: 10.1111/bcp.15100] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Sasaki H, Saisho Y, Inaishi J, Itoh H. Revisiting Regulators of Human β-cell Mass to Achieve β-cell-centric Approach Toward Type 2 Diabetes. J Endocr Soc 2021;5:bvab128. [PMID: 34405128 DOI: 10.1210/jendso/bvab128] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Ueda Y, Matsuda Y, Murata T, Hoshi Y, Kabata K, Ono M, Kinoshita H, Igoshi K, Yasuda S. Investigation of Total Polyphenol Content, Antioxidant Activity, and Carbohydrate-hydrolyzing Enzyme Inhibition of Yacon Leaves among Four Domestic Cultivars and a Peru Line for over Four Years. JARQ 2021;55:347-58. [DOI: 10.6090/jarq.55.347] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Bonsembiante L, Targher G, Maffeis C. Type 2 Diabetes and Dietary Carbohydrate Intake of Adolescents and Young Adults: What Is the Impact of Different Choices? Nutrients 2021;13:3344. [PMID: 34684345 DOI: 10.3390/nu13103344] [Reference Citation Analysis]
81 Jeong GH, Kim TH. Plasma-Induced Oxidation Products of (-)-Epigallocatechin Gallate with Digestive Enzymes Inhibitory Effects. Molecules 2021;26:5799. [PMID: 34641343 DOI: 10.3390/molecules26195799] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
82 Thiruvengadam S, Peter PR. Management of type 2 diabetes without insulin: An update for the PCP. Dis Mon 2021;:101290. [PMID: 34563347 DOI: 10.1016/j.disamonth.2021.101290] [Reference Citation Analysis]
83 Morgunova TB, Glinkina IV, Fadeev VV. Prediabetes: challenges and opportunities. Medicinskij sovet 2021. [DOI: 10.21518/2079-701x-2021-12-220-227] [Reference Citation Analysis]
84 Zhang S, Wang Y, Han L, Fu X, Wang S, Li W, Han W. Targeting N-Terminal Human Maltase-Glucoamylase to Unravel Possible Inhibitors Using Molecular Docking, Molecular Dynamics Simulations, and Adaptive Steered Molecular Dynamics Simulations. Front Chem 2021;9:711242. [PMID: 34527658 DOI: 10.3389/fchem.2021.711242] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
85 Xing Y, Ren X, Li X, Sui L, Shi X, Sun Y, Quan C, Xiu Z, Dong Y. Baicalein Enhances the Effect of Acarbose on the Improvement of Nonalcoholic Fatty Liver Disease Associated with Prediabetes via the Inhibition of De Novo Lipogenesis. J Agric Food Chem 2021;69:9822-36. [PMID: 34406004 DOI: 10.1021/acs.jafc.1c04194] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
86 Chen Q, Toy JYH, Seta C, Yeo TC, Huang D. Inhibition Effect of Extract of Psychotria viridiflora Stem on α-Amylase and α-Glucosidase and Its Application in Lowering the Digestibility of Noodles. Front Nutr 2021;8:701114. [PMID: 34458304 DOI: 10.3389/fnut.2021.701114] [Reference Citation Analysis]
87 Jonas DE, Crotty K, Yun JDY, Middleton JC, Feltner C, Taylor-Phillips S, Barclay C, Dotson A, Baker C, Balio CP, Voisin CE, Harris RP. Screening for Prediabetes and Type 2 Diabetes: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2021;326:744-60. [PMID: 34427595 DOI: 10.1001/jama.2021.10403] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
88 Escalada San Martín J. Prediabetes: what are we talking about? Advances in Laboratory Medicine / Avances en Medicina de Laboratorio 2021;2:305-308. [DOI: 10.1515/almed-2021-0034] [Reference Citation Analysis]
89 Chiavaroli L, Lee D, Ahmed A, Cheung A, Khan TA, Blanco S, Mejia, Mirrahimi A, Jenkins DJA, Livesey G, Wolever TMS, Rahelić D, Kahleová H, Salas-Salvadó J, Kendall CWC, Sievenpiper JL. Effect of low glycaemic index or load dietary patterns on glycaemic control and cardiometabolic risk factors in diabetes: systematic review and meta-analysis of randomised controlled trials. BMJ 2021;374:n1651. [PMID: 34348965 DOI: 10.1136/bmj.n1651] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 24.0] [Reference Citation Analysis]
90 Escalada San Martín J. Prediabetes ¿de qué estamos hablando? Advances in Laboratory Medicine / Avances en Medicina de Laboratorio 2021;2:309-312. [DOI: 10.1515/almed-2021-0030] [Reference Citation Analysis]
91 Fattaheian-Dehkordi S, Hojjatifard R, Saeedi M, Khanavi M. A Review on Antidiabetic Activity of Centaurea spp.: A New Approach for Developing Herbal Remedies. Evid Based Complement Alternat Med 2021;2021:5587938. [PMID: 34285703 DOI: 10.1155/2021/5587938] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
92 Araki E, Goto A, Kondo T, Noda M, Noto H, Origasa H, Osawa H, Taguchi A, Tanizawa Y, Tobe K, Yoshioka N. Japanese Clinical Practice Guideline for Diabetes 2019. J Diabetes Investig 2020;11:1020-76. [PMID: 33021749 DOI: 10.1111/jdi.13306] [Cited by in Crossref: 80] [Cited by in F6Publishing: 86] [Article Influence: 80.0] [Reference Citation Analysis]
93 Sundar S, Thangamani L, Piramanayagam S, Rahul CN, Aiswarya N, Sekar K, Natarajan J. Screening of FDA-approved compound library identifies potential small-molecule inhibitors of SARS-CoV-2 non-structural proteins NSP1, NSP4, NSP6 and NSP13: molecular modeling and molecular dynamics studies. J Proteins Proteom 2021;:1-15. [PMID: 34121824 DOI: 10.1007/s42485-021-00067-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
94 Cignarelli A, Genchi VA, D'Oria R, Giordano F, Caruso I, Perrini S, Natalicchio A, Laviola L, Giorgino F. Role of Glucose-Lowering Medications in Erectile Dysfunction. J Clin Med 2021;10:2501. [PMID: 34198786 DOI: 10.3390/jcm10112501] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
95 Naik B, Mattaparthi VSK, Gupta N, Ojha R, Das P, Singh S, Prajapati VK, Prusty D. Chemical system biology approach to identify multi-targeting FDA inhibitors for treating COVID-19 and associated health complications. J Biomol Struct Dyn 2021;:1-25. [PMID: 34062110 DOI: 10.1080/07391102.2021.1931451] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
96 Charifi W, Fauveau V, Francese L, Grosfeld A, Le Gall M, Ourabah S, Ellero-simatos S, Viel T, Cauzac M, Gueddouri D, Benhamed F, Tavitian B, Dentin R, Burnol A, Postic C, Guilmeau S. Loss of intestinal ChREBP impairs absorption of dietary sugars and prevents glycemic excursion curves.. [DOI: 10.1101/2021.05.18.444615] [Reference Citation Analysis]
97 Lee S, Zhou J, Wong WT, Liu T, Wu WKK, Wong ICK, Zhang Q, Tse G. Glycemic and lipid variability for predicting complications and mortality in diabetes mellitus using machine learning. BMC Endocr Disord 2021;21:94. [PMID: 33947391 DOI: 10.1186/s12902-021-00751-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 22.0] [Reference Citation Analysis]
98 Landeros-martínez L, Gutiérrez-méndez N, Palomares-báez JP, Sánchez-bojorge N, Flores-de los Ríos JP, Piñón-castillo HA, Chávez-rojo MA, Rodríguez-valdez L. The Oxidative Process of Acarbose, Maysin, and Luteolin with Maltase-Glucoamylase: Molecular Docking and Molecular Dynamics Study. Applied Sciences 2021;11:4067. [DOI: 10.3390/app11094067] [Reference Citation Analysis]
99 Gulnaz A, Nadeem J, Han JH, Lew LC, Son JD, Park YH, Rather IA, Hor YY. Lactobacillus Sps in Reducing the Risk of Diabetes in High-Fat Diet-Induced Diabetic Mice by Modulating the Gut Microbiome and Inhibiting Key Digestive Enzymes Associated with Diabetes. Biology (Basel) 2021;10:348. [PMID: 33924088 DOI: 10.3390/biology10040348] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
100 Kamruzzaman M, Horowitz M, Jones KL, Marathe CS. Gut-Based Strategies to Reduce Postprandial Glycaemia in Type 2 Diabetes. Front Endocrinol (Lausanne) 2021;12:661877. [PMID: 33897622 DOI: 10.3389/fendo.2021.661877] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
101 Altaff SM, Raja Rajeswari T, Subramanyam C. Synthesis, α -amylase inhibitory activity evaluation and in silico molecular docking study of some new phosphoramidates containing heterocyclic ring. Phosphorus, Sulfur, and Silicon and the Related Elements 2021;196:389-97. [DOI: 10.1080/10426507.2020.1845679] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
102 Święcicka-Klama A, Połtyn-Zaradna K, Szuba A, Zatońska K. The Natural Course of Impaired Fasting Glucose. Adv Exp Med Biol 2021;1324:41-50. [PMID: 32767267 DOI: 10.1007/5584_2020_571] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
103 Yang L, Xue Y, Wei J, Dai Q, Li P. Integrating metabolomic data with machine learning approach for discovery of Q-markers from Jinqi Jiangtang preparation against type 2 diabetes. Chin Med 2021;16:30. [PMID: 33741031 DOI: 10.1186/s13020-021-00438-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
104 Alssema M, Ruijgrok C, Blaak EE, Egli L, Dussort P, Vinoy S, Dekker JM, Denise Robertson M. Effects of alpha-glucosidase-inhibiting drugs on acute postprandial glucose and insulin responses: a systematic review and meta-analysis. Nutr Diabetes 2021;11:11. [PMID: 33658478 DOI: 10.1038/s41387-021-00152-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
105 Babatunde O, Hameed S, Salar U, Chigurupati S, Wadood A, Rehman AU, Venugopal V, Khan KM, Taha M, Perveen S. Dihydroquinazolin-4(1H)-one derivatives as novel and potential leads for diabetic management. Mol Divers 2021. [PMID: 33650031 DOI: 10.1007/s11030-021-10196-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Yamamoto H, Konishi A, Shinke T, Otake H, Kuroda M, Osue T, Sawada T, Takaya T, Kawai H, Hashimoto N, Ohara T, Hirota Y, Sakaguchi K, Omori T, Ogawa W, Hirata KI. The impact of vildagliptin on the daily glucose profile and coronary plaque stability in impaired glucose tolerance patients with coronary artery disease: VOGUE-A multicenter randomized controlled trial. BMC Cardiovasc Disord 2021;21:92. [PMID: 33588758 DOI: 10.1186/s12872-021-01902-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Chen Y, Armstrong Z, Artola M, Florea BI, Kuo CL, de Boer C, Rasmussen MS, Abou Hachem M, van der Marel GA, Codée JDC, Aerts JMFG, Davies GJ, Overkleeft HS. Activity-Based Protein Profiling of Retaining α-Amylases in Complex Biological Samples. J Am Chem Soc 2021;143:2423-32. [PMID: 33497208 DOI: 10.1021/jacs.0c13059] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
108 Sievenpiper JL. Low-carbohydrate diets and cardiometabolic health: the importance of carbohydrate quality over quantity. Nutr Rev 2020;78:69-77. [PMID: 32728757 DOI: 10.1093/nutrit/nuz082] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 30.0] [Reference Citation Analysis]
109 Akshatha JV, SantoshKumar HS, Prakash HS, Nalini MS. In silico docking studies of α-amylase inhibitors from the anti-diabetic plant Leucas ciliata Benth. and an endophyte, Streptomyces longisporoflavus. 3 Biotech 2021;11:51. [PMID: 33489670 DOI: 10.1007/s13205-020-02547-0] [Reference Citation Analysis]
110 Fedullo AL, Schiattarella A, Morlando M, Raguzzini A, Toti E, De Franciscis P, Peluso I. Mediterranean Diet for the Prevention of Gestational Diabetes in the Covid-19 Era: Implications of Il-6 In Diabesity. Int J Mol Sci 2021;22:1213. [PMID: 33530554 DOI: 10.3390/ijms22031213] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 30.0] [Reference Citation Analysis]
111 Thiel AL, Ragab M, Wagner AE, Divanovic S, Derer S, Sina C. Purification and Functional Characterization of the Chloroform/Methanol-Soluble Protein 3 (CM3) From Triticum aestivum in Drosophila melanogaster. Front Nutr 2020;7:607937. [PMID: 33425975 DOI: 10.3389/fnut.2020.607937] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
112 Lankatillake C, Luo S, Flavel M, Lenon GB, Gill H, Huynh T, Dias DA. Screening natural product extracts for potential enzyme inhibitors: protocols, and the standardisation of the usage of blanks in α-amylase, α-glucosidase and lipase assays. Plant Methods 2021;17:3. [PMID: 33407662 DOI: 10.1186/s13007-020-00702-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 17.0] [Reference Citation Analysis]
113 Macchiarini F, Miller RA, Strong R, Rosenthal N, Harrison DE. NIA Interventions Testing Program: A collaborative approach for investigating interventions to promote healthy aging. Handbook of the Biology of Aging 2021. [DOI: 10.1016/b978-0-12-815962-0.00010-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
114 Freichel M, Mengel K. Antidiabetika. Arzneiverordnungs-Report 2021 2021. [DOI: 10.1007/978-3-662-63825-5_13] [Reference Citation Analysis]
115 Jayawardena B, Madushika Wariyapperuma WN, Thammitiyagodage M, Karunakaran R, Sisira Kumara WS. Hypoglycemic and anti-lipidemic properties of Cinnamomum zeylanicum (”Sri Wijaya” accession) water-soluble nutraceutical in streptozotocin-induced diabetic and healthy wistar rats. Phcog Mag 2021;17:188. [DOI: 10.4103/pm.pm_334_20] [Reference Citation Analysis]
116 Goriacko P, Veltri KT. Adverse Drug Effects Involving the Gastrointestinal System (Pharmacist Perspective). Geriatric Gastroenterology 2021. [DOI: 10.1007/978-3-030-30192-7_10] [Reference Citation Analysis]
117 Inaishi J, Saisho Y. Beta-Cell Mass in Obesity and Type 2 Diabetes, and Its Relation to Pancreas Fat: A Mini-Review. Nutrients 2020;12:E3846. [PMID: 33339276 DOI: 10.3390/nu12123846] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 12.0] [Reference Citation Analysis]
118 Matz K, Tuomilehto J, Teuschl Y, Dachenhausen A, Brainin M. Comparison of oral glucose tolerance test and HbA1c in detection of disorders of glucose metabolism in patients with acute stroke. Cardiovasc Diabetol 2020;19:204. [PMID: 33278898 DOI: 10.1186/s12933-020-01182-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
119 Shintani H, Shintani T. Effects of antidiabetic drugs that cause glucose excretion directly from the body on mortality. Medicine in Drug Discovery 2020;8:100062. [DOI: 10.1016/j.medidd.2020.100062] [Reference Citation Analysis]
120 Borg MJ, Rayner CK, Jones KL, Horowitz M, Xie C, Wu T. Gastrointestinal Mechanisms Underlying the Cardiovascular Effect of Metformin. Pharmaceuticals (Basel) 2020;13:E410. [PMID: 33266396 DOI: 10.3390/ph13110410] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
121 Gong L, Feng D, Wang T, Ren Y, Liu Y, Wang J. Inhibitors of α-amylase and α-glucosidase: Potential linkage for whole cereal foods on prevention of hyperglycemia. Food Sci Nutr 2020;8:6320-37. [PMID: 33312519 DOI: 10.1002/fsn3.1987] [Cited by in Crossref: 51] [Cited by in F6Publishing: 57] [Article Influence: 25.5] [Reference Citation Analysis]
122 Du X, Wang X, Yan X, Yang Y, Li Z, Jiang Z, Ni H. Hypoglycaemic effect of all-trans astaxanthin through inhibiting α-glucosidase. Journal of Functional Foods 2020;74:104168. [DOI: 10.1016/j.jff.2020.104168] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
123 Smina CS, Lalitha P, Nagabhushana H, Sharma SC. Terminalia bellirica dried fruit and seed extract offers alpha-amylase inhibitory potential in tackling diabetes. Appl Nanosci 2020;10:4325-39. [DOI: 10.1007/s13204-020-01549-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
124 Lestari OA, Dewi YSK, Putri M. Mutu Glikemik Kue Bingke Variasi Umbi di Kota Pontianak. J Mutu Pangan 2020;7:80-84. [DOI: 10.29244/jmpi.2020.7.2.80] [Reference Citation Analysis]
125 Munshi MN, Meneilly GS, Rodríguez-Mañas L, Close KL, Conlin PR, Cukierman-Yaffe T, Forbes A, Ganda OP, Kahn CR, Huang E, Laffel LM, Lee CG, Lee S, Nathan DM, Pandya N, Pratley R, Gabbay R, Sinclair AJ. Diabetes in ageing: pathways for developing the evidence base for clinical guidance. Lancet Diabetes Endocrinol 2020;8:855-67. [PMID: 32946822 DOI: 10.1016/S2213-8587(20)30230-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
126 Williamson G, Sheedy K. Effects of Polyphenols on Insulin Resistance. Nutrients 2020;12:E3135. [PMID: 33066504 DOI: 10.3390/nu12103135] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
127 Tao T, Zhang Y, Zhu YC, Fu JR, Wang YY, Cai J, Ma JY, Xu Y, Gao YN, Sun Y, Fan W, Liu W. Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study. J Clin Endocrinol Metab 2021;106:e1420-32. [PMID: 32995892 DOI: 10.1210/clinem/dgaa692] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
128 Nyenwe E, James D, Wan J, Dagogo-Jack S. Glycemic Response to Oral Dexamethasone Predicts Incident Prediabetes in Normoglycemic Subjects With Parental Diabetes. J Endocr Soc 2020;4:bvaa137. [PMID: 33134765 DOI: 10.1210/jendso/bvaa137] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
129 Ke C, Stukel TA, Shah BR, Lau E, Ma RC, So WY, Kong AP, Chow E, Chan JCN, Luk A. Age at diagnosis, glycemic trajectories, and responses to oral glucose-lowering drugs in type 2 diabetes in Hong Kong: A population-based observational study. PLoS Med 2020;17:e1003316. [PMID: 32946450 DOI: 10.1371/journal.pmed.1003316] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
130 Xiong Y, Ng K, Zhang P, Warner RD, Shen S, Tang HY, Liang Z, Fang Z. In Vitro α-Glucosidase and α-Amylase Inhibitory Activities of Free and Bound Phenolic Extracts from the Bran and Kernel Fractions of Five Sorghum Grain Genotypes. Foods 2020;9:E1301. [PMID: 32942661 DOI: 10.3390/foods9091301] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
131 Xiao B, Xiao Y, Ning H, Han X, Li W, Ma Y, Zhao N, Du G, Dong Y, Jung JH, She Z. In vitro dual-target activities and in vivo antidiabetic effect of 3-hydroxy-N-(p-hydroxy-phenethyl) phthalimide in high-fat diet and streptozotocin-induced diabetic golden hamsters. Med Chem Res 2020;29:2077-88. [DOI: 10.1007/s00044-020-02628-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
132 Dayma V, Chopra J, Sharma P, Dwivedi A, Tripathi IP, Bhargava A, Murugesan V, Goswami AK, Baroliya PK. Synthesis, antidiabetic, antioxidant and anti-inflammatory activities of novel hydroxytriazenes based on sulpha drugs. Heliyon 2020;6:e04787. [PMID: 32913908 DOI: 10.1016/j.heliyon.2020.e04787] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
133 Naveed A, Farrukh L, Sana MK, Naveed B, Randhawa FA. Pharmacological Primary Prevention of Diabetes Mellitus Type II: A Narrative Review. Cureus 2020;12:e10033. [PMID: 32999773 DOI: 10.7759/cureus.10033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
134 Al-moalemi H, Altowayti W, Mohd Bohari SP. Antidiabetic Effect of Abrus precatorius Methanol Leaves Extract towards Glucose Absorption via in vitro Study. International Journal of Life Sciences and Biotechnology 2020. [DOI: 10.38001/ijlsb.701093] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
135 Chen Y, Shen T, Zhong L, Liu Z, Dong X, Huang T, Wang Q, Xiao H. Research Progress of Chloroquine and Hydroxychloroquine on the COVID-19 and Their Potential Risks in Clinic Use. Front Pharmacol 2020;11:1167. [PMID: 32848774 DOI: 10.3389/fphar.2020.01167] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
136 Araki E, Goto A, Kondo T, Noda M, Noto H, Origasa H, Osawa H, Taguchi A, Tanizawa Y, Tobe K, Yoshioka N. Japanese Clinical Practice Guideline for Diabetes 2019. Diabetol Int 2020;11:165-223. [PMID: 32802702 DOI: 10.1007/s13340-020-00439-5] [Cited by in Crossref: 97] [Cited by in F6Publishing: 112] [Article Influence: 48.5] [Reference Citation Analysis]
137 Chawla R, Madhu SV, Makkar BM, Ghosh S, Saboo B, Kalra S; On behalf of RSSDI-ESI Consensus Group. RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020. Int J Diabetes Dev Ctries 2020;40:1-122. [DOI: 10.1007/s13410-020-00819-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
138 Romeo GR, Lee J, Mulla CM, Noh Y, Holden C, Lee BC. Influence of Cinnamon on Glycemic Control in Individuals With Prediabetes: A Randomized Controlled Trial. J Endocr Soc 2020;4:bvaa094. [PMID: 33123653 DOI: 10.1210/jendso/bvaa094] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
139 Östman E, Samigullin A, Heyman-Lindén L, Andersson K, Björck I, Öste R, Humpert PM. A novel nutritional supplement containing amino acids and chromium decreases postprandial glucose response in a randomized, double-blind, placebo-controlled study. PLoS One 2020;15:e0234237. [PMID: 32579549 DOI: 10.1371/journal.pone.0234237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
140 Wang C, Zhang X, Yu M. Rapid Determination of Acarbose in Tablets by 1H NMR Spectroscopy. CPA 2020;16:585-590. [DOI: 10.2174/1573412915666181224125141] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
141 Sotomayor-beltran C, Perez-siguas R, Matta-solis E, Matta-solis H. The Relationship between the Risks of Developing Type 2 Diabetes Mellitus and Cardiovascular Diseases. TOCMJ 2020;14:13-7. [DOI: 10.2174/18741924020140100013] [Reference Citation Analysis]
142 Kwun SY, Bae YW, Yoon JA, Park EH, Kim MD. Isolation of acid tolerant lactic acid bacteria and evaluation of α-glucosidase inhibitory activity. Food Sci Biotechnol 2020;29:1125-30. [PMID: 32670666 DOI: 10.1007/s10068-020-00760-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
143 Adriana Stoica R, Simona Ștefan D, Rizzo M, Iulia Suceveanu A, Paul Suceveanu A, Serafinceanu C, Pantea-stoian A. Metformin Indications, Dosage, Adverse Reactions, and Contraindications. Metformin 2020. [DOI: 10.5772/intechopen.88675] [Reference Citation Analysis]
144 Bostock-cox B. Pre-diabetes and cardiovascular risk: detonating the time bomb. Practice Nursing 2020;31:200-205. [DOI: 10.12968/pnur.2020.31.5.200] [Reference Citation Analysis]
145 Oh MR, Jung SJ, Bae EJ, Park BH, Chae SW. Clinical Characteristics and Associated Risk Factors of Prediabetes in the Southwestern Region of Korea from 2010-2019. J Clin Med 2020;9:E1114. [PMID: 32295016 DOI: 10.3390/jcm9041114] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
146 Li Y, Li Z, Wang R, Mi B, Jiang T, Lu M, Liu J, Wang B, Zhang D, Xu Q, Huang Y. Alleviating the Hydrolysis of Carbohydrates, Tangzhiqing (TZQ) Decreased the Postprandial Glycemia in Healthy Volunteers: An Eight-Period Crossover Study. Evid Based Complement Alternat Med 2020;2020:8138195. [PMID: 32256656 DOI: 10.1155/2020/8138195] [Reference Citation Analysis]
147 Sallar A, Dagogo-Jack S. Regression from prediabetes to normal glucose regulation: State of the science. Exp Biol Med (Maywood) 2020;245:889-96. [PMID: 32212859 DOI: 10.1177/1535370220915644] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
148 Sintsova OV, Leychenko EV, Gladkikh IN, Kalinovskii AP, Monastyrnaya MM, Kozlovskaya EP. Magnificamide Is a New Effective Mammalian α-Amylase Inhibitor. Dokl Biochem Biophys 2019;489:385-7. [PMID: 32130606 DOI: 10.1134/S1607672919060097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
149 Bevan G, De Poli C, Keng MJ, Raine R. How valid are projections of the future prevalence of diabetes? Rapid reviews of prevalence-based and Markov chain models and comparisons of different models' projections for England. BMJ Open 2020;10:e033483. [PMID: 32132137 DOI: 10.1136/bmjopen-2019-033483] [Reference Citation Analysis]
150 Magge SN, Silverstein J, Elder D, Nadeau K, Hannon TS. Evaluation and Treatment of Prediabetes in Youth. J Pediatr. 2020;219:11-22. [PMID: 32143933 DOI: 10.1016/j.jpeds.2019.12.061] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
151 Kang B, Skonberg DI, Myracle AD. Anti-Hyperglycemic Effects of Green Crab Hydrolysates Derived by Commercially Available Enzymes. Foods 2020;9:E258. [PMID: 32121110 DOI: 10.3390/foods9030258] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
152 Acet T. Determining the phenolic components by using HPLC and biological activity of Centaurea triumfetti. Plant Biosystems - An International Journal Dealing with all Aspects of Plant Biology 2021;155:159-64. [DOI: 10.1080/11263504.2020.1722275] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
153 Holmbäck U, Forslund A, Grudén S, Alderborn G, Söderhäll A, Hellström PM, Lennernäs H. Effects of a novel combination of orlistat and acarbose on tolerability, appetite, and glucose metabolism in persons with obesity. Obes Sci Pract 2020;6:313-23. [PMID: 32523721 DOI: 10.1002/osp4.405] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
154 Pinaffi ACDC, Sampaio GR, Soares MJ, Shahidi F, de Camargo AC, Torres EAFS. Insoluble-Bound Polyphenols Released from Guarana Powder: Inhibition of Alpha-Glucosidase and Proanthocyanidin Profile. Molecules 2020;25:E679. [PMID: 32033416 DOI: 10.3390/molecules25030679] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
155 Avcı D, Altürk S, Sönmez F, Tamer Ö, Başoğlu A, Atalay Y, Kurt BZ, Dege N. Synthesis, spectral properties, in vitro α‐glucosidase inhibitory activity and quantum chemical calculations of novel mixed‐ligand M(II) complexes containing 1,10‐phenanthroline. Appl Organometal Chem 2020;34. [DOI: 10.1002/aoc.5412] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
156 Özcan K. Antibacterial, antioxidant and enzyme inhibition activity capacities of Doronicum macrolepis (FREYN&SINT): An endemic plant from Turkey. Saudi Pharm J 2020;28:95-100. [PMID: 31920435 DOI: 10.1016/j.jsps.2019.11.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
157 Verdura S, Cuyàs E, Cortada E, Brunet J, Lopez-Bonet E, Martin-Castillo B, Bosch-Barrera J, Encinar JA, Menendez JA. Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity. Aging (Albany NY) 2020;12:8-34. [PMID: 31901900 DOI: 10.18632/aging.102646] [Cited by in Crossref: 64] [Cited by in F6Publishing: 65] [Article Influence: 32.0] [Reference Citation Analysis]
158 Kim JD, Lee W. Prevention of Type 2 Diabetes. Cardiovasc Prev Pharmacother 2020;2:63. [DOI: 10.36011/cpp.2020.2.e10] [Reference Citation Analysis]
159 Freichel M, Mengel K. Antidiabetika. Arzneiverordnungs-Report 2020 2020. [DOI: 10.1007/978-3-662-62168-4_12] [Reference Citation Analysis]
160 Vounzoulaki E, Seidu S. Gestational Diabetes Mellitus. Obesity and Diabetes 2020. [DOI: 10.1007/978-3-030-53370-0_35] [Reference Citation Analysis]
161 Young E, Nwatu C. Prediabetes in sub-saharan Africa: Pathophysiology, predictors, and prevalence. Niger J Med 2020;29:343. [DOI: 10.4103/njm.njm_30_20] [Reference Citation Analysis]
162 Goriacko P, Veltri KT. Adverse Drug Effects Involving the Gastrointestinal System (Pharmacist Perspective). Geriatric Gastroenterology 2020. [DOI: 10.1007/978-3-319-90761-1_10-1] [Reference Citation Analysis]
163 Rigato M, Fadini GP, Avogaro A. Diabetes and the Cardiovascular System. Endocrinology 2020. [DOI: 10.1007/978-3-030-36694-0_6] [Reference Citation Analysis]
164 Merino B, Fernández-Díaz CM, Cózar-Castellano I, Perdomo G. Intestinal Fructose and Glucose Metabolism in Health and Disease. Nutrients 2019;12:E94. [PMID: 31905727 DOI: 10.3390/nu12010094] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 12.0] [Reference Citation Analysis]
165 Son HU, Yoon EK, Yoo CY, Park CH, Bae MA, Kim TH, Lee CH, Lee KW, Seo H, Kim KJ, Lee SH. Effects of Synergistic Inhibition on α-glucosidase by Phytoalexins in Soybeans. Biomolecules 2019;9:E828. [PMID: 31817312 DOI: 10.3390/biom9120828] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
166 Knowler WC, Crandall JP. Pharmacologic Randomized Clinical Trials in Prevention of Type 2 Diabetes. Curr Diab Rep 2019;19:154. [PMID: 31792721 DOI: 10.1007/s11892-019-1268-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
167 Razavi-Nematollahi L, Ismail-Beigi F. Adverse Effects of Glycemia-Lowering Medications in Type 2 Diabetes. Curr Diab Rep 2019;19:132. [PMID: 31748838 DOI: 10.1007/s11892-019-1266-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
168 Villa-Rodriguez JA, Ifie I, Gonzalez-Aguilar GA, Roopchand DE. The Gastrointestinal Tract as Prime Site for Cardiometabolic Protection by Dietary Polyphenols. Adv Nutr 2019;10:999-1011. [PMID: 31144710 DOI: 10.1093/advances/nmz038] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
169 Schuler J, Samudrala R. Fingerprinting CANDO: Increased Accuracy with Structure- and Ligand-Based Shotgun Drug Repurposing. ACS Omega 2019;4:17393-403. [PMID: 31656912 DOI: 10.1021/acsomega.9b02160] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 6.3] [Reference Citation Analysis]
170 Coleman RL, Scott CAB, Lang Z, Bethel MA, Tuomilehto J, Holman RR. Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes. Cardiovasc Diabetol 2019;18:135. [PMID: 31623625 DOI: 10.1186/s12933-019-0933-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
171 Sintsova O, Gladkikh I, Kalinovskii A, Zelepuga E, Monastyrnaya M, Kim N, Shevchenko L, Peigneur S, Tytgat J, Kozlovskaya E, Leychenko E. Magnificamide, a β-Defensin-Like Peptide from the Mucus of the Sea Anemone Heteractis magnifica, Is a Strong Inhibitor of Mammalian α-Amylases. Mar Drugs 2019;17:E542. [PMID: 31546678 DOI: 10.3390/md17100542] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
172 Okada H, Tanaka M, Hasegawa G, Nakajima H, Kadono M, Okada Y, Hirata A, Oyamada H, Yamane T, Fukui M. Comparison of the Efficacy of Repaglinide Versus the Combination of Mitiglinide and Voglibose on Glycemic Variability in Japanese Patients with Type 2 Diabetes. Curr Pharm Des 2020;25:4600-5. [PMID: 31538887 DOI: 10.2174/1381612825666190920124853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
173 Wasserman DH, Wang TJ, Brown NJ. The Vasculature in Prediabetes. Circ Res 2018;122:1135-50. [PMID: 29650631 DOI: 10.1161/CIRCRESAHA.118.311912] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 21.3] [Reference Citation Analysis]
174 Lankatillake C, Huynh T, Dias DA. Understanding glycaemic control and current approaches for screening antidiabetic natural products from evidence-based medicinal plants. Plant Methods 2019;15:105. [PMID: 31516543 DOI: 10.1186/s13007-019-0487-8] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 17.0] [Reference Citation Analysis]
175 Holt RIG. Association Between Antipsychotic Medication Use and Diabetes. Curr Diab Rep 2019;19:96. [PMID: 31478094 DOI: 10.1007/s11892-019-1220-8] [Cited by in Crossref: 41] [Cited by in F6Publishing: 47] [Article Influence: 13.7] [Reference Citation Analysis]
176 Yamamoto K, Ito T, Nagasato T, Shinnakasu A, Kurano M, Arimura A, Arimura H, Hashiguchi H, Deguchi T, Maruyama I, Nishio Y. Effects of glycemic control and hypoglycemia on Thrombus formation assessed using automated microchip flow chamber system: an exploratory observational study. Thromb J 2019;17:17. [PMID: 31496922 DOI: 10.1186/s12959-019-0206-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
177 Khan RMM, Chua ZJY, Tan JC, Yang Y, Liao Z, Zhao Y. From Pre-Diabetes to Diabetes: Diagnosis, Treatments and Translational Research. Medicina (Kaunas). 2019;55. [PMID: 31470636 DOI: 10.3390/medicina55090546] [Cited by in Crossref: 77] [Cited by in F6Publishing: 85] [Article Influence: 25.7] [Reference Citation Analysis]
178 Salvatore T, Nevola R, Pafundi PC, Monaco L, Ricozzi C, Imbriani S, Rinaldi L, Sasso FC. Incretin Hormones: The Link between Glycemic Index and Cardiometabolic Diseases. Nutrients 2019;11:E1878. [PMID: 31412576 DOI: 10.3390/nu11081878] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
179 Shaw JE. Prediabetes: lifestyle, pharmacotherapy or regulation? Ther Adv Endocrinol Metab 2019;10:2042018819863020. [PMID: 31321022 DOI: 10.1177/2042018819863020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
180 Sheng Z, Cao JY, Pang YC, Xu HC, Chen JW, Yuan JH, Wang R, Zhang CS, Wang LX, Dong J. Effects of Lifestyle Modification and Anti-diabetic Medicine on Prediabetes Progress: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne) 2019;10:455. [PMID: 31354627 DOI: 10.3389/fendo.2019.00455] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
181 Nathan DM, Bennett PH, Crandall JP, Edelstein SL, Goldberg RB, Kahn SE, Knowler WC, Mather KJ, Mudaliar S, Orchard TJ, Temprosa M, White NH; Research Group. Does diabetes prevention translate into reduced long-term vascular complications of diabetes? Diabetologia 2019;62:1319-28. [PMID: 31270584 DOI: 10.1007/s00125-019-4928-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 9.7] [Reference Citation Analysis]
182 Livesey G, Taylor R, Livesey HF, Buyken AE, Jenkins DJA, Augustin LSA, Sievenpiper JL, Barclay AW, Liu S, Wolever TMS, Willett WC, Brighenti F, Salas-Salvadó J, Björck I, Rizkalla SW, Riccardi G, Vecchia C, Ceriello A, Trichopoulou A, Poli A, Astrup A, Kendall CWC, Ha MA, Baer-Sinnott S, Brand-Miller JC. Dietary Glycemic Index and Load and the Risk of Type 2 Diabetes: Assessment of Causal Relations. Nutrients 2019;11:E1436. [PMID: 31242690 DOI: 10.3390/nu11061436] [Cited by in Crossref: 73] [Cited by in F6Publishing: 77] [Article Influence: 24.3] [Reference Citation Analysis]
183 Haslacher H, Fallmann H, Waldhäusl C, Hartmann E, Wagner OF, Waldhäusl WK. Obesity: outcome of standardized life-style change in a rehabilitation clinic. An observational study. Diabetes Metab Syndr Obes 2019;12:813-20. [PMID: 31213867 DOI: 10.2147/DMSO.S197495] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
184 Yamaoka K, Nemoto A, Tango T. Comparison of the Effectiveness of Lifestyle Modification with Other Treatments on the Incidence of Type 2 Diabetes in People at High Risk: A Network Meta-Analysis. Nutrients 2019;11:E1373. [PMID: 31248094 DOI: 10.3390/nu11061373] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
185 Adis Medical Writers. Aim to normalize glucose levels and reduce cardiovascular mortality when managing type 2 diabetes in the elderly. Drugs Ther Perspect 2019;35:271-277. [DOI: 10.1007/s40267-019-00619-7] [Reference Citation Analysis]
186 Zhang T, Su G, Mi SH, Yang HX, Xin W, Dai WL, Liu JH. Association Between Blood Glucose Variability and the Characteristics of Vulnerable Plaque in Elderly Non-ST Segment Elevation Acute Coronary Syndrome Patients. Int Heart J 2019;60:569-76. [PMID: 31019178 DOI: 10.1536/ihj.18-503] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
187 Liu Z, Yang Y, Dong W, Liu Q, Wang R, Pang J, Xia X, Zhu X, Liu S, Shen Z, Xiao Z, Liu Y. Investigation on the Enzymatic Profile of Mulberry Alkaloids by Enzymatic Study and Molecular Docking. Molecules 2019;24:E1776. [PMID: 31071910 DOI: 10.3390/molecules24091776] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 5.7] [Reference Citation Analysis]
188 Schlicker L, Boers HM, Dudek CA, Zhao G, Barua A, Trezzi JP, Meyer-Hermann M, Jacobs DM, Hiller K. Postprandial Metabolic Effects of Fiber Mixes Revealed by in vivo Stable Isotope Labeling in Humans. Metabolites 2019;9:E91. [PMID: 31067731 DOI: 10.3390/metabo9050091] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
189 Zand A, Ibrahim K, Patham B. Prediabetes: Why Should We Care? Methodist Debakey Cardiovasc J 2018;14:289-97. [PMID: 30788015 DOI: 10.14797/mdcj-14-4-289] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 8.3] [Reference Citation Analysis]
190 Qureshi M, Gammoh E, Shakil J, Robbins R. Update on Management of Type 2 Diabetes for Cardiologists. Methodist Debakey Cardiovasc J 2018;14:273-80. [PMID: 30788013 DOI: 10.14797/mdcj-14-4-273] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
191 Kyriachenko Y, Falalyeyeva T, Korotkyi O, Molochek N, Kobyliak N. Crosstalk between gut microbiota and antidiabetic drug action. World J Diabetes 2019; 10(3): 154-168 [PMID: 30891151 DOI: 10.4239/wjd.v10.i3.154] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 44] [Article Influence: 15.0] [Reference Citation Analysis]
192 Livesey G, Livesey H. Coronary Heart Disease and Dietary Carbohydrate, Glycemic Index, and Glycemic Load: Dose-Response Meta-analyses of Prospective Cohort Studies. Mayo Clin Proc Innov Qual Outcomes 2019;3:52-69. [PMID: 30899909 DOI: 10.1016/j.mayocpiqo.2018.12.007] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 13.3] [Reference Citation Analysis]
193 Ito T, Ichihashi T, Fujita H, Sugiura T, Yamamoto J, Kitada S, Nakasuka K, Kawada Y, Ohte N. The impact of intraday glucose variability on coronary artery spasm in patients with dysglycemia. Heart Vessels 2019;34:1250-7. [PMID: 30712094 DOI: 10.1007/s00380-019-01353-w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
194 Wang W, Lee ET, Howard BV, Devereux R, Zhang Y, Stoner JA. Large Cohort Data Based Cost-Effective Disease Prevention Design Strategy: Strong Heart Study. World J Cardiovasc Dis 2018;8:588-601. [PMID: 30687583 DOI: 10.4236/wjcd.2018.812058] [Reference Citation Analysis]
195 Fernando IT, Perera KI, Athauda SBP, Sivakanesan R, Kumar NS, Jayasinghe L. Heat stability of the in vitro inhibitory effect of spices on lipase, amylase, and glucosidase enzymes. Food Sci Nutr 2019;7:425-32. [PMID: 30847119 DOI: 10.1002/fsn3.797] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
196 Xie H, Zhao Q, Zhang X, Kang Q, Bai L. Comparative functional genomics of the acarbose producers reveals potential targets for metabolic engineering. Synth Syst Biotechnol 2019;4:49-56. [PMID: 30723817 DOI: 10.1016/j.synbio.2019.01.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
197 Nakanekar A, Kohli K, Tatke P. Ayurvedic polyherbal combination (PDBT) for prediabetes: A randomized double blind placebo controlled study. J Ayurveda Integr Med 2019;10:284-9. [PMID: 30661947 DOI: 10.1016/j.jaim.2018.05.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
198 Derevitskii IV, Kovalchuk SV. Analysis course of the disease of type 2 diabetes patients using Markov chains and clustering methods. Procedia Computer Science 2019;156:114-122. [DOI: 10.1016/j.procs.2019.08.186] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
199 Rigato M, Fadini GP, Avogaro A. Diabetes and the Cardiovascular System. Endocrinology 2019. [DOI: 10.1007/978-3-319-27316-7_6-2] [Reference Citation Analysis]
200 Chon DA, Oxman RT, Mullur RS, Weinreb JE. Diabetic Pharmacotherapies in Kidney Disease. Endocrine Disorders in Kidney Disease 2019. [DOI: 10.1007/978-3-319-97765-2_5] [Reference Citation Analysis]
201 Yin S, Shibata M, Hagiwara T. Extraction of Bioactive Compounds from Stems of <i>Undaria pinnatifida</i>. FSTR 2019;25:765-73. [DOI: 10.3136/fstr.25.765] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
202 Kohda Y, Matsumura H. Obesity-related hypertension and enhanced plasma orexin-A level are attenuated by the consumption of thiamine water in diabetic rats under cerebral oxidative stress conditions. Fundam Toxicol Sci 2019;6:383-390. [DOI: 10.2131/fts.6.383] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
203 Cook CB, Chakkera H. Diabetes Mellitus and Renal Transplantation. Endocrine Disorders in Kidney Disease 2019. [DOI: 10.1007/978-3-319-97765-2_6] [Reference Citation Analysis]
204 Mesures hygiéno-diététiques et états diabétiques. Diabetologie 2019. [DOI: 10.1016/b978-2-294-75889-8.00006-3] [Reference Citation Analysis]
205 Hanefeld M, Mertes G. Treatment: Alpha Glucosidase Inhibitors. Encyclopedia of Endocrine Diseases 2019. [DOI: 10.1016/b978-0-12-801238-3.65370-9] [Reference Citation Analysis]
206 Freichel M, Mengel K. Antidiabetika. Arzneiverordnungs-Report 2019 2019. [DOI: 10.1007/978-3-662-59046-1_15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
207 Rigato M, Fadini GP, Avogaro A. Diabetes and the Cardiovascular System. Endocrinology 2019. [DOI: 10.1007/978-3-319-27316-7_6-3] [Reference Citation Analysis]
208 Shukla A, Mandel L. A Patient with High Cardiometabolic Risk. Obesity Management 2019. [DOI: 10.1007/978-3-030-01039-3_3] [Reference Citation Analysis]
209 Al-qawasmeh RH, Tayyem RF. Dietary and Lifestyle Risk Factors and Metabolic Syndrome: Literature Review. Curr Res Nutr Food Sci 2018;6:594-608. [DOI: 10.12944/crnfsj.6.3.03] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
210 Moelands SV, Lucassen PL, Akkermans RP, De Grauw WJ, Van de Laar FA. Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus. Cochrane Database Syst Rev 2018;12:CD005061. [PMID: 30592787 DOI: 10.1002/14651858.CD005061.pub3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
211 American Diabetes Association. 3. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019;42:S29-33. [PMID: 30559229 DOI: 10.2337/dc19-S003] [Cited by in Crossref: 91] [Cited by in F6Publishing: 98] [Article Influence: 22.8] [Reference Citation Analysis]
212 Aguayo-Mazzucato C, Diaque P, Hernandez S, Rosas S, Kostic A, Caballero AE. Understanding the growing epidemic of type 2 diabetes in the Hispanic population living in the United States. Diabetes Metab Res Rev 2019;35:e3097. [PMID: 30445663 DOI: 10.1002/dmrr.3097] [Cited by in Crossref: 55] [Cited by in F6Publishing: 59] [Article Influence: 13.8] [Reference Citation Analysis]
213 Chin C, Hsieh S, Tseng VS. Effective Risk Assessment of Type 2 Diabetes Using Diagnostic Information Retrieval. 2018 Joint 10th International Conference on Soft Computing and Intelligent Systems (SCIS) and 19th International Symposium on Advanced Intelligent Systems (ISIS) 2018. [DOI: 10.1109/scis-isis.2018.00042] [Reference Citation Analysis]
214 Jafarian N, Sheikhha MH, Sahraee Z, Samadani AA. Investigation of HTTLPR gene polymorphism fluctuation in type II diabetes. Journal of Cellular Immunotherapy 2018;4:79-82. [DOI: 10.1016/j.jocit.2018.10.001] [Reference Citation Analysis]
215 Shintani H, Shintani T, Ashida H, Sato M. Calorie Restriction Mimetics: Upstream-Type Compounds for Modulating Glucose Metabolism. Nutrients 2018;10:E1821. [PMID: 30469486 DOI: 10.3390/nu10121821] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 9.8] [Reference Citation Analysis]
216 Adua E, Anto EO, Roberts P, Kantanka OS, Aboagye E, Wang W. The potential of N-glycosylation profiles as biomarkers for monitoring the progression of Type II diabetes mellitus towards diabetic kidney disease. J Diabetes Metab Disord 2018;17:233-46. [PMID: 30918859 DOI: 10.1007/s40200-018-0365-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
217 Rhee SY, Chon S, Ahn KJ, Woo JT; Korean Diabetes Prevention Study Investigators. Hospital-Based Korean Diabetes Prevention Study: A Prospective, Multi-Center, Randomized, Open-Label Controlled Study. Diabetes Metab J 2019;43:49-58. [PMID: 30398039 DOI: 10.4093/dmj.2018.0033] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
218 Xiang AH, Trigo E, Martinez M, Katkhouda N, Beale E, Wang X, Wu J, Chow T, Montgomery C, Nayak KS, Hendee F, Buchanan TA; RISE Consortium., RISE Collaborators. Impact of Gastric Banding Versus Metformin on β-Cell Function in Adults With Impaired Glucose Tolerance or Mild Type 2 Diabetes. Diabetes Care 2018;41:2544-51. [PMID: 30282699 DOI: 10.2337/dc18-1662] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
219 Echouffo-Tcheugui JB, Kengne AP, Ali MK. Issues in Defining the Burden of Prediabetes Globally. Curr Diab Rep 2018;18:105. [PMID: 30229351 DOI: 10.1007/s11892-018-1089-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
220 Dugan J, Cantillep A, Newberry K, Shubrook J. A call to action on prediabetes. JAAPA 2018;31:26-30. [PMID: 30204618 DOI: 10.1097/01.JAA.0000545064.33107.8f] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
221 Sakamoto M. Type 2 Diabetes and Glycemic Variability: Various Parameters in Clinical Practice. J Clin Med Res 2018;10:737-42. [PMID: 30214644 DOI: 10.14740/jocmr3556w] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
222 Tong YZ, Tong NW, Teng WP, Mu YM, Zhao JJ, Shan ZY, Ning G; Chinese Society of Endocrinology. Consensus on the Prevention of Type 2 Diabetes in Chinese Adults. Chin Med J (Engl) 2017;130:600-6. [PMID: 28229993 DOI: 10.4103/0366-6999.200532] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
223 Riyaphan J, Jhong CH, Lin SR, Chang CH, Tsai MJ, Lee DN, Sung PJ, Leong MK, Weng CF. Hypoglycemic Efficacy of Docking Selected Natural Compounds against α-Glucosidase and α-Amylase. Molecules 2018;23:E2260. [PMID: 30189596 DOI: 10.3390/molecules23092260] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
224 Luk AOY, Zee BCY, Chong M, Ozaki R, Rausch CW, Chan MHM, Ma RCW, Kong APS, Chow FCC, Chan JCN. A proof-of-concept study to evaluate the efficacy and safety of BTI320 on post-prandial hyperglycaemia in Chinese subjects with pre-diabetes. BMC Endocr Disord 2018;18:59. [PMID: 30170579 DOI: 10.1186/s12902-018-0288-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
225 Malunga LN, Joseph Thandapilly S, Ames N. Cereal‐derived phenolic acids and intestinal alpha glucosidase activity inhibition: Structural activity relationship. J Food Biochem 2018;42:e12635. [DOI: 10.1111/jfbc.12635] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
226 Adamska-Patruno E, Billing-Marczak K, Orlowski M, Gorska M, Krotkiewski M, Kretowski A. A Synergistic Formulation of Plant Extracts Decreases Postprandial Glucose and Insulin Peaks: Results from Two Randomized, Controlled, Cross-Over Studies Using Real-World Meals. Nutrients 2018;10:E956. [PMID: 30044398 DOI: 10.3390/nu10080956] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
227 Fajtova V. Short-Term Sitagliptin-Metformin Therapy is More Effective Than Metformin or Placebo in Prior Gestational Diabetic Women With Impaired Glucose Regulation. Endocrine Practice 2018;24:695-697. [DOI: 10.4158/ep-2018-0103] [Reference Citation Analysis]
228 Liang Q, Qu Z, Liang Y, Feng Q, Niu X, Bai T, Wang Y, Song Q, Adelson DL. Zuo Gui Wan Alters Expression of Energy Metabolism Genes and Prevents Cell Death in High-Glucose Loaded Mouse Embryos. Evid Based Complement Alternat Med 2018;2018:2409471. [PMID: 30046334 DOI: 10.1155/2018/2409471] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
229 LeBlanc ES, Pratley RE, Dawson-Hughes B, Staten MA, Sheehan PR, Lewis MR, Peters A, Kim SH, Chatterjee R, Aroda VR, Chadha C, Neff LM, Brodsky IG, Rosen C, Desouza CV, Foreyt JP, Hsia DS, Johnson KC, Raskin P, Kashyap SR, O'Neil P, Phillips LS, Rasouli N, Liao EP, Robbins DC, Pittas AG; D2d Research Group. Baseline Characteristics of the Vitamin D and Type 2 Diabetes (D2d) Study: A Contemporary Prediabetes Cohort That Will Inform Diabetes Prevention Efforts. Diabetes Care 2018;41:1590-9. [PMID: 29941495 DOI: 10.2337/dc18-0240] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
230 Takasu S, Parida IS, Onose S, Ito J, Ikeda R, Yamagishi K, Higuchi O, Tanaka F, Kimura T, Miyazawa T, Nakagawa K. Evaluation of the anti-hyperglycemic effect and safety of microorganism 1-deoxynojirimycin. PLoS One 2018;13:e0199057. [PMID: 29897983 DOI: 10.1371/journal.pone.0199057] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
231 Barbot M, Ceccato F, Scaroni C. Diabetes Mellitus Secondary to Cushing's Disease. Front Endocrinol (Lausanne) 2018;9:284. [PMID: 29915558 DOI: 10.3389/fendo.2018.00284] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
232 Theodorakis MJ, Coleman RL, Feng H, Chan J, Chiasson JL, Ge J, Gerstein HC, Huo Y, Lang Z, McMurray JJ, Rydén L, Schröder S, Tendera M, Tuomilehto J, Yang W, Hu D, Pan C, Holman RR; ACE Study Group. Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants. Am Heart J 2018;199:170-5. [PMID: 29754657 DOI: 10.1016/j.ahj.2017.09.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
233 Patton A, Church T, Wilson C, Thuma J, Goetz DJ, Berryman DE, List EO, Schwartz F, McCall KD. Phenylmethimazole abrogates diet-induced inflammation, glucose intolerance and NAFLD. J Endocrinol 2018;237:337-51. [PMID: 29666152 DOI: 10.1530/JOE-18-0078] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
234 Villa-Rodriguez JA, Kerimi A, Abranko L, Tumova S, Ford L, Blackburn RS, Rayner C, Williamson G. Acute metabolic actions of the major polyphenols in chamomile: an in vitro mechanistic study on their potential to attenuate postprandial hyperglycaemia. Sci Rep 2018;8:5471. [PMID: 29615674 DOI: 10.1038/s41598-018-23736-1] [Cited by in Crossref: 38] [Cited by in F6Publishing: 43] [Article Influence: 9.5] [Reference Citation Analysis]
235 Hongchang Y, Xueping W, Min W. Effect of conventional medical treatment plus Qigong exercise on type 2 diabetes mellitus in Chinese patients: A Meta-analysis. Journal of Traditional Chinese Medicine 2018;38:167-174. [DOI: 10.1016/j.jtcm.2018.04.002] [Reference Citation Analysis]
236 Bae JH, Kim LK, Min SH, Ahn CH, Cho YM. Postprandial glucose-lowering effect of premeal consumption of protein-enriched, dietary fiber-fortified bar in individuals with type 2 diabetes mellitus or normal glucose tolerance. J Diabetes Investig 2018;9:1110-8. [PMID: 29502350 DOI: 10.1111/jdi.12831] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
237 Haneda M, Noda M, Origasa H, Noto H, Yabe D, Fujita Y, Goto A, Kondo T, Araki E. Japanese Clinical Practice Guideline for Diabetes 2016. Diabetol Int 2018;9:1-45. [PMID: 30603347 DOI: 10.1007/s13340-018-0345-3] [Cited by in Crossref: 126] [Cited by in F6Publishing: 105] [Article Influence: 31.5] [Reference Citation Analysis]
238 Haneda M, Noda M, Origasa H, Noto H, Yabe D, Fujita Y, Goto A, Kondo T, Araki E. Japanese Clinical Practice Guideline for Diabetes 2016. J Diabetes Investig 2018. [PMID: 29582574 DOI: 10.1111/jdi.12810] [Cited by in Crossref: 137] [Cited by in F6Publishing: 144] [Article Influence: 34.3] [Reference Citation Analysis]
239 Alva ML. A Review of the Impacts of Different Approaches for Diabetes Prevention and a Framework for Making Investment Decisions. Int J Environ Res Public Health 2018;15:E522. [PMID: 29543711 DOI: 10.3390/ijerph15030522] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
240 Kiss R, Szabó K, Gesztelyi R, Somodi S, Kovács P, Szabó Z, Németh J, Priksz D, Kurucz A, Juhász B, Szilvássy Z. Insulin-Sensitizer Effects of Fenugreek Seeds in Parallel with Changes in Plasma MCH Levels in Healthy Volunteers. Int J Mol Sci 2018;19:E771. [PMID: 29518003 DOI: 10.3390/ijms19030771] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
241 Schnell O, Standl E, Catrinoiu D, Genovese S, Lalic N, Lalic K, Skrha J, Valensi P, Ceriello A. Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol 2018;17:30. [PMID: 29458368 DOI: 10.1186/s12933-018-0667-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
242 Jeon JY, Lee SJ, Lee S, Kim SJ, Han SJ, Kim HJ, Kim DJ, Kim YS, Woo JT, Ahn KJ, Nam M, Baik SH, Park Y, Lee KW. Failure of monotherapy in clinical practice in patients with type 2 diabetes: The Korean National Diabetes Program. J Diabetes Investig 2018;9:1144-52. [PMID: 29328551 DOI: 10.1111/jdi.12801] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
243 Fadini GP, Sarangdhar M, Avogaro A. Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System. BMJ Open Diabetes Res Care 2018;6:e000475. [PMID: 29449951 DOI: 10.1136/bmjdrc-2017-000475] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
244 Cehic MG, Nundall N, Greenfield JR, Macdonald PS. Management Strategies for Posttransplant Diabetes Mellitus after Heart Transplantation: A Review. J Transplant. 2018;2018:1025893. [PMID: 29623219 DOI: 10.1155/2018/1025893] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
245 Weng J, Ji L, Jia W, Lu J, Zhou Z, Zou D, Zhu D, Chen L, Chen L, Guo L, Guo X, Ji Q, Li Q, Li X, Liu J, Ran X, Shan Z, Shi L, Song G, Yang L, Yang Y, Yang W; Chinese Diabetes Society. Standards of care for type 2 diabetes in China. Diabetes Metab Res Rev 2016;32:442-58. [PMID: 27464265 DOI: 10.1002/dmrr.2827] [Cited by in Crossref: 187] [Cited by in F6Publishing: 204] [Article Influence: 46.8] [Reference Citation Analysis]
246 Akolade JO, Na’allah A, Sulyman AO, Abdulazeez AT, Atoti AO, Isiaku MB. Antidiabetic Screening of Phenolic-rich Extracts of Selected Medicinal Spices. Iran J Sci Technol Trans Sci 2019;43:357-67. [DOI: 10.1007/s40995-017-0410-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
247 Li YR, Tsai SS, Chen DY, Chen ST, Sun JH, Chang HY, Liou MJ, Chen TH. Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke. Cardiovasc Diabetol 2018;17:2. [PMID: 29301579 DOI: 10.1186/s12933-017-0655-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
248 Hummel S, Beyerlein A, Pfirrmann M, Hofelich A, Much D, Hivner S, Bunk M, Herbst M, Peplow C, Walter M, Kohn D, Hummel N, Kratzsch J, Hummel M, Füchtenbusch M, Hasford J, Ziegler AG; PINGUIN Study Group. Efficacy of vildagliptin for prevention of postpartum diabetes in women with a recent history of insulin-requiring gestational diabetes: A phase II, randomized, double-blind, placebo-controlled study. Mol Metab 2018;9:168-75. [PMID: 29396374 DOI: 10.1016/j.molmet.2017.12.015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
249 Rigato M, Fadini GP, Avogaro A. Diabetes and the Cardiovascular System. Endocrinology 2018. [DOI: 10.1007/978-3-319-44433-8_6] [Reference Citation Analysis]
250 Freichel M, Mengel K. Antidiabetika. Arzneiverordnungs-Report 2018 2018. [DOI: 10.1007/978-3-662-57386-0_14] [Reference Citation Analysis]
251 Bianchi C, Daniele G, Dardano A, Del Prato S. Treatment with Oral Drugs. Endocrinology 2018. [DOI: 10.1007/978-3-319-45015-5_19] [Reference Citation Analysis]
252 Knowler WC. Prevention of Type 2 Diabetes. Endocrinology 2018. [DOI: 10.1007/978-3-319-27317-4_16-1] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
253 Bianchi C, Daniele G, Dardano A, Del Prato S. Treatment with Oral Drugs. Endocrinology 2018. [DOI: 10.1007/978-3-319-27317-4_19-1] [Reference Citation Analysis]
254 Moore LE. Type 2 Diabetes. Diabetes in Pregnancy 2018. [DOI: 10.1007/978-3-319-65518-5_5] [Reference Citation Analysis]
255 Marx N, Reith S. Managing Chronic Coronary Artery Disease in Patients with Diabetes. Chronic Coronary Artery Disease 2018. [DOI: 10.1016/b978-0-323-42880-4.00024-8] [Reference Citation Analysis]
256 Bae JH, Cho YM. Effect of Nutrient Preload and Food Order on Glucose, Insulin, and Gut Hormones. J Korean Diabetes 2018;19:193. [DOI: 10.4093/jkd.2018.19.4.193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
257 Perreault L. Prevention of Type 2 Diabetes. Contemporary Diabetes 2018. [DOI: 10.1007/978-3-319-61013-9_2] [Reference Citation Analysis]
258 Joung H, Kwon H. Pharmacological Intervention for the Prevention of Diabetes Mellitus. J Korean Diabetes 2018;19:140. [DOI: 10.4093/jkd.2018.19.3.140] [Reference Citation Analysis]
259 Rigato M, Fadini GP, Avogaro A. Diabetes and the Cardiovascular System. Endocrinology 2018. [DOI: 10.1007/978-3-319-27316-7_6-1] [Reference Citation Analysis]
260 Riccardi G, Vitale M, Giacco R. Treatment of Diabetes with Lifestyle Changes: Diet. Endocrinology 2018. [DOI: 10.1007/978-3-319-27317-4_18-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
261 Riccardi G, Vitale M, Giacco R. Treatment of Diabetes with Lifestyle Changes: Diet. Endocrinology 2018. [DOI: 10.1007/978-3-319-45015-5_18] [Reference Citation Analysis]
262 Knowler WC. Prevention of Type 2 Diabetes. Endocrinology 2018. [DOI: 10.1007/978-3-319-45015-5_16] [Reference Citation Analysis]
263 Haw JS, Galaviz KI, Straus AN, Kowalski AJ, Magee MJ, Weber MB, Wei J, Narayan KMV, Ali MK. Long-term Sustainability of Diabetes Prevention Approaches: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Intern Med 2017;177:1808-17. [PMID: 29114778 DOI: 10.1001/jamainternmed.2017.6040] [Cited by in Crossref: 167] [Cited by in F6Publishing: 173] [Article Influence: 33.4] [Reference Citation Analysis]
264 Faure S. Les inhibiteurs des alpha-glucosidases. Actualités Pharmaceutiques 2017;56:18-20. [DOI: 10.1016/j.actpha.2017.09.021] [Reference Citation Analysis]
265 Nurhayati R, Miftakhussolikhah, Frediansyah A, Rachmah DL. Lactic Acid Bacteria Producing Inhibitor of Alpha Glucosidase Isolated from Ganyong ( Canna Edulis ) and Kimpul ( Xanthosoma sagittifolium ). IOP Conf Ser : Earth Environ Sci 2017;101:012009. [DOI: 10.1088/1755-1315/101/1/012009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
266 Pal DK, Bhalla A, Bammidi S, Telles S, Kohli A, Kumar S, Devi P, Kaur N, Sharma K, Kumar R, Malik N, Thakur V, Bhargava GG, Goyal AK, Devi G, Chauhan S, Singh G, Ahmad S, Joshi M, Narwal S, Sharma K, Tyagi R, Modgil S, Bali P, Bhatt V, Sharma J, Singh A, Negi J, Rajesh SK, Sharma G, Sharma P, Vats R, Nagarathna R, Bhavanani AB, Burugupalli KM, Vetrivendan R, Nagendra H, Anand A. Can Yoga-Based Diabetes Management Studies Facilitate Integrative Medicine in India Current Status and Future Directions. Integr Med Int 2019;4:125-41. [DOI: 10.1159/000479816] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
267 Gu Y, Wang X, Li J, Zhang Y, Zhong H, Liu R, Zhang D, Feng Q, Xie X, Hong J, Ren H, Liu W, Ma J, Su Q, Zhang H, Yang J, Wang X, Zhao X, Gu W, Bi Y, Peng Y, Xu X, Xia H, Li F, Xu X, Yang H, Xu G, Madsen L, Kristiansen K, Ning G, Wang W. Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment. Nat Commun 2017;8:1785. [PMID: 29176714 DOI: 10.1038/s41467-017-01682-2] [Cited by in Crossref: 215] [Cited by in F6Publishing: 220] [Article Influence: 43.0] [Reference Citation Analysis]
268 Cvetanović A, Zeković Z, Švarc-gajić J, Razić S, Damjanović A, Zengin G, Delerue-matos C, Moreira M. A new source for developing multi-functional products: biological and chemical perspectives on subcritical water extracts of Sambucus ebulus L.: A new source for developing multi-functional products. J Chem Technol Biotechnol 2018;93:1097-104. [DOI: 10.1002/jctb.5468] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
269 Luthra T, Agarwal R, Estari M, Adepally U, Sen S. A novel library of -arylketones as potential inhibitors of α-glucosidase: Their design, synthesis, in vitro and in vivo studies. Sci Rep 2017;7:13246. [PMID: 29038580 DOI: 10.1038/s41598-017-13798-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
270 Uryas’ev OM, Morgunova ZA, Gorbunova DY, Shcherbakova ON, Pyko AA. Modern aspects of the treatment and prevention of diabetes type 2 in patients with metabolic syndrome. Kazan Med J 2017;98:770-774. [DOI: 10.17750/kmj2017-770] [Reference Citation Analysis]
271 Pang B, Zhang Y, Liu J, He LS, Zheng YJ, Lian FM, Tong XL. Prevention of Type 2 Diabetes with the Chinese Herbal Medicine Tianqi Capsule: A Systematic Review and Meta-Analysis. Diabetes Ther 2017;8:1227-42. [PMID: 29027648 DOI: 10.1007/s13300-017-0316-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
272 Borczak B, Sikora M, Sikora E, Dobosz A, Kapusta-duch J. Glycaemic index of wheat bread: Glycaemic index of bread. Starch - Stärke 2018;70:1700022. [DOI: 10.1002/star.201700022] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
273 Hanefeld M, Pistrosch F, Bornstein SR, Birkenfeld AL. The metabolic vascular syndrome - guide to an individualized treatment. Rev Endocr Metab Disord 2016;17:5-17. [PMID: 26956847 DOI: 10.1007/s11154-016-9345-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
274 Nauck MA, Meier JJ. Break point instead of ACE: acarbose, post-load glycaemic excursions, and cardiovascular events. Lancet Diabetes Endocrinol 2017;5:843-5. [PMID: 28917542 DOI: 10.1016/S2213-8587(17)30318-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
275 Herman WH. The global agenda for the prevention of type 2 diabetes. Nutr Rev 2017;75:13-8. [PMID: 28049746 DOI: 10.1093/nutrit/nuw034] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
276 Lautenbach A, Aberle J. Metabolische Chirurgie zur Prävention des Typ-2-Diabetes. Diabetologe 2017;13:408-411. [DOI: 10.1007/s11428-017-0248-0] [Reference Citation Analysis]
277 Müller UA. Therapie postprandialer Blutzuckerspitzen – sinnvoll oder nur Blutzuckerkosmetik? Diabetologe 2017;13:427-432. [DOI: 10.1007/s11428-017-0260-4] [Reference Citation Analysis]
278 Wang SL, Dong WB, Dong XL, Zhu WM, Wang FF, Han F, Yan X. Comparison of twelve single-drug regimens for the treatment of type 2 diabetes mellitus. Oncotarget 2017;8:72700-13. [PMID: 29069819 DOI: 10.18632/oncotarget.20282] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
279 Hao L, Schlussel Y, Fieselmann K, Schneider SH, Shapses SA. Appetite and Gut Hormones Response to a Putative α-Glucosidase Inhibitor, Salacia Chinensis, in Overweight/Obese Adults: A Double Blind Randomized Controlled Trial. Nutrients 2017;9:E869. [PMID: 28805670 DOI: 10.3390/nu9080869] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
280 Aroda VR, Knowler WC, Crandall JP, Perreault L, Edelstein SL, Jeffries SL, Molitch ME, Pi-Sunyer X, Darwin C, Heckman-Stoddard BM, Temprosa M, Kahn SE, Nathan DM; Diabetes Prevention Program Research Group. Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. Diabetologia 2017;60:1601-11. [PMID: 28770322 DOI: 10.1007/s00125-017-4361-9] [Cited by in Crossref: 88] [Cited by in F6Publishing: 94] [Article Influence: 17.6] [Reference Citation Analysis]
281 Hodes RJ, Sierra F, Austad SN, Epel E, Neigh GN, Erlandson KM, Schafer MJ, LeBrasseur NK, Wiley C, Campisi J, Sehl ME, Scalia R, Eguchi S, Kasinath BS, Halter JB, Cohen HJ, Demark-Wahnefried W, Ahles TA, Barzilai N, Hurria A, Hunt PW. Disease drivers of aging. Ann N Y Acad Sci 2016;1386:45-68. [PMID: 27943360 DOI: 10.1111/nyas.13299] [Cited by in Crossref: 78] [Cited by in F6Publishing: 80] [Article Influence: 15.6] [Reference Citation Analysis]
282 Owens DR, Monnier L, Hanefeld M. A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus. Diabetes Obes Metab 2017;19:1645-54. [PMID: 28474401 DOI: 10.1111/dom.12998] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
283 Sharma DC, Asirvatham A, Singh P. Dose Modification of Antidiabetic Agents in Patients with Type 2 Diabetes Mellitus and Heart Failure. Indian J Endocrinol Metab 2017;21:618-29. [PMID: 28670548 DOI: 10.4103/ijem.IJEM_442_16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
284 Brannick B, Wynn A, Dagogo-Jack S. Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications. Exp Biol Med (Maywood) 2016;241:1323-31. [PMID: 27302176 DOI: 10.1177/1535370216654227] [Cited by in Crossref: 76] [Cited by in F6Publishing: 81] [Article Influence: 15.2] [Reference Citation Analysis]
285 Mirasol R, Thai AC, Salahuddin AA, Tan K, Deerochanawong C, Mohamed M, Saraswati MR, Sethi BK, Shah S, Soetedjo NN, Suraamornkul S, Tan R, Uddin F. A Consensus of Key Opinion Leaders on the Management of Pre-diabetes in the Asia-Pacific Region. J ASEAN Fed Endocr Soc 2017;32:6-12. [PMID: 33442078 DOI: 10.15605/jafes.032.01.02] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
286 Liu Z, Zhao X, Sun W, Wang Y, Liu S, Kang L. Metformin combined with acarbose vs. single medicine in the treatment of type 2 diabetes: A meta-analysis. Exp Ther Med 2017;13:3137-45. [PMID: 28588669 DOI: 10.3892/etm.2017.4333] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
287 Shi YL, Liu WJ, Zhang XF, Su WJ, Chen NN, Lu SH, Wang LY, Shi XL, Li ZB, Yang SY. Effect of Chinese Herbal Medicine Jinlida Granule in Treatment of Patients with Impaired Glucose Tolerance. Chin Med J (Engl) 2016;129:2281-6. [PMID: 27647185 DOI: 10.4103/0366-6999.190676] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
288 Krentz AJ, Sinclair AJ. Glucose-lowering drugs. Diabetes in Old Age 2017. [DOI: 10.1002/9781118954621.ch21] [Reference Citation Analysis]
289 Raffaghello L, Longo V. Metabolic Alterations at the Crossroad of Aging and Oncogenesis. Int Rev Cell Mol Biol 2017;332:1-42. [PMID: 28526131 DOI: 10.1016/bs.ircmb.2017.01.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
290 Liu X, Shi J, Wang A, Song Q, Huang Z, Zhu C, Du X, Zhang Y, Chen S, Wang X, Wu S. Changes in ideal cardiovascular health status and risk of new-onset type 2 diabetes: The Kailuan prospective study. Medicine (Baltimore) 2016;95:e4571. [PMID: 27559955 DOI: 10.1097/MD.0000000000004571] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
291 Malik M, Jarosz S. Synthesis of polyhydroxylated decalins via two consecutive one-pot reactions: 1,4-addition/aldol reaction followed by RCM/syn-dihydroxylation. Beilstein J Org Chem 2016;12:2602-8. [PMID: 28144329 DOI: 10.3762/bjoc.12.255] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
292 Xu J, Rajaratnam R. Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes. Cardiovasc Diabetol. 2017;16:18. [PMID: 28148253 DOI: 10.1186/s12933-017-0499-5] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 6.8] [Reference Citation Analysis]
293 Belhadj-mostefa A, Bouafia S, Valensi P. Le score FINDRISK prédit une dysglycémie méconnue. Influence du sexe. Médecine des Maladies Métaboliques 2017;11:87-92. [DOI: 10.1016/s1957-2557(17)30024-x] [Reference Citation Analysis]
294 Zhang X, Fang Z, Zhang C, Xia H, Jie Z, Han X, Chen Y, Ji L. Effects of Acarbose on the Gut Microbiota of Prediabetic Patients: A Randomized, Double-blind, Controlled Crossover Trial. Diabetes Ther. 2017;8:293-307. [PMID: 28130771 DOI: 10.1007/s13300-017-0226-y] [Cited by in Crossref: 87] [Cited by in F6Publishing: 89] [Article Influence: 17.4] [Reference Citation Analysis]
295 Harumi Higuchi Dos Santos M, Sharma A, Sun JL, Pieper K, McMurray JJ, Holman RR, Lopes RD. International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial. J Am Heart Assoc 2017;6:e003892. [PMID: 28087508 DOI: 10.1161/JAHA.116.003892] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
296 Luo Y, Paul SK, Zhou X, Chang C, Chen W, Guo X, Yang J, Ji L, Wang H. Rationale, Design, and Baseline Characteristics of Beijing Prediabetes Reversion Program: A Randomized Controlled Clinical Trial to Evaluate the Efficacy of Lifestyle Intervention and/or Pioglitazone in Reversion to Normal Glucose Tolerance in Prediabetes. J Diabetes Res 2017;2017:7602408. [PMID: 28168204 DOI: 10.1155/2017/7602408] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
297 Valenzuela-garcía LF, Matsuzawa Y, Lerman A. The Effect of Cardiovascular Risk Factors on the Coronary Circulation. Physiological Assessment of Coronary Stenoses and the Microcirculation 2017. [DOI: 10.1007/978-1-4471-5245-3_6] [Reference Citation Analysis]
298 Freichel M, Mengel K. Antidiabetika. Arzneiverordnungs-Report 2017 2017. [DOI: 10.1007/978-3-662-54630-7_14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
299 Chen X, Lu Y, Fan Y, Shen Y. Voglibose. Validamycin and its Derivatives 2017. [DOI: 10.1016/b978-0-08-100999-4.00005-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
300 Nakamura S, Shimada K, Tanabe G, Muraoka O, Nakanishi I. Computational Study on the Comparative Differences in the Activity of Inhibitors of Human versus Rat Alpha-Glucosidase. OJMC 2017;07:19-28. [DOI: 10.4236/ojmc.2017.72002] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
301 Dagogo-jack S. Primary Prevention of Type 2 Diabetes: An Imperative for Developing Countries. Diabetes Mellitus in Developing Countries and Underserved Communities 2017. [DOI: 10.1007/978-3-319-41559-8_2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
302 Horton ES. Prevention of Type 2 Diabetes Mellitus. Principles of Diabetes Mellitus 2017. [DOI: 10.1007/978-3-319-18741-9_50] [Reference Citation Analysis]
303 Ríos J, Andújar I. Lanostanoids from Fungi as Potential Medicinal Agents. Fungal Metabolites 2017. [DOI: 10.1007/978-3-319-25001-4_19] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
304 Bray GA. Obesity and the Risk for Type 2 Diabetes. Nutrition in the Prevention and Treatment of Disease 2017. [DOI: 10.1016/b978-0-12-802928-2.00030-8] [Reference Citation Analysis]
305 Shi BY. The importance and strategy of diabetes prevention. Chronic Dis Transl Med 2016;2:204-7. [PMID: 29063043 DOI: 10.1016/j.cdtm.2016.11.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
306 American Diabetes Association. 8. Pharmacologic Approaches to Glycemic Treatment. Diabetes Care 2017;40:S64-74. [PMID: 27979895 DOI: 10.2337/dc17-S011] [Cited by in Crossref: 273] [Cited by in F6Publishing: 293] [Article Influence: 45.5] [Reference Citation Analysis]
307 Ma RC, Tong PC. Epidemiology of Type 2 Diabetes. Textbook of Diabetes 2016. [DOI: 10.1002/9781118924853.ch4] [Reference Citation Analysis]
308 Bailey CJ, Krentz AJ. Oral Glucose-Lowering Agents. Textbook of Diabetes 2016. [DOI: 10.1002/9781118924853.ch31] [Reference Citation Analysis]
309 Masumoto N, Otsuki H, Iwakawa S, Inada S, Goya K, Sho H, Suzuki S, Kurebayashi S, Hashimoto K, Koga M. Effects of alogliptin on the ratio of glycated albumin to HbA1c in patients with type 2 diabetes mellitus. Diabetol Int 2017;8:212-7. [PMID: 30603324 DOI: 10.1007/s13340-016-0298-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
310 Ren F, Chen L, Tong Q. Highly improved acarbose production of Actinomyces through the combination of ARTP and penicillin susceptible mutant screening. World J Microbiol Biotechnol 2017;33:16. [PMID: 27896580 DOI: 10.1007/s11274-016-2156-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
311 Brewer RA, Gibbs VK, Smith DL Jr. Targeting glucose metabolism for healthy aging. Nutr Healthy Aging 2016;4:31-46. [PMID: 28035340 DOI: 10.3233/NHA-160007] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 7.5] [Reference Citation Analysis]
312 . Glycemic Index and Diabetes Mellitus. In: Philippou E, editor. The Glycemic Index. Taylor & Francis Group: CRC Press; 2016. pp. 45-77. [DOI: 10.1201/9781315371764-5] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
313 Liu S, Yu Z, Zhu H, Zhang W, Chen Y. In vitro α-glucosidase inhibitory activity of isolated fractions from water extract of Qingzhuan dark tea. BMC Complement Altern Med 2016;16:378. [PMID: 27681250 DOI: 10.1186/s12906-016-1361-0] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 9.0] [Reference Citation Analysis]
314 Glycemic Index and Cardiovascular Disease Risk Prevention and Management. The Glycemic Index 2016. [DOI: 10.1201/9781315371764-6] [Reference Citation Analysis]
315 Castro-Acosta ML, Smith L, Miller RJ, McCarthy DI, Farrimond JA, Hall WL. Drinks containing anthocyanin-rich blackcurrant extract decrease postprandial blood glucose, insulin and incretin concentrations. J Nutr Biochem 2016;38:154-61. [PMID: 27764725 DOI: 10.1016/j.jnutbio.2016.09.002] [Cited by in Crossref: 78] [Cited by in F6Publishing: 80] [Article Influence: 13.0] [Reference Citation Analysis]
316 Singh KA, Devi R K B, Singh KL. Β-CELL FAILURE AND PRESERVATION IN TYPE 2 DIABETES MELLITUS: A REVIEW. jemds 2016;5:5315-5321. [DOI: 10.14260/jemds/2016/1204] [Reference Citation Analysis]
317 Zhang L, Chen Q, Li L, Kwong JS, Jia P, Zhao P, Wang W, Zhou X, Zhang M, Sun X. Alpha-glucosidase inhibitors and hepatotoxicity in type 2 diabetes: a systematic review and meta-analysis. Sci Rep 2016;6:32649. [PMID: 27596383 DOI: 10.1038/srep32649] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 6.5] [Reference Citation Analysis]
318 Espinoza SE, Wang CP, Tripathy D, Clement SC, Schwenke DC, Banerji MA, Bray GA, Buchanan TA, Henry RR, Kitabchi AE, Mudaliar S, Stentz FB, Reaven PD, DeFronzo RA, Musi N. Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance. Age (Dordr) 2016;38:485-93. [PMID: 27585671 DOI: 10.1007/s11357-016-9946-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
319 Rezai M, Jamshidi M, Mohammadbeigi R, Seyedoshohadaei F, Mohammadipour S, Moradi G. Comparing the Effect of Metformin and Acarbose Accompanying Clomiphene on the Successful Ovulation Induction in Infertile Women with Polycystic Ovary Syndrome. Glob J Health Sci 2016;8:54516. [PMID: 27157179 DOI: 10.5539/gjhs.v8n9p281] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
320 Newman JC, Milman S, Hashmi SK, Austad SN, Kirkland JL, Halter JB, Barzilai N. Strategies and Challenges in Clinical Trials Targeting Human Aging. J Gerontol A Biol Sci Med Sci 2016;71:1424-34. [PMID: 27535968 DOI: 10.1093/gerona/glw149] [Cited by in Crossref: 99] [Cited by in F6Publishing: 101] [Article Influence: 16.5] [Reference Citation Analysis]
321 Naidoo P, Wing J, Rambiritch V. Effect of Sitagliptin and Metformin on Prediabetes Progression to Type 2 Diabetes - A Randomized, Double-Blind, Double-Arm, Multicenter Clinical Trial: Protocol for the Sitagliptin and Metformin in PreDiabetes (SiMePreD) Study. JMIR Res Protoc 2016;5:e145. [PMID: 27491324 DOI: 10.2196/resprot.5073] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
322 Li M, Huang X, Ye H, Chen Y, Yu J, Yang J, Zhang X. Randomized, Double-Blinded, Double-Dummy, Active-Controlled, and Multiple-Dose Clinical Study Comparing the Efficacy and Safety of Mulberry Twig (Ramulus Mori, Sangzhi) Alkaloid Tablet and Acarbose in Individuals with Type 2 Diabetes Mellitus. Evid Based Complement Alternat Med 2016;2016:7121356. [PMID: 27547230 DOI: 10.1155/2016/7121356] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
323 Tahrani AA, Barnett AH, Bailey CJ. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat Rev Endocrinol. 2016;12:566-592. [PMID: 27339889 DOI: 10.1038/nrendo.2016.86] [Cited by in Crossref: 215] [Cited by in F6Publishing: 223] [Article Influence: 35.8] [Reference Citation Analysis]
324 Stull AJ. Lifestyle Approaches and Glucose Intolerance. Am J Lifestyle Med 2016;10:406-16. [PMID: 30202302 DOI: 10.1177/1559827614554186] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
325 Boers HM, MacAulay K, Murray P, Seijen Ten Hoorn J, Hoogenraad AR, Peters HPF, Vente-Spreeuwenberg MAM, Mela DJ. Efficacy of different fibres and flour mixes in South-Asian flatbreads for reducing post-prandial glucose responses in healthy adults. Eur J Nutr 2017;56:2049-60. [PMID: 27324141 DOI: 10.1007/s00394-016-1242-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
326 Kodali VRR, Ali I. Prediabetes: the cat is out! Int J Diabetes Dev Ctries 2016;36:143-5. [DOI: 10.1007/s13410-016-0513-6] [Reference Citation Analysis]
327 Wang A, Chen G, Su Z, Liu X, Liu X, Li H, Luo Y, Tao L, Guo J, Liu L, Chen S, Wu S, Guo X. Risk scores for predicting incidence of type 2 diabetes in the Chinese population: the Kailuan prospective study. Sci Rep 2016;6:26548. [PMID: 27221651 DOI: 10.1038/srep26548] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
328 Ahn CH, Yoon JW, Hahn S, Moon MK, Park KS, Cho YM. Evaluation of Non-Laboratory and Laboratory Prediction Models for Current and Future Diabetes Mellitus: A Cross-Sectional and Retrospective Cohort Study. PLoS One 2016;11:e0156155. [PMID: 27214034 DOI: 10.1371/journal.pone.0156155] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
329 Song X, Qiu M, Zhang X, Wang H, Tong W, Ju L, Gu L, Sun S, Zhang H, Wang W, Tian J. Gender-related affecting factors of prediabetes on its 10-year outcome. BMJ Open Diabetes Res Care. 2016;4:e000169. [PMID: 27239315 DOI: 10.1136/bmjdrc-2015-000169] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
330 Scherbaum WA. α-Glukosidase-Hemmer und Thiazolidindione (Glitazone). Diabetologe 2016;12:178-183. [DOI: 10.1007/s11428-016-0085-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
331 Naik D, Thomas N. Yoga- a potential solution for diabetes & metabolic syndrome. Indian J Med Res 2015;141:753-6. [PMID: 26205017 DOI: 10.4103/0971-5916.160689] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
332 Zhang M, Zhang H, Wang C, Ren Y, Wang B, Zhang L, Yang X, Zhao Y, Han C, Pang C, Yin L, Xue Y, Zhao J, Hu D. Development and Validation of a Risk-Score Model for Type 2 Diabetes: A Cohort Study of a Rural Adult Chinese Population. PLoS One 2016;11:e0152054. [PMID: 27070555 DOI: 10.1371/journal.pone.0152054] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
333 Hostalek U, Gwilt M, Hildemann S. Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention. Drugs 2015;75:1071-94. [PMID: 26059289 DOI: 10.1007/s40265-015-0416-8] [Cited by in Crossref: 143] [Cited by in F6Publishing: 109] [Article Influence: 23.8] [Reference Citation Analysis]
334 Patel PA, Scott CG, Rodeheffer RJ, Chen HH. The Natural History of Patients With Isolated Metabolic Syndrome. Mayo Clin Proc 2016;91:623-33. [PMID: 27063063 DOI: 10.1016/j.mayocp.2016.02.026] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
335 Sun S, Kadouh HC, Zhu W, Zhou K. Bioactivity-guided isolation and purification of α-glucosidase inhibitor, 6-O-D-glycosides, from Tinta Cão grape pomace. J Funct Foods 2016;23:573-9. [PMID: 30381790 DOI: 10.1016/j.jff.2016.03.009] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
336 Manaf A, Tjandrawinata RR, Malinda D. Insulin sensitizer in prediabetes: a clinical study with DLBS3233, a combined bioactive fraction of Cinnamomum burmanii and Lagerstroemia speciosa. Drug Des Devel Ther 2016;10:1279-89. [PMID: 27099473 DOI: 10.2147/DDDT.S97568] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
337 Luo G. Automatically explaining machine learning prediction results: a demonstration on type 2 diabetes risk prediction. Health Inf Sci Syst 2016;4:2. [PMID: 26958341 DOI: 10.1186/s13755-016-0015-4] [Cited by in Crossref: 63] [Cited by in F6Publishing: 64] [Article Influence: 10.5] [Reference Citation Analysis]
338 Ou HT, Chang KC, Li CY, Wu JS. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study. Cardiovasc Diabetol 2016;15:41. [PMID: 26932742 DOI: 10.1186/s12933-016-0350-4] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 8.5] [Reference Citation Analysis]
339 Kirkland JL. Translating the Science of Aging into Therapeutic Interventions. Cold Spring Harb Perspect Med 2016;6:a025908. [PMID: 26931808 DOI: 10.1101/cshperspect.a025908] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 7.0] [Reference Citation Analysis]
340 McCoy RG, Nori VS, Smith SA, Hane CA. Development and Validation of HealthImpact: An Incident Diabetes Prediction Model Based on Administrative Data. Health Serv Res 2016;51:1896-918. [PMID: 26898782 DOI: 10.1111/1475-6773.12461] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
341 Hanefeld M, Monnier L, Schnell O, Owens D. Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials. Diabetes Ther 2016;7:187-201. [DOI: 10.1007/s13300-016-0153-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
342 Rasmussen SS, Johansen NB, Witte DR, Borch-Johnsen K, Sandbaek A, Lauritzen T, Jørgensen ME. Incidence of register-based diabetes 10 years after a stepwise diabetes screening programme: the ADDITION-Denmark study. Diabetologia 2016;59:989-97. [PMID: 26857739 DOI: 10.1007/s00125-016-3887-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
343 Augustin LS, Chiavaroli L, Campbell J, Ezatagha A, Jenkins AL, Esfahani A, Kendall CW. Post-prandial glucose and insulin responses of hummus alone or combined with a carbohydrate food: a dose-response study. Nutr J 2016;15:13. [PMID: 26818604 DOI: 10.1186/s12937-016-0129-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
344 Anand SS, Hawkes C, de Souza RJ, Mente A, Dehghan M, Nugent R, Zulyniak MA, Weis T, Bernstein AM, Krauss RM, Kromhout D, Jenkins DJA, Malik V, Martinez-Gonzalez MA, Mozaffarian D, Yusuf S, Willett WC, Popkin BM. Food Consumption and its Impact on Cardiovascular Disease: Importance of Solutions Focused on the Globalized Food System: A Report From the Workshop Convened by the World Heart Federation. J Am Coll Cardiol 2015;66:1590-614. [PMID: 26429085 DOI: 10.1016/j.jacc.2015.07.050] [Cited by in Crossref: 271] [Cited by in F6Publishing: 222] [Article Influence: 45.2] [Reference Citation Analysis]
345 Freichel M, Mengel K. Antidiabetika. Arzneiverordnungs-Report 2016 2016. [DOI: 10.1007/978-3-662-50351-5_14] [Reference Citation Analysis]
346 Riaz M, Zia-ul-haq M, Saad B. The Role of Anthocyanins in Obesity and Diabetes. Anthocyanins and Human Health: Biomolecular and therapeutic aspects 2016. [DOI: 10.1007/978-3-319-26456-1_8] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
347 Numao S. A single bout of exercise and postprandial hyperglycemia caused by high-fat diet. JPFSM 2016;5:181-185. [DOI: 10.7600/jpfsm.5.181] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
348 Kirkland JL, Tchkonia T. The Way Forward: Translation. Advances in Geroscience 2016. [DOI: 10.1007/978-3-319-23246-1_19] [Reference Citation Analysis]
349 Bishop DB, O’connor PJ, Kidney RS, Haire-joshu D. 12. Diabetes. CHRONIC DISEASE EPIDEMIOLOGY, PREVENTION, AND CONTROL, 4th edition 2016. [DOI: 10.2105/9780875532783ch12] [Reference Citation Analysis]
350 Hivert M, Knowler WC. Diabetes Prevention. The Genetics of Type 2 Diabetes and Related Traits 2016. [DOI: 10.1007/978-3-319-01574-3_25] [Reference Citation Analysis]
351 Lacetera A, Galante S, Jiménez-barbero J, Martín-santamaría S. Glycans in Medicinal Chemistry. Reference Module in Chemistry, Molecular Sciences and Chemical Engineering 2016. [DOI: 10.1016/b978-0-12-409547-2.11712-3] [Reference Citation Analysis]
352 Stirban OA, Tschöpe D. Wie kriegt man das Gefäßrisiko in den Griff? Info Diabetol 2015;9:34-45. [DOI: 10.1007/s15034-015-0499-z] [Reference Citation Analysis]
353 Dunning T. Lifestyle management, including nutrition, of diabetes in older people. Advanced Nutrition and Dietetics in Diabetes 2015. [DOI: 10.1002/9781119121725.ch26] [Reference Citation Analysis]
354 DiNicolantonio JJ, Bhutani J, O'Keefe JH. Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes. Open Heart 2015;2:e000327. [PMID: 26512331 DOI: 10.1136/openhrt-2015-000327] [Cited by in Crossref: 92] [Cited by in F6Publishing: 96] [Article Influence: 13.1] [Reference Citation Analysis]
355 Ponnusamy S, Haldar S, Mulani F, Zinjarde S, Thulasiram H, RaviKumar A. Gedunin and Azadiradione: Human Pancreatic Alpha-Amylase Inhibiting Limonoids from Neem (Azadirachta indica) as Anti-Diabetic Agents. PLoS One 2015;10:e0140113. [PMID: 26469405 DOI: 10.1371/journal.pone.0140113] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 6.3] [Reference Citation Analysis]
356 Basavareddy A, Dass AS, Narayana S. Prediabetes Awareness and Practice Among Indian Doctors- A Cross-sectional Study. J Clin Diagn Res 2015;9:FC01-3. [PMID: 26435963 DOI: 10.7860/JCDR/2015/13391.6290] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
357 Schwarz PE. [Screening and prevention of diabetes]. Internist (Berl) 2015;56:1124-33. [PMID: 26428521 DOI: 10.1007/s00108-015-3737-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
358 Courtney MR, Moler EJ, Osborne JA, Whitney G, Conard SE. An exploratory retrospective assessment of a quantitative measure of diabetes risk: medical management and patient impact in a primary care setting. Diabetes Metab Syndr Obes 2015;8:447-53. [PMID: 26425102 DOI: 10.2147/DMSO.S78810] [Reference Citation Analysis]
359 Kanat M, DeFronzo RA, Abdul-Ghani MA. Treatment of prediabetes. World J Diabetes 2015; 6(12): 1207-1222 [PMID: 26464759 DOI: 10.4239/wjd.v6.i12.1207] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 46] [Article Influence: 6.3] [Reference Citation Analysis]
360 Liu Y, Cotillard A, Vatier C, Bastard JP, Fellahi S, Stévant M, Allatif O, Langlois C, Bieuvelet S, Brochot A, Guilbot A, Clément K, Rizkalla SW. A Dietary Supplement Containing Cinnamon, Chromium and Carnosine Decreases Fasting Plasma Glucose and Increases Lean Mass in Overweight or Obese Pre-Diabetic Subjects: A Randomized, Placebo-Controlled Trial. PLoS One 2015;10:e0138646. [PMID: 26406981 DOI: 10.1371/journal.pone.0138646] [Cited by in Crossref: 31] [Cited by in F6Publishing: 46] [Article Influence: 4.4] [Reference Citation Analysis]
361 Popp Switzer M, Elhanafi S, San Juan ZT. Change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance. Curr Cardiol Rep 2015;17:562. [PMID: 25638410 DOI: 10.1007/s11886-015-0562-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
362 Wang H, Liu T, Qiu Q, Karp E, Ding P, He Y, Chen W. Development and validation of a simple risk score for prevalent undiagnosed type 2 diabetes in Southern Chinese population. Int J Diabetes Dev Ctries 2015;35:318-326. [DOI: 10.1007/s13410-014-0285-9] [Reference Citation Analysis]
363 Tundis R, Marrelli M, Conforti F, Tenuta MC, Bonesi M, Menichini F, Loizzo M. Trifolium pratense and T. repens (Leguminosae): Edible Flower Extracts as Functional Ingredients. Foods 2015;4:338-48. [PMID: 28231209 DOI: 10.3390/foods4030338] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
364 Fox CS, Golden SH, Anderson C, Bray GA, Burke LE, de Boer IH, Deedwania P, Eckel RH, Ershow AG, Fradkin J, Inzucchi SE, Kosiborod M, Nelson RG, Patel MJ, Pignone M, Quinn L, Schauer PR, Selvin E, Vafiadis DK; American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health., Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Surgery and Anesthesia, Council on Quality of Care and Outcomes Research., American Diabetes Association. Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Diabetes Care 2015;38:1777-803. [PMID: 26246459 DOI: 10.2337/dci15-0012] [Cited by in Crossref: 274] [Cited by in F6Publishing: 295] [Article Influence: 39.1] [Reference Citation Analysis]
365 Holt RI. The prevention of diabetes and cardiovascular disease in people with schizophrenia. Acta Psychiatr Scand 2015;132:86-96. [PMID: 25976975 DOI: 10.1111/acps.12443] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
366 Pratama Y, Sarjono PR, Mulyani NS. Skrining Metabolit Sekunder Bakteri Endofit yang Berfungsi sebagai Antidiabetes dari Daun Mimba (Azadirachta Indica). J Kim Sains Apl 2015;18:73-78. [DOI: 10.14710/jksa.18.2.73-78] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
367 Kaku K, Kadowaki T, Terauchi Y, Okamoto T, Sato A, Okuyama K, Arjona Ferreira JC, Goldstein BJ. Sitagliptin improves glycaemic excursion after a meal or after an oral glucose load in Japanese subjects with impaired glucose tolerance. Diabetes Obes Metab 2015;17:1033-41. [PMID: 26094974 DOI: 10.1111/dom.12507] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
368 Hannon TS, Kirkman MS, Patel YR, Considine RV, Mather KJ. Profound defects in β-cell function in screen-detected type 2 diabetes are not improved with glucose-lowering treatment in the Early Diabetes Intervention Program (EDIP). Diabetes Metab Res Rev 2014;30:767-76. [PMID: 24819707 DOI: 10.1002/dmrr.2553] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
369 Dhanya R, Arun KB, Nisha VM, Syama HP, Nisha P, Santhosh Kumar TR, Jayamurthy P. Preconditioning L6 Muscle Cells with Naringin Ameliorates Oxidative Stress and Increases Glucose Uptake. PLoS One 2015;10:e0132429. [PMID: 26147673 DOI: 10.1371/journal.pone.0132429] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
370 Aroda VR, Getaneh A. Guiding diabetes screening and prevention: rationale, recommendations and remaining challenges. Expert Rev Endocrinol Metab 2015;10:381-98. [PMID: 30293496 DOI: 10.1586/17446651.2015.1054280] [Reference Citation Analysis]
371 Mata-cases M, Artola S, Escalada J, Ezkurra-loyola P, Ferrer-garcía J, Fornos J, Girbés J, Rica I. Consenso sobre la detección y el manejo de la prediabetes. Grupo de Trabajo de Consensos y Guías Clínicas de la Sociedad Española de Diabetes. SEMERGEN - Medicina de Familia 2015;41:266-78. [DOI: 10.1016/j.semerg.2014.12.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
372 Srinivasan S, Florez JC. Therapeutic Challenges in Diabetes Prevention: We Have Not Found the "Exercise Pill". Clin Pharmacol Ther 2015;98:162-9. [PMID: 25974616 DOI: 10.1002/cpt.146] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
373 Rodrigues MRDS, Santo MA, Favero GM, Vieira EC, Artoni RF, Nogaroto V, Moura EG, Lisboa P, Milleo FQ. Metabolic surgery and intestinal gene expression: Digestive tract and diabetes evolution considerations. World J Gastroenterol 2015; 21(22): 6990-6998 [PMID: 26078577 DOI: 10.3748/wjg.v21.i22.6990] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
374 Trivin C, Metzger M, Haymann JP, Boffa JJ, Flamant M, Vrtovsnik F, Houillier P, Stengel B, Thervet E; NephroTest Study Group. Glycated Hemoglobin Level and Mortality in a Nondiabetic Population with CKD. Clin J Am Soc Nephrol 2015;10:957-64. [PMID: 25979978 DOI: 10.2215/CJN.08540814] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
375 Mata-cases M, Artola S, Escalada J, Ezkurra-loyola P, Ferrer-garcía JC, Fornos JA, Girbés J, Rica I. Consenso sobre la detección y el manejo de la prediabetes. Grupo de Trabajo de Consensos y Guías Clínicas de la Sociedad Española de Diabetes. Avances en Diabetología 2015;31:89-101. [DOI: 10.1016/j.avdiab.2014.10.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
376 Kuang L, Huang Z, Hong Z, Chen A, Li Y. Predictability of 1-h postload plasma glucose concentration: A 10-year retrospective cohort study. J Diabetes Investig 2015;6:647-54. [PMID: 26543538 DOI: 10.1111/jdi.12353] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
377 Fiorentino TV, Hribal ML, Perticone M, Andreozzi F, Sciacqua A, Perticone F, Sesti G. Unfavorable inflammatory profile in adults at risk of type 2 diabetes identified by hemoglobin A1c levels according to the American Diabetes Association criteria. Acta Diabetol 2015;52:349-56. [PMID: 25246028 DOI: 10.1007/s00592-014-0647-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
378 Chen X, Chen L, Ding R, Shi Q, Zhang Y, Hu D. A preliminary investigation of EZSCAN™ screening for impaired glucose tolerance and diabetes in a patient population. Exp Ther Med 2015;9:1688-94. [PMID: 26136878 DOI: 10.3892/etm.2015.2358] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
379 Bansal N. Prediabetes diagnosis and treatment: A review. World J Diabetes 2015; 6(2): 296-303 [PMID: 25789110 DOI: 10.4239/wjd.v6.i2.296] [Cited by in CrossRef: 242] [Cited by in F6Publishing: 256] [Article Influence: 34.6] [Reference Citation Analysis]
380 Astrup A. Treatment of obesity: lifestyle and pharmacotherapy. International Textbook of Diabetes Mellitus 2015. [DOI: 10.1002/9781118387658.ch33] [Reference Citation Analysis]
381 Yates T, Davies MJ. Prevention of type 2 diabetes. International Textbook of Diabetes Mellitus 2015. [DOI: 10.1002/9781118387658.ch38] [Reference Citation Analysis]
382 Qiao Q, Williams DE, Imperatore G, Venkat Narayan K, Tuomilehto J. Epidemiology and geography of type 2 diabetes mellitus. International Textbook of Diabetes Mellitus 2015. [DOI: 10.1002/9781118387658.ch3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
383 Mata-Cases M, Artola S, Escalada J, Ezkurra-Loyola P, Ferrer-García JC, Fornos JA, Girbés J, Rica I; Grupo de Trabajo de Consensos y Guías Clínicas de la Sociedad Española de Diabetes. [Consensus on the detection and management of prediabetes. Consensus and Clinical Guidelines Working Group of the Spanish Diabetes Society]. Aten Primaria 2015;47:456-68. [PMID: 25735589 DOI: 10.1016/j.aprim.2014.12.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
384 Mata-cases M, Artola S, Escalada J, Ezkurra-loyola P, Ferrer-garcía J, Fornos J, Girbés J, Rica I. Consensus on the detection and management of prediabetes. Consensus and Clinical Guidelines Working Group of the Spanish Diabetes Society. Revista Clínica Española (English Edition) 2015;215:117-29. [DOI: 10.1016/j.rceng.2014.10.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
385 Saisho Y. β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes. World J Diabetes 2015; 6(1): 109-124 [PMID: 25685282 DOI: 10.4239/wjd.v6.i1.109] [Cited by in CrossRef: 120] [Cited by in F6Publishing: 125] [Article Influence: 17.1] [Reference Citation Analysis]
386 Herman WH, Taylor GW, Jacobson JJ, Burke R, Brown MB. Screening for prediabetes and type 2 diabetes in dental offices. J Public Health Dent 2015;75:175-82. [PMID: 25662777 DOI: 10.1111/jphd.12082] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 7.1] [Reference Citation Analysis]
387 Morris D. Interventions that prevent prediabetes from becoming type 2. Independent Nurse 2015;2015:36-7. [DOI: 10.12968/indn.2015.2.36] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
388 McCarty MF, DiNicolantonio JJ. Acarbose, lente carbohydrate, and prebiotics promote metabolic health and longevity by stimulating intestinal production of GLP-1. Open Heart 2015;2:e000205. [PMID: 25685364 DOI: 10.1136/openhrt-2014-000205] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
389 Wang H, Liu T, Qiu Q, Ding P, He YH, Chen WQ. A simple risk score for identifying individuals with impaired fasting glucose in the Southern Chinese population. Int J Environ Res Public Health 2015;12:1237-52. [PMID: 25625405 DOI: 10.3390/ijerph120201237] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
390 Tripathy D, Cobb JE, Gall W, Adam KP, George T, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Reaven PD, Musi N, Ferrannini E, DeFronzo RA. A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW study. J Clin Endocrinol Metab 2015;100:1855-62. [PMID: 25603459 DOI: 10.1210/jc.2014-3824] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
391 Færch K, Vistisen D, Johansen NB, Jørgensen ME. Cardiovascular risk stratification and management in pre-diabetes. Curr Diab Rep 2014;14:493. [PMID: 24743942 DOI: 10.1007/s11892-014-0493-1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
392 Freichel M, Mengel K. Antidiabetika. Arzneiverordnungs-Report 2015 2015. [DOI: 10.1007/978-3-662-47186-9_10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
393 Numao S. Role of Physical Exercise on Postprandial Blood Glucose Responses to Low-Carbohydrate/High-Fat Diet Intake. Physical Activity, Exercise, Sedentary Behavior and Health 2015. [DOI: 10.1007/978-4-431-55333-5_13] [Reference Citation Analysis]
394 Jeon JY, Kim DJ. Need for Diabetes Prevention Study. J Korean Diabetes 2015;16:161. [DOI: 10.4093/jkd.2015.16.3.161] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
395 Horton ES. Prevention of Type 2 Diabetes Mellitus. Principles of Diabetes Mellitus 2015. [DOI: 10.1007/978-3-319-20797-1_50-1] [Reference Citation Analysis]
396 Larson L, Carpenter M. Diabetes and Pregnancy. Medical Management of the Pregnant Patient 2015. [DOI: 10.1007/978-1-4614-1244-1_4] [Reference Citation Analysis]
397 Ríos J, Andújar I. Lanostanoids from Fungi as Potential Medicinal Agents. Fungal Metabolites 2015. [DOI: 10.1007/978-3-319-19456-1_19-1] [Reference Citation Analysis]
398 Holt RI, Mitchell AJ. Diabetes mellitus and severe mental illness: mechanisms and clinical implications. Nat Rev Endocrinol. 2015;11:79-89. [PMID: 25445848 DOI: 10.1038/nrendo.2014.203] [Cited by in Crossref: 88] [Cited by in F6Publishing: 92] [Article Influence: 11.0] [Reference Citation Analysis]
399 Sesti G, Fiorentino TV, Succurro E, Perticone M, Arturi F, Sciacqua A, Perticone F. Elevated 1-h post-load plasma glucose levels in subjects with normal glucose tolerance are associated with unfavorable inflammatory profile. Acta Diabetol 2014;51:927-32. [PMID: 24619654 DOI: 10.1007/s00592-013-0539-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
400 Kodali VR. Albuminuria in prediabetes: time to intervene? Endocrine 2015;48:355-7. [PMID: 25370435 DOI: 10.1007/s12020-014-0468-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
401 Sénéchal M, Slaght J, Bharti N, Bouchard DR. Independent and combined effect of diet and exercise in adults with prediabetes. Diabetes Metab Syndr Obes 2014;7:521-9. [PMID: 25382981 DOI: 10.2147/DMSO.S62367] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
402 Sawhney A, Rothkopf M. Metabolic Syndrome. Metabolic Medicine and Surgery 2014. [DOI: 10.1201/b17616-7] [Reference Citation Analysis]
403 Matsuzawa Y, Guddeti RR, Kwon TG, Lerman LO, Lerman A. Treating coronary disease and the impact of endothelial dysfunction. Prog Cardiovasc Dis 2015;57:431-42. [PMID: 25459974 DOI: 10.1016/j.pcad.2014.10.004] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 5.6] [Reference Citation Analysis]
404 Tang M, Chen K, Yang F, Liu W. Exposure to organochlorine pollutants and type 2 diabetes: a systematic review and meta-analysis. PLoS One 2014;9:e85556. [PMID: 25329153 DOI: 10.1371/journal.pone.0085556] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
405 Saisho Y. Glycemic variability and oxidative stress: a link between diabetes and cardiovascular disease? Int J Mol Sci. 2014;15:18381-18406. [PMID: 25314300 DOI: 10.3390/ijms151018381] [Cited by in Crossref: 101] [Cited by in F6Publishing: 103] [Article Influence: 12.6] [Reference Citation Analysis]
406 Merlotti C, Morabito A, Ceriani V, Pontiroli AE. Prevention of type 2 diabetes in obese at-risk subjects: a systematic review and meta-analysis. Acta Diabetol 2014;51:853-63. [PMID: 25085464 DOI: 10.1007/s00592-014-0624-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 4.5] [Reference Citation Analysis]
407 Yokoh H, Kobayashi K, Sato Y, Takemoto M, Uchida D, Kanatsuka A, Kuribayashi N, Terano T, Hashimoto N, Sakurai K. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin-1): A multicenter, randomized, open-label, non-inferiority trial. J Diabetes Investig. 2015;6:182-191. [PMID: 25802726 DOI: 10.1111/jdi.12282] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
408 McGovern A, Butler L, Jones S, van Vlymen J, Sadek K, Munro N, Carr H, de Lusignan S. Diabetes screening after gestational diabetes in England: a quantitative retrospective cohort study. Br J Gen Pract 2014;64:e17-23. [PMID: 24567578 DOI: 10.3399/bjgp14X676410] [Cited by in Crossref: 57] [Cited by in F6Publishing: 60] [Article Influence: 7.1] [Reference Citation Analysis]
409 Pittas AG, Dawson-Hughes B, Sheehan PR, Rosen CJ, Ware JH, Knowler WC, Staten MA; D2d Research Group. Rationale and design of the Vitamin D and Type 2 Diabetes (D2d) study: a diabetes prevention trial. Diabetes Care 2014;37:3227-34. [PMID: 25205139 DOI: 10.2337/dc14-1005] [Cited by in Crossref: 62] [Cited by in F6Publishing: 64] [Article Influence: 7.8] [Reference Citation Analysis]
410 Isfort M, Stevens SC, Schaffer S, Jong CJ, Wold LE. Metabolic dysfunction in diabetic cardiomyopathy. Heart Fail Rev 2014;19:35-48. [PMID: 23443849 DOI: 10.1007/s10741-013-9377-8] [Cited by in Crossref: 82] [Cited by in F6Publishing: 72] [Article Influence: 10.3] [Reference Citation Analysis]
411 Kalra S. Incretin enhancement without hyperinsulinemia: α-glucosidase inhibitors. Expert Rev Endocrinol Metab 2014;9:423-5. [PMID: 30736205 DOI: 10.1586/17446651.2014.931807] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
412 Bhardwaj J, Yadav SK. Drought Stress Tolerant Horse Gram for Sustainable Agriculture. In: Lichtfouse E, editor. Sustainable Agriculture Reviews. Cham: Springer International Publishing; 2015. pp. 293-328. [DOI: 10.1007/978-3-319-09132-7_7] [Cited by in Crossref: 4] [Article Influence: 0.5] [Reference Citation Analysis]
413 Glauber H, Karnieli E. Preventing type 2 diabetes mellitus: a call for personalized intervention. Perm J 2013;17:74-9. [PMID: 24355893 DOI: 10.7812/TPP/12-143] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
414 Chasan-Taber L. Lifestyle interventions to reduce risk of diabetes among women with prior gestational diabetes mellitus. Best Pract Res Clin Obstet Gynaecol 2015;29:110-22. [PMID: 25220104 DOI: 10.1016/j.bpobgyn.2014.04.019] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
415 Saisho Y. Importance of Beta Cell Function for the Treatment of Type 2 Diabetes. J Clin Med 2014;3:923-43. [PMID: 26237486 DOI: 10.3390/jcm3030923] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
416 . The 2012 SEMDSA Guideline for the Management of Type 2 Diabetes (Revised). Journal of Endocrinology, Metabolism and Diabetes of South Africa 2014;17:S1-S95. [DOI: 10.1080/22201009.2012.10872287] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
417 Sesti G, Hribal ML, Fiorentino TV, Sciacqua A, Perticone F. Elevated 1 h postload plasma glucose levels identify adults with normal glucose tolerance but increased risk of non-alcoholic fatty liver disease. BMJ Open Diabetes Res Care 2014;2:e000016. [PMID: 25452862 DOI: 10.1136/bmjdrc-2014-000016] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
418 Nakamura K, Oe H, Kihara H, Shimada K, Fukuda S, Watanabe K, Takagi T, Yunoki K, Miyoshi T, Hirata K, Yoshikawa J, Ito H. DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study. Cardiovasc Diabetol 2014;13:110. [PMID: 25074318 DOI: 10.1186/s12933-014-0110-2] [Cited by in Crossref: 93] [Cited by in F6Publishing: 94] [Article Influence: 11.6] [Reference Citation Analysis]
419 Lattanzio S, Santilli F, Liani R, Vazzana N, Ueland T, Di Fulvio P, Formoso G, Consoli A, Aukrust P, Davì G. Circulating dickkopf-1 in diabetes mellitus: association with platelet activation and effects of improved metabolic control and low-dose aspirin. J Am Heart Assoc 2014;3:e001000. [PMID: 25037197 DOI: 10.1161/JAHA.114.001000] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 5.4] [Reference Citation Analysis]
420 Cao L, Li J, Wu H, Liu GJ, Dong BR, Lü Q. Pioglitazone for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database of Systematic Reviews 2014. [DOI: 10.1002/14651858.cd009989.pub2] [Reference Citation Analysis]
421 Punthakee Z, Miller ME, Simmons DL, Riddle MC, Ismail-Beigi F, Brillon DJ, Bergenstal RM, Savage PJ, Hramiak I, Largay JF, Sood A, Gerstein HC; ACCORD Group of Investigators. Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial. Diabetologia 2014;57:2030-7. [PMID: 24985147 DOI: 10.1007/s00125-014-3318-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
422 Perreault L, Temprosa M, Mather KJ, Horton E, Kitabchi A, Larkin M, Montez MG, Thayer D, Orchard TJ, Hamman RF. Regression from prediabetes to normal glucose regulation is associated with reduction in cardiovascular risk: results from the Diabetes Prevention Program outcomes study. Diabetes Care. 2014;37:2622-2631. [PMID: 24969574 DOI: 10.2337/dc14-0656] [Cited by in Crossref: 77] [Cited by in F6Publishing: 80] [Article Influence: 9.6] [Reference Citation Analysis]
423 Maekawa S, Kawahara T, Nomura R, Murase T, Ann Y, Oeholm M, Harada M. Retrospective study on the efficacy of a low-carbohydrate diet for impaired glucose tolerance. Diabetes Metab Syndr Obes 2014;7:195-201. [PMID: 24966689 DOI: 10.2147/DMSO.S62681] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
424 Hwee J, Cauch-Dudek K, Victor JC, Ng R, Shah BR. Utilization of Diabetes Education Centres in Ontario by people without diabetes. Can J Diabetes 2014;38:186-90. [PMID: 24909089 DOI: 10.1016/j.jcjd.2013.10.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
425 Philip E, Sundaram ML, Das R, Chauhan SK, Deshpande S, Ambhore S, Rathod R, Manjrekar P. Acarbose improves glycemic control as add-on or monotherapy in Indian type-2 diabetes: Findings from the GlucoVIP multinational observational study. Indian J Endocrinol Metab 2013;17:S674-9. [PMID: 24910836 DOI: 10.4103/2230-8210.123565] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
426 Sakuma M, Sasaki M, Katsuda S, Kobayashi K, Takaya C, Umeda M, Arai H. Assessment of metabolic status in young Japanese females using postprandial glucose and insulin levels. J Clin Biochem Nutr 2014;54:204-9. [PMID: 24895484 DOI: 10.3164/jcbn.13-104] [Reference Citation Analysis]
427 Samad MB, Kabir AU, D'Costa NM, Akhter F, Ahmed A, Jahan MR, Hannan JM. Ethanolic Extract of Butea monosperma Leaves Elevate Blood Insulin Level in Type 2 Diabetic Rats, Stimulate Insulin Secretion in Isolated Rat Islets, and Enhance Hepatic Glycogen Formation. Evid Based Complement Alternat Med 2014;2014:356290. [PMID: 24860609 DOI: 10.1155/2014/356290] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
428 Banu S, Jabir NR, Manjunath NC, Khan MS, Ashraf GM, Kamal MA, Tabrez S. Reduction of post-prandial hyperglycemia by mulberry tea in type-2 diabetes patients. Saudi J Biol Sci 2015;22:32-6. [PMID: 25561880 DOI: 10.1016/j.sjbs.2014.04.005] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 4.8] [Reference Citation Analysis]
429 Horikawa Y, Enya M, Iizuka K, Chen GY, Kawachi S, Suwa T, Takeda J. Synergistic effect of α-glucosidase inhibitors and dipeptidyl peptidase 4 inhibitor treatment. J Diabetes Investig 2011;2:200-3. [PMID: 24843484 DOI: 10.1111/j.2040-1124.2010.00081.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
430 Asai A, Nakagawa K, Higuchi O, Kimura T, Kojima Y, Kariya J, Miyazawa T, Oikawa S. Effect of mulberry leaf extract with enriched 1-deoxynojirimycin content on postprandial glycemic control in subjects with impaired glucose metabolism. J Diabetes Investig 2011;2:318-23. [PMID: 24843505 DOI: 10.1111/j.2040-1124.2011.00101.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 67] [Article Influence: 8.3] [Reference Citation Analysis]
431 Maddaloni E, Pozzilli P. Will we ever cure diabetes? Diabetes Management 2014;4:219-221. [DOI: 10.2217/dmt.14.6] [Reference Citation Analysis]
432 Bhupathiraju SN, Tobias DK, Malik VS, Pan A, Hruby A, Manson JE, Willett WC, Hu FB. Glycemic index, glycemic load, and risk of type 2 diabetes: results from 3 large US cohorts and an updated meta-analysis. Am J Clin Nutr. 2014;100:218-232. [PMID: 24787496 DOI: 10.3945/ajcn.113.079533] [Cited by in Crossref: 252] [Cited by in F6Publishing: 259] [Article Influence: 31.5] [Reference Citation Analysis]
433 Standl E, Theodorakis MJ, Erbach M, Schnell O, Tuomilehto J. On the potential of acarbose to reduce cardiovascular disease. Cardiovasc Diabetol 2014;13:81. [PMID: 24742256 DOI: 10.1186/1475-2840-13-81] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 4.3] [Reference Citation Analysis]
434 Dabelea D, Ma Y, Knowler WC, Marcovina S, Saudek CD, Arakaki R, White NH, Kahn SE, Orchard TJ, Goldberg R, Palmer J, Hamman RF; Diabetes Prevention Program Research Group. Diabetes autoantibodies do not predict progression to diabetes in adults: the Diabetes Prevention Program. Diabet Med 2014;31:1064-8. [PMID: 24646311 DOI: 10.1111/dme.12437] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
435 Yu X, Chen P, Wang H, Jin H, Jia W, Wang L. Clinical study of exercise on improvement of β-cell function and insulin resistance in non-diabetic young offsprings of diabetic patients. J Endocrinol Invest 2014;37:353-8. [PMID: 24682911 DOI: 10.1007/s40618-013-0033-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
436 Bondar' IA, Demin AA, Shabel'nikova OY, Onyanova VA. Assessment of carotid intima-media thickness in patients with type 2 diabetes mellitus and arterial hypertension. Diabetes mellitus 2014;17:41-46. [DOI: 10.14341/dm2014141-46] [Reference Citation Analysis]
437 Curtis JM, Knowler WC. Classification, epidemiology, diagnosis, and risk factors of diabetes. Diabetes Mellitus and Oral Health 2014. [DOI: 10.1002/9781118887837.ch2] [Reference Citation Analysis]
438 Portero McLellan KC, Wyne K, Villagomez ET, Hsueh WA. Therapeutic interventions to reduce the risk of progression from prediabetes to type 2 diabetes mellitus. Ther Clin Risk Manag 2014;10:173-88. [PMID: 24672242 DOI: 10.2147/TCRM.S39564] [Cited by in Crossref: 9] [Cited by in F6Publishing: 36] [Article Influence: 1.1] [Reference Citation Analysis]
439 Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract 2014;2014:943162. [PMID: 24711954 DOI: 10.1155/2014/943162] [Cited by in Crossref: 943] [Cited by in F6Publishing: 1103] [Article Influence: 117.9] [Reference Citation Analysis]
440 Dyson PA. Addressing noncommunicable disease at the population level: a focus on diabetes. Diabetes Management 2014;4:153-163. [DOI: 10.2217/dmt.13.75] [Reference Citation Analysis]
441 Guo F, Moellering DR, Garvey WT. Use of HbA1c for diagnoses of diabetes and prediabetes: comparison with diagnoses based on fasting and 2-hr glucose values and effects of gender, race, and age. Metab Syndr Relat Disord. 2014;12:258-268. [PMID: 24512556 DOI: 10.1089/met.2013.0128] [Cited by in Crossref: 73] [Cited by in F6Publishing: 71] [Article Influence: 9.1] [Reference Citation Analysis]
442 Knowler WC, Ackermann RT. Preventing diabetes in American Indian communities. Diabetes Care 2013;36:1820-2. [PMID: 23801794 DOI: 10.2337/dc12-2635] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
443 Panwar H, Calderwood D, Grant IR, Grover S, Green BD. Lactobacillus strains isolated from infant faeces possess potent inhibitory activity against intestinal alpha- and beta-glucosidases suggesting anti-diabetic potential. Eur J Nutr. 2014;53:1465-1474. [PMID: 24414142 DOI: 10.1007/s00394-013-0649-9] [Cited by in Crossref: 73] [Cited by in F6Publishing: 63] [Article Influence: 9.1] [Reference Citation Analysis]
444 Laakso M. Challenges in studies of the genetic basis of Type 2 diabetes. Expert Review of Endocrinology & Metabolism 2014;2:451-9. [DOI: 10.1586/17446651.2.4.451] [Reference Citation Analysis]
445 Hanefeld M. Acarbose revisited for efficacy, safety and cardiovascular benefits: a key role for controlling glycemic variability. Expert Review of Endocrinology & Metabolism 2014;7:395-405. [DOI: 10.1586/eem.12.35] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
446 Müller G, Weser G, Schwarz PE. The European perspective of diabetes prevention: the need for individualization of diabetes prevention. J Endocrinol Invest 2013;36:352-7. [PMID: 23712196 DOI: 10.1007/BF03347104] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
447 Tang H, Chen CY. Design of Glucagon-Like Peptide-1 Receptor Agonist for Diabetes Mellitus from Traditional Chinese Medicine. Evidence-Based Complementary and Alternative Medicine 2014;2014:1-17. [DOI: 10.1155/2014/385120] [Reference Citation Analysis]
448 Schulze MB, Hu FB. Epidemiology of Diabetes. Handbook of Epidemiology 2014. [DOI: 10.1007/978-0-387-09834-0_66] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
449 Freichel M, Mengel K. Antidiabetika. Arzneiverordnungs- Report 2014 2014. [DOI: 10.1007/978-3-662-43487-1_11] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
450 Kaku K. 8. Progress in Treatment of Diabetes. J Jpn Soc Intern Med 2014;103:2275-2281. [DOI: 10.2169/naika.103.2275] [Reference Citation Analysis]
451 Huang PL, Huang PL. Diabetes Mellitus and the Metabolic Syndrome. MGH Cardiology Board Review 2014. [DOI: 10.1007/978-1-4471-4483-0_7] [Reference Citation Analysis]
452 Ammon HPT, Burchard A, Drexel H, Füchtenbusch M, Häring H, Hauner H, Joost H, Matthaei S, Merkel M, Müller-wieland D, Pfohl M, Roden M, Rustenbeck I, Säly C, Schatz H, Schifferdecker E, Schinner S, Schwarz P, Szendrödi J, Vonbank A, Wascher T, Zeyfang A. Typ-2-Diabetes. Diabetologie kompakt 2014. [DOI: 10.1007/978-3-642-41358-2_4] [Reference Citation Analysis]
453 Mesures hygiénodiététiques et états diabétiques. Diabétologie 2014. [DOI: 10.1016/b978-2-294-73954-5.00006-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
454 Genuth SM. How does pioglitazone prevent progression of impaired glucose tolerance to diabetes? Diabetes 2013;62:3663-5. [PMID: 24158994 DOI: 10.2337/db13-1175] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
455 Lee MY, Choi DS, Lee MK, Lee HW, Park TS, Kim DM, Chung CH, Kim DK, Kim IJ, Jang HC, Park YS, Kwon HS, Lee SH, Shin HK. Comparison of acarbose and voglibose in diabetes patients who are inadequately controlled with basal insulin treatment: randomized, parallel, open-label, active-controlled study. J Korean Med Sci 2014;29:90-7. [PMID: 24431911 DOI: 10.3346/jkms.2014.29.1.90] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
456 Dabhi AS, Bhatt NR, Shah MJ. Voglibose: an alpha glucosidase inhibitor. J Clin Diagn Res 2013;7:3023-7. [PMID: 24551718 DOI: 10.7860/JCDR/2013/6373.3838] [Cited by in Crossref: 10] [Cited by in F6Publishing: 23] [Article Influence: 1.1] [Reference Citation Analysis]
457 Wentworth JM, Hensman T, Playfair J, Laurie C, Ritchie ME, Brown WA, Skinner S, Shaw JE, O'Brien PE. Laparoscopic adjustable gastric banding and progression from impaired fasting glucose to diabetes. Diabetologia 2014;57:463-8. [PMID: 24310563 DOI: 10.1007/s00125-013-3129-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
458 Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383:1068-1083. [PMID: 24315620 DOI: 10.1016/s0140-6736(13)62154-6] [Cited by in Crossref: 942] [Cited by in F6Publishing: 990] [Article Influence: 104.7] [Reference Citation Analysis]
459 Chakkera HA, Weil EJ, Pham PT, Pomeroy J, Knowler WC. Can new-onset diabetes after kidney transplant be prevented? Diabetes Care. 2013;36:1406-1412. [PMID: 23613600 DOI: 10.2337/dc12-2067] [Cited by in Crossref: 51] [Cited by in F6Publishing: 56] [Article Influence: 5.7] [Reference Citation Analysis]
460 Augustin LSA. Glycaemic index in chronic disease. Nutrafoods 2013;12:117-25. [DOI: 10.1007/s13749-013-0061-3] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
461 Ruiz Gracía T, Calle Pascual A. Estado actual del tratamiento farmacológico de la diabetes mellitus. Una aproximación práctica. Medicine - Programa de Formación Médica Continuada Acreditado 2013;11:2730-2740. [DOI: 10.1016/s0304-5412(13)70691-7] [Reference Citation Analysis]
462 . Réduction du risque de diabète. Canadian Journal of Diabetes 2013;37:S607. [DOI: 10.1016/j.jcjd.2013.07.002] [Reference Citation Analysis]
463 RISE Consortium. Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span. Diabetes Care. 2014;37:780-788. [PMID: 24194506 DOI: 10.2337/dc13-1879] [Cited by in Crossref: 64] [Cited by in F6Publishing: 70] [Article Influence: 7.1] [Reference Citation Analysis]
464 Kovács G, Buday B, Fék A, Literáti-nagy B, Pauer J, Pach P, Vitai M, Péterfai É, Korányi L. Metabolic differences in healthy first-degree female relatives of type 2 diabetic patients. Orvosi Hetilap 2013;154:1747-1753. [DOI: 10.1556/oh.2013.29737] [Reference Citation Analysis]
465 Marini MA, Frontoni S, Succurro E, Arturi F, Fiorentino TV, Sciacqua A, Hribal ML, Perticone F, Sesti G. Decreased insulin clearance in individuals with elevated 1-h post-load plasma glucose levels. PLoS One 2013;8:e77440. [PMID: 24194886 DOI: 10.1371/journal.pone.0077440] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
466 Koteshwar P, Raveendra KR, Allan JJ, Goudar KS, Venkateshwarlu K, Agarwal A. Effect of NR-Salacia on post-prandial hyperglycemia: A randomized double blind, placebo-controlled, crossover study in healthy volunteers. Pharmacogn Mag 2013;9:344-9. [PMID: 24124287 DOI: 10.4103/0973-1296.117831] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
467 Ransom T, Goldenberg R, Mikalachki A, Prebtani AP, Punthakee Z. Réduction du risque de diabète. Canadian Journal of Diabetes 2013;37:S377-S380. [DOI: 10.1016/j.jcjd.2013.07.033] [Reference Citation Analysis]
468 Meneilly GS, Knip A, Tessier D. Le diabète chez les personnes âgées. Canadian Journal of Diabetes 2013;37:S567-S574. [DOI: 10.1016/j.jcjd.2013.07.041] [Reference Citation Analysis]
469 Wang Y, Yu L, Zheng Y, Wang Y, Shen Y. Acarbose Isolation with Gel Type Strong Acid Cation Exchange Resin: Equilibrium, Kinetic and Thermodynamic Studies. Chinese Journal of Chemical Engineering 2013;21:1106-13. [DOI: 10.1016/s1004-9541(13)60583-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
470 Defronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Kitabchi AE, Mudaliar S. Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk. Diabetes Care. 2013;36:3607-3612. [PMID: 24062330 DOI: 10.2337/dc13-0520] [Cited by in Crossref: 41] [Cited by in F6Publishing: 47] [Article Influence: 4.6] [Reference Citation Analysis]
471 Herman WH. The economic costs of diabetes: is it time for a new treatment paradigm? Diabetes Care 2013;36:775-6. [PMID: 23520368 DOI: 10.2337/dc13-0270] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 6.3] [Reference Citation Analysis]
472 Page KA, Reisman T. Interventions to preserve beta-cell function in the management and prevention of type 2 diabetes. Curr Diab Rep 2013;13:252-60. [PMID: 23371283 DOI: 10.1007/s11892-013-0363-2] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
473 Khavandi K, Amer H, Ibrahim B, Brownrigg J. Strategies for preventing type 2 diabetes: an update for clinicians. Ther Adv Chronic Dis. 2013;4:242-261. [PMID: 23997928 DOI: 10.1177/2040622313494986] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
474 Green JB. Diabetes trials: is an ounce of prevention enough? Expert Rev Endocrinol Metab 2013;8:419-21. [PMID: 30754187 DOI: 10.1586/17446651.2013.827382] [Reference Citation Analysis]
475 Zhang X, Shen D, Fang Z, Jie Z, Qiu X, Zhang C, Chen Y, Ji L. Human gut microbiota changes reveal the progression of glucose intolerance. PLoS One. 2013;8:e71108. [PMID: 24013136 DOI: 10.1371/journal.pone.0071108] [Cited by in Crossref: 481] [Cited by in F6Publishing: 503] [Article Influence: 53.4] [Reference Citation Analysis]
476 García de la Torre N, Durán A, Del Valle L, Fuentes M, Barca I, Martín P, Montañez C, Perez-Ferre N, Abad R, Sanz F, Galindo M, Rubio MA, Calle-Pascual AL. Early management of type 2 diabetes based on a SMBG strategy: the way to diabetes regression--the St Carlos study : a 3-year, prospective, randomized, clinic-based, interventional study with parallel groups. Acta Diabetol 2013;50:607-14. [PMID: 23532298 DOI: 10.1007/s00592-013-0467-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
477 Mannucci E, Monami M, Dicembrini I, Rotella C. The impossible return to the Garden of Eden: The ORIGIN trial and the original sin of early insulin treatment of type 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases 2013;23:e35-e36. [DOI: 10.1016/j.numecd.2013.02.008] [Reference Citation Analysis]
478 Kondo Y, Harada N, Sozu T, Hamasaki A, Yamane S, Muraoka A, Harada T, Shibue K, Nasteska D, Joo E, Sasaki K, Inagaki N. A hospital-based cross-sectional study to develop an estimation formula for 2-h post-challenge plasma glucose for screening impaired glucose tolerance. Diabetes Research and Clinical Practice 2013;101:218-225. [DOI: 10.1016/j.diabres.2013.05.013] [Reference Citation Analysis]
479 Kamisah Y, Othman F, Qodriyah HM, Jaarin K. Parkia speciosa Hassk.: A Potential Phytomedicine. Evid Based Complement Alternat Med 2013;2013:709028. [PMID: 23956777 DOI: 10.1155/2013/709028] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
480 Makrilakis K, Liatis S, Gilis-januszewska A, Schwarz P. Diabetes Prevention in Practice: Examples from the Real World. Prevention of Diabetes 2013. [DOI: 10.1002/9781118661321.ch8] [Reference Citation Analysis]
481 Cahn A, Raz I, Itzhak B. Practical Approach to the Implementation of Diabetes Prevention. Prevention of Diabetes 2013. [DOI: 10.1002/9781118661321.ch13] [Reference Citation Analysis]
482 Bhowmik B, Telle Hjellset V, Hussain A. Global Migration and Prevention of Diabetes. Prevention of Diabetes 2013. [DOI: 10.1002/9781118661321.ch7] [Reference Citation Analysis]
483 Seshiah V, Balaji V. Primordial prevention: maternal health and diabetes. Diabetes Management 2013;3:333-341. [DOI: 10.2217/dmt.13.24] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
484 Maria Rotella C, Pala L, Mannucci E. Role of insulin in the type 2 diabetes therapy: past, present and future. Int J Endocrinol Metab 2013;11:137-44. [PMID: 24348585 DOI: 10.5812/ijem.7551] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
485 Jerzak KJ, Pallan S, Gerstein HC. Willingness to take drugs to prevent serious chronic diseases. J Diabetes 2014;6:76-80. [PMID: 23773579 DOI: 10.1111/1753-0407.12069] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
486 Tripolt NJ, Eder M, Stojakovic T, Pilz S, Pieber TR, Sourij H. Comment on: Davidson et al. High-dose vitamin D supplementation in people with prediabetes and hypovitaminosis D. Diabetes Care 2013;36:260-266. Diabetes Care 2013;36:e81. [PMID: 23704689 DOI: 10.2337/dc13-0332] [Reference Citation Analysis]
487 Cabrera-rode E, Orlandi N, Padrón Y, Arranz C, Olano R, Machado M, Hernández-yero A, Calderín R, Domínguez E. Effect of Diamel in patients with metabolic syndrome: A randomized double-blind placebo-controlled study (Diamel对代谢综合征患者的影响:一项随机双盲安慰剂对照研究). Journal of Diabetes 2013;5:180-191. [DOI: 10.1111/1753-0407.12007] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
488 Harayama T, Yoshida T, Yoshioka K, Kogure A, Sakai R, Yasui T, Kondo Y, Fukui M, Hasegawa G, Nakamura N. Correlation between weight loss and improvement of diabetes mellitus among obese type 2 diabetic patients. Diabetol Int 2013;4:132-137. [DOI: 10.1007/s13340-013-0107-1] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
489 Reducing the Risk of Developing Diabetes. Canadian Journal of Diabetes 2013;37:S298. [DOI: 10.1016/j.jcjd.2013.02.004] [Reference Citation Analysis]
490 Monsalve FA, Pyarasani RD, Delgado-Lopez F, Moore-Carrasco R. Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases. Mediators Inflamm. 2013;2013:549627. [PMID: 23781121 DOI: 10.1155/2013/549627] [Cited by in Crossref: 207] [Cited by in F6Publishing: 217] [Article Influence: 23.0] [Reference Citation Analysis]
491 Wang Z, Wang J, Chan P. Treating type 2 diabetes mellitus with traditional chinese and Indian medicinal herbs. Evid Based Complement Alternat Med 2013;2013:343594. [PMID: 23737828 DOI: 10.1155/2013/343594] [Cited by in Crossref: 31] [Cited by in F6Publishing: 49] [Article Influence: 3.4] [Reference Citation Analysis]
492 Barnett AH, Grice J. Overview of Current Diabetes Management. New Mechanisms in Glucose Control 2013. [DOI: 10.1002/9781118682197.ch2] [Reference Citation Analysis]
493 Sakaguchi K, Hirota Y, Hashimoto N, Ogawa W, Hamaguchi T, Matsuo T, Miyagawa J, Namba M, Sato T, Okada S, Tomita K, Matsuhisa M, Kaneto H, Kosugi K, Maegawa H, Nakajima H, Kashiwagi A. Evaluation of a minimally invasive system for measuring glucose area under the curve during oral glucose tolerance tests: usefulness of sweat monitoring for precise measurement. J Diabetes Sci Technol 2013;7:678-88. [PMID: 23759401 DOI: 10.1177/193229681300700313] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
494 McEwen LN, Adams SR, Schmittdiel JA, Ferrara A, Selby JV, Herman WH. Screening for impaired fasting glucose and diabetes using available health plan data. J Diabetes Complications 2013;27:580-7. [PMID: 23587840 DOI: 10.1016/j.jdiacomp.2013.01.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
495 Tschöpe D, Hanefeld M, Meier JJ, Gitt AK, Halle M, Bramlage P, Schumm-Draeger PM. The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes. Cardiovasc Diabetol 2013;12:62. [PMID: 23574917 DOI: 10.1186/1475-2840-12-62] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
496 Lakey WC, Barnard K, Batch BC, Chiswell K, Tasneem A, Green JB. Are current clinical trials in diabetes addressing important issues in diabetes care? Diabetologia 2013;56:1226-35. [PMID: 23564296 DOI: 10.1007/s00125-013-2890-4] [Cited by in Crossref: 41] [Cited by in F6Publishing: 47] [Article Influence: 4.6] [Reference Citation Analysis]
497 Bozorgmanesh M, Hadaegh F, Azizi F. Transportability of the updated diabetes prediction model from Atherosclerosis Risk in Communities Study to a Middle Eastern adult population: community-based cohort study. Acta Diabetol 2013;50:175-81. [PMID: 21120544 DOI: 10.1007/s00592-010-0241-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
498 Gohlke H, Albus C, Bönner G, Darius H, Eckert S, Gohlke-bärwolf C, Gysan D, Hahmann H, Halle M, Hambrecht R, Mathes P, Predel H, Sauer † G, von Schacky C, Schuler G, Siegrist J, Thiery J, Tschöpe D, Völler H, Wirth A. Empfehlungen der Projektgruppe Prävention der DGK zur risikoadjustierten Prävention von Herz- und Kreislauferkrankungen. Kardiologe 2013;7:141-156. [DOI: 10.1007/s12181-012-0468-x] [Reference Citation Analysis]
499 Xue YP, Qin JW, Wang YJ, Wang YS, Zheng YG. Enhanced production of acarbose and concurrently reduced formation of impurity c by addition of validamine in fermentation of Actinoplanes utahensis ZJB-08196. Biomed Res Int 2013;2013:705418. [PMID: 23484146 DOI: 10.1155/2013/705418] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
500 Kurozumi A, Okada Y, Mori H, Arao T, Tanaka Y. Efficacy of α-glucosidase inhibitors combined with dipeptidyl-peptidase-4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoring. J Diabetes Investig 2013;4:393-8. [PMID: 24843685 DOI: 10.1111/jdi.12059] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
501 Suvag S, Utzschneider KM, Kahn SE. Treatment with Thiazolidinediones. The Metabolic Syndrome 2013. [DOI: 10.1007/978-3-7091-1331-8_9] [Reference Citation Analysis]
502 Freichel M, Mengel K. Antidiabetika. Arzneiverordnungs-Report 2013 2013. [DOI: 10.1007/978-3-642-37124-0_11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
503 Feghali MN, Driggers RW, Miodovnik M, Umans JG. Diabetes in Pregnancy. Clinical Pharmacology During Pregnancy 2013. [DOI: 10.1016/b978-0-12-386007-1.00016-7] [Reference Citation Analysis]
504 Ahrén B. Glucose: Glucose Tolerance. Encyclopedia of Human Nutrition 2013. [DOI: 10.1016/b978-0-12-375083-9.00134-3] [Reference Citation Analysis]
505 Nishimura R. 1. Glycemic Variations and Risk of Cardiovascular Disease. J Jpn Soc Intern Med 2013;102:922-930. [DOI: 10.2169/naika.102.922] [Reference Citation Analysis]
506 Stein SA, Lamos EM, Davis SN. A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf. 2013;12:153-175. [PMID: 23241069 DOI: 10.1517/14740338.2013.752813] [Cited by in Crossref: 194] [Cited by in F6Publishing: 204] [Article Influence: 19.4] [Reference Citation Analysis]
507 Matfin G, Pratley RE. Advances in the treatment of prediabetes. Ther Adv Endocrinol Metab 2010;1:5-14. [PMID: 23148144 DOI: 10.1177/2042018810366429] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
508 Eccleston JL, Koh C, Markello TC, Gahl WA, Heller T. An apparent homozygous deletion in maltase-glucoamylase, a lesson in the evolution of SNP arrays. Mol Genet Metab 2012;107:674-8. [PMID: 23137569 DOI: 10.1016/j.ymgme.2012.10.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
509 Derosa G, Maffioli P. α-Glucosidase inhibitors and their use in clinical practice. Arch Med Sci 2012;8:899-906. [PMID: 23185202 DOI: 10.5114/aoms.2012.31621] [Cited by in Crossref: 199] [Cited by in F6Publishing: 215] [Article Influence: 19.9] [Reference Citation Analysis]
510 Freeman JS, Horton ES. What Have We Learned About the Treatment of Type 2 Diabetes? The Evolving Paradigms. American Journal of Therapeutics 2012;19:449-64. [DOI: 10.1097/mjt.0b013e31826fc5e5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
511 Sapwarobol S, Adisakwattana S, Changpeng S, Ratanawachirin W, Tanruttanawong K, Boonyarit W. Postprandial blood glucose response to grape seed extract in healthy participants: A pilot study. Pharmacogn Mag. 2012;8:192-196. [PMID: 23060692 DOI: 10.4103/0973-1296.99283] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
512 Rosak C, Mertes G. Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations. Diabetes Metab Syndr Obes. 2012;5:357-367. [PMID: 23093911 DOI: 10.2147/dmso.s28340] [Cited by in Crossref: 98] [Cited by in F6Publishing: 111] [Article Influence: 9.8] [Reference Citation Analysis]
513 Rawal LB, Tapp RJ, Williams ED, Chan C, Yasin S, Oldenburg B. Prevention of type 2 diabetes and its complications in developing countries: a review. Int J Behav Med 2012;19:121-33. [PMID: 21590464 DOI: 10.1007/s12529-011-9162-9] [Cited by in Crossref: 83] [Cited by in F6Publishing: 72] [Article Influence: 8.3] [Reference Citation Analysis]
514 Choudhary N, Kalra S, Unnikrishnan AG, Ajish TP. Preventive pharmacotherapy in type 2 diabetes mellitus. Indian J Endocrinol Metab 2012;16:33-43. [PMID: 22276251 DOI: 10.4103/2230-8210.91183] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
515 Romero Rey M, Álvarez Gutiérrez J, Gómez Lucas E, Lozano García J. Recomendaciones para el empleo de antidiabéticos orales en la diabetes tipo 2. Medicine - Programa de Formación Médica Continuada Acreditado 2012;11:1112-1116. [DOI: 10.1016/s0304-5412(12)70435-3] [Reference Citation Analysis]
516 Romero Rey M, Álvarez Gutiérrez J, Gómez Lucas E, Lozano García J. Manejo terapéutico de la hiperglucemia en la diabetes tipo 2. Antidiabéticos orales. Medicine - Programa de Formación Médica Continuada Acreditado 2012;11:1073-1081. [DOI: 10.1016/s0304-5412(12)70430-4] [Reference Citation Analysis]
517 Gómez Lucas E, Romero Rey V, Álvarez Gutiérrez J, Lozano García J. Guía de insulinoterapia. Medicine - Programa de Formación Médica Continuada Acreditado 2012;11:1096-1105. [DOI: 10.1016/s0304-5412(12)70433-x] [Reference Citation Analysis]
518 Twig G, Afek A, Shamiss A, Derazne E, Tzur D, Gordon B, Tirosh A. White blood cells count and incidence of type 2 diabetes in young men. Diabetes Care 2013;36:276-82. [PMID: 22961572 DOI: 10.2337/dc11-2298] [Cited by in Crossref: 73] [Cited by in F6Publishing: 79] [Article Influence: 7.3] [Reference Citation Analysis]
519 Blaak EE, Antoine JM, Benton D, Björck I, Bozzetto L, Brouns F, Diamant M, Dye L, Hulshof T, Holst JJ, Lamport DJ, Laville M, Lawton CL, Meheust A, Nilson A, Normand S, Rivellese AA, Theis S, Torekov SS, Vinoy S. Impact of postprandial glycaemia on health and prevention of disease. Obes Rev 2012;13:923-84. [PMID: 22780564 DOI: 10.1111/j.1467-789X.2012.01011.x] [Cited by in Crossref: 241] [Cited by in F6Publishing: 255] [Article Influence: 24.1] [Reference Citation Analysis]
520 Cao L, Li J, Wu H, Liu GJ, Dong BR, Lü Q. Pioglitazone for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database of Systematic Reviews 2012. [DOI: 10.1002/14651858.cd009989] [Reference Citation Analysis]
521 Buchanan TA, Xiang AH, Page KA. Gestational diabetes mellitus: risks and management during and after pregnancy. Nat Rev Endocrinol. 2012;8:639-649. [PMID: 22751341 DOI: 10.1038/nrendo.2012.96] [Cited by in Crossref: 344] [Cited by in F6Publishing: 359] [Article Influence: 34.4] [Reference Citation Analysis]
522 Piguel X, Hadjadj S. Stratégie thérapeutique dans le traitement du diabète de type 2. EMC - Endocrinologie - Nutrition 2012;9:1-8. [DOI: 10.1016/s1155-1941(12)53865-5] [Reference Citation Analysis]
523 Kitasato L, Tojo T, Hatakeyama Y, Kameda R, Hashikata T, Yamaoka-Tojo M. Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide. Cardiovasc Diabetol 2012;11:79. [PMID: 22748110 DOI: 10.1186/1475-2840-11-79] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
524 Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE; Diabetes Prevention Program Research Group. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 2012;379:2243-51. [PMID: 22683134 DOI: 10.1016/S0140-6736(12)60525-X] [Cited by in Crossref: 288] [Cited by in F6Publishing: 313] [Article Influence: 28.8] [Reference Citation Analysis]
525 Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379:2279-2290. [PMID: 22683128 DOI: 10.1016/s0140-6736(12)60283-9] [Cited by in Crossref: 1388] [Cited by in F6Publishing: 1478] [Article Influence: 138.8] [Reference Citation Analysis]
526 Carnevale Schianca GP, Sola D, Rossi L, Fra GP, Bartoli E. The management of type 2 diabetic patients with hypoglycemic agents. ISRN Endocrinol 2012;2012:601380. [PMID: 22577575 DOI: 10.5402/2012/601380] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
527 Shankaracharya, Odedra D, Samanta S, Vidyarthi AS. Computational intelligence-based diagnosis tool for the detection of prediabetes and type 2 diabetes in India. Rev Diabet Stud 2012;9:55-62. [PMID: 22972445 DOI: 10.1900/RDS.2012.9.55] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
528 Tolkacheva VV, Villevalde SV, Kobalava ZD. Carbohydrate metabolism and transformation of pre-diabetes into type 2 diabetes mellitus depending on diagnostic methods in nondiabetic patients with hypertension and high cardiovascular risk. Arter gipertenz 2012;18:83-95. [DOI: 10.18705/1607-419x-2012-18-2-83-95] [Reference Citation Analysis]
529 Weikel KA, Chiu CJ, Taylor A. Nutritional modulation of age-related macular degeneration. Mol Aspects Med 2012;33:318-75. [PMID: 22503690 DOI: 10.1016/j.mam.2012.03.005] [Cited by in Crossref: 58] [Cited by in F6Publishing: 62] [Article Influence: 5.8] [Reference Citation Analysis]
530 Sinclair AJ, Meneilly GS. Diabetes Mellitus. Pathy's Principles and Practice of Geriatric Medicine 2012. [DOI: 10.1002/9781119952930.ch101] [Reference Citation Analysis]
531 Farhan S, Jarai R, Tentzeris I, Kautzky-Willer A, Samaha E, Smetana P, Jakl-Kotauschek G, Wojta J, Huber K. Comparison of HbA1c and oral glucose tolerance test for diagnosis of diabetes in patients with coronary artery disease. Clin Res Cardiol 2012;101:625-30. [PMID: 22391987 DOI: 10.1007/s00392-012-0435-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
532 Kumar RV, Sinha VR. A novel synergistic galactomannan-based unit dosage form for sustained release of acarbose. AAPS PharmSciTech 2012;13:262-75. [PMID: 22234597 DOI: 10.1208/s12249-011-9724-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
533 Home P, Almaatouq M. Improving health outcomes in 2011 for people with type 2 diabetes: A report from a symposium held on the occasion of the International Diabetes Federation World Diabetes Congress, Dubai, 5–8 December 2011. Diabetes & Vascular Disease 2012;12:101-108. [DOI: 10.1177/1474651412443389] [Reference Citation Analysis]
534 Marini MA, Succurro E, Frontoni S, Mastroianni S, Arturi F, Sciacqua A, Lauro R, Hribal ML, Perticone F, Sesti G. Insulin sensitivity, β-cell function, and incretin effect in individuals with elevated 1-hour postload plasma glucose levels. Diabetes Care 2012;35:868-72. [PMID: 22357182 DOI: 10.2337/dc11-2181] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 5.6] [Reference Citation Analysis]
535 Weikel KA, Fitzgerald P, Shang F, Caceres MA, Bian Q, Handa JT, Stitt AW, Taylor A. Natural history of age-related retinal lesions that precede AMD in mice fed high or low glycemic index diets. Invest Ophthalmol Vis Sci 2012;53:622-32. [PMID: 22205601 DOI: 10.1167/iovs.11-8545] [Cited by in Crossref: 35] [Cited by in F6Publishing: 42] [Article Influence: 3.5] [Reference Citation Analysis]
536 Song MK, Um JY, Jang HJ, Lee BC. Beneficial effect of dietary Ephedra sinica on obesity and glucose intolerance in high-fat diet-fed mice. Exp Ther Med 2012;3:707-12. [PMID: 22969956 DOI: 10.3892/etm.2012.462] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
537 Morrison KM, Xu L, Tarnopolsky M, Yusuf Z, Atkinson SA, Yusuf S. Screening for dysglycemia in overweight youth presenting for weight management. Diabetes Care 2012;35:711-6. [PMID: 22271926 DOI: 10.2337/dc11-1659] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
538 Schwarz PE, Greaves CJ, Lindström J, Yates T, Davies MJ. Nonpharmacological interventions for the prevention of type 2 diabetes mellitus. Nat Rev Endocrinol 2012;8:363-73. [PMID: 22249519 DOI: 10.1038/nrendo.2011.232] [Cited by in Crossref: 88] [Cited by in F6Publishing: 94] [Article Influence: 8.8] [Reference Citation Analysis]
539 Davidson MB. Counterpoint: postprandial glucose levels are not a clinically important treatment target. Diabetes Care 2010;33:1908-10. [PMID: 20668159 DOI: 10.2337/dc10-0712] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
540 Karam JG, Mcfarlane SI. Prevention of Type 2 Diabetes: Evidence from Clinical Trials. Diabetes and Hypertension 2012. [DOI: 10.1007/978-1-60327-357-2_12] [Reference Citation Analysis]
541 Freichel M, Mengel K. Antidiabetika. Arzneiverordnungs-Report 2012 2012. [DOI: 10.1007/978-3-642-29242-2_11] [Reference Citation Analysis]
542 Barzilay J. The Pre-Diabetic, Insulin-Resistant State. The Epidemiology of Aging 2012. [DOI: 10.1007/978-94-007-5061-6_25] [Reference Citation Analysis]
543 Watanabe H, Suzuki S, Iwata M, Sakamoto K, Inoue T, Banno Y. Effect of Transcutaneous Electrical Muscle Stimulation on Glucose Tolerance and Insulin Sensitivity of Rats. Rigakuryoho kagaku 2012;27:503-508. [DOI: 10.1589/rika.27.503] [Reference Citation Analysis]
544 Alsahli M, Gerich JE. Pathogenesis of Type 2 Diabetes. Atlas of Diabetes 2012. [DOI: 10.1007/978-1-4614-1028-7_7] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
545 Yoo HJ. Pharmacotherapy for Postprandial Hyperglycemia in Type 2 Diabetes. J Korean Diabetes 2012;13:39. [DOI: 10.4093/jkd.2012.13.1.39] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
546 Ueki K. 4. New Diagnostic Criteria of Diabetes and International Harmonization of HbA1c. J Jpn Soc Intern Med 2012;101:959-964. [DOI: 10.2169/naika.101.959] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
547 Zhou K, Hogan S, Canning C, Sun S. Inhibition of Intestinal α-Glucosidases and Anti-Postprandial Hyperglycemic Effect of Grape Seed Extract. ACS Symposium Series 2012. [DOI: 10.1021/bk-2012-1093.ch025] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
548 Tirosh A. Screening for Prediabetes and Diabetes. Prevention of Type 2 Diabetes 2012. [DOI: 10.1007/978-1-4614-3314-9_7] [Reference Citation Analysis]
549 Kishimoto M, Noda M. A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers. Cardiovasc Diabetol. 2011;10:115. [PMID: 22189184 DOI: 10.1186/1475-2840-10-115] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
550 Faure S. Inhibiteurs des alphaglucosidases. Actualités Pharmaceutiques 2011;50:53-55. [DOI: 10.1016/s0515-3700(11)71107-7] [Reference Citation Analysis]
551 Kishimura H, Fukumorita K, Adachi K, Chiba S, Nagai Y, Katayama S, Nakajima S, Saeki H. A TRYPSIN INHIBITOR IN THE VISCERA OF JAPANESE COMMON SQUID (TODARODES PACIFICUS) ELICITS INSULINOTROPIC EFFECTS IN DIABETIC GK RATS: HYPOGLYCEMIC EFFECTS OF SQUID VISCERA. Journal of Food Biochemistry 2012;36:93-8. [DOI: 10.1111/j.1745-4514.2010.00515.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
552 Kalra S, Malik S, John M. Gestational diabetes mellitus: A window of opportunity. Indian J Endocrinol Metab 2011;15:149-51. [PMID: 21897889 DOI: 10.4103/2230-8210.83395] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
553 Garber AJ. Incretin therapy--present and future. Rev Diabet Stud. 2011;8:307-322. [PMID: 22262069 DOI: 10.1900/rds.2011.8.307] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
554 Seguí Díaz M, Mediavilla Bravo J, Comas Samper J, Barquilla García A, Carramiñana Barrera F. Prevención de la diabetes mellitus 2. SEMERGEN - Medicina de Familia 2011;37:496-503. [DOI: 10.1016/j.semerg.2011.06.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
555 Retnakaran R, Qi Y, Harris SB, Hanley AJ, Zinman B. Changes over time in glycemic control, insulin sensitivity, and beta-cell function in response to low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance. Diabetes Care 2011;34:1601-4. [PMID: 21709296 DOI: 10.2337/dc11-0046] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
556 Kahn SE, Utzschneider KM. What's next for diabetes prevention? Diabetes Care 2011;34:1678-80. [PMID: 21709302 DOI: 10.2337/dc11-0694] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
557 Hanefeld M, Schaper F. Drug therapy for the prevention of type 2 diabetes – is there a medical rationale? Diabetes & Vascular Disease 2011;11:168-74. [DOI: 10.1177/1474651411403987] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
558 Hanefeld M, Schatz U, Schaper F. Treatments for the Metabolic Syndrome. The Metabolic Syndrome 2011. [DOI: 10.1002/9781444347319.ch18] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
559 Sullivan SD, Ratner RE. Should the metabolic syndrome patient with prediabetes be offered pharmacotherapy? Curr Diab Rep 2011;11:91-8. [PMID: 21207204 DOI: 10.1007/s11892-010-0170-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
560 Nomura S, Omoto S, Yokoi T, Fujita S, Ozasa R, Eguchi N, Shouzu A. Effects of miglitol in platelet-derived microparticle, adiponectin, and selectin level in patients with type 2 diabetes mellitus. Int J Gen Med 2011;4:539-45. [PMID: 21845063 DOI: 10.2147/IJGM.S22115] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
561 Hayashi T, Mori T, Yamashita C, Miyamura M. Regulation of oxidative stress and cardioprotection in diabetes mellitus. Curr Cardiol Rev 2008;4:251-8. [PMID: 20066132 DOI: 10.2174/157340308786349426] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
562 Sasaki M, Joh T, Koikeda S, Kataoka H, Tanida S, Oshima T, Ogasawara N, Ohara H, Nakao H, Kamiya T. A novel strategy in production of oligosaccharides in digestive tract: prevention of postprandial hyperglycemia and hyperinsulinemia. J Clin Biochem Nutr 2007;41:191-6. [PMID: 18299715 DOI: 10.3164/jcbn.2007027] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
563 Profit L, Chrisp P, Nadin C. Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus. Core Evid 2008;3:13-30. [PMID: 20694081 DOI: 10.3355/ce.2008.009] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
564 DeFronzo RA, Abdul-Ghani M. Type 2 diabetes can be prevented with early pharmacological intervention. Diabetes Care 2011;34 Suppl 2:S202-9. [PMID: 21525456 DOI: 10.2337/dc11-s221] [Cited by in Crossref: 94] [Cited by in F6Publishing: 102] [Article Influence: 8.5] [Reference Citation Analysis]
565 Chiasson J, Bernard S. Reducing cardiovascular risk factors in patients with prediabetes. Diabetes Management 2011;1:423-438. [DOI: 10.2217/dmt.11.28] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
566 Ngatena IJ, Kapustin JF. Preventing Type 2 Diabetes: What Really Works? The Journal for Nurse Practitioners 2011;7:550-558. [DOI: 10.1016/j.nurpra.2011.01.002] [Reference Citation Analysis]
567 Lu YH, Lu JM, Wang SY, Li CL, Zheng RP, Tian H, Wang XL. Outcome of intensive integrated intervention in participants with impaired glucose regulation in China. Adv Ther 2011;28:511-9. [PMID: 21533568 DOI: 10.1007/s12325-011-0022-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
568 Buijsse B, Simmons RK, Griffin SJ, Schulze MB. Risk assessment tools for identifying individuals at risk of developing type 2 diabetes. Epidemiol Rev. 2011;33:46-62. [PMID: 21622851 DOI: 10.1093/epirev/mxq019] [Cited by in Crossref: 185] [Cited by in F6Publishing: 199] [Article Influence: 16.8] [Reference Citation Analysis]
569 Adisakwattana S, Yibchok-Anun S, Charoenlertkul P, Wongsasiripat N. Cyanidin-3-rutinoside alleviates postprandial hyperglycemia and its synergism with acarbose by inhibition of intestinal α-glucosidase. J Clin Biochem Nutr 2011;49:36-41. [PMID: 21765605 DOI: 10.3164/jcbn.10-116] [Cited by in Crossref: 78] [Cited by in F6Publishing: 83] [Article Influence: 7.1] [Reference Citation Analysis]
570 Cezaretto A, Siqueira-Catania A, de Barros CR, Salvador EP, Ferreira SR. Benefits on quality of life concomitant to metabolic improvement in intervention program for prevention of diabetes mellitus. Qual Life Res. 2012;21:105-113. [PMID: 21538199 DOI: 10.1007/s11136-011-9919-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
571 Klein A, Chernyak N, Brinks R, Genz J, Icks A. Kosteneffektivität der Primärprävention des Typ-2-Diabetes. Praev Gesundheitsf 2011;6:102-110. [DOI: 10.1007/s11553-010-0273-y] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
572 American Diabetes Association. Standards of medical care in diabetes--2011. Diabetes Care. 2011;34 Suppl 1:S11-S61. [PMID: 21193625 DOI: 10.2337/dc11-s011] [Cited by in Crossref: 1811] [Cited by in F6Publishing: 2033] [Article Influence: 164.6] [Reference Citation Analysis]
573 DREAM Trial Investigators. Incidence of diabetes following ramipril or rosiglitazone withdrawal. Diabetes Care. 2011;34:1265-1269. [PMID: 21515846 DOI: 10.2337/dc10-1567] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
574 Souto SB, Souto EB, Braga DC, Medina JL. Prevention and current onset delay approaches of type 2 diabetes mellitus (T2DM). Eur J Clin Pharmacol 2011;67:653-61. [PMID: 21468743 DOI: 10.1007/s00228-011-1038-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
575 Herman WH. The economics of diabetes prevention. Med Clin North Am 2011;95:373-84, viii. [PMID: 21281839 DOI: 10.1016/j.mcna.2010.11.010] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
576 Muthusamy K, Vella A. Is Prediabetes a Risk Factor or is it a Disease? Clinical Dilemmas in Diabetes 2011. [DOI: 10.1002/9781444340280.ch1] [Reference Citation Analysis]
577 Menéndez Torre E, Lafita Tejedor FJ, Artola Menéndez S, Millán Núñez-Cortés J, Alonso García A, Puig Domingo M, García Solans JR, Alvarez Guisasola F, García Alegría J, Mediavilla Bravo J, Miranda Fernández-Santos C, Romero González R; Grupo de Trabajo de Consensos y Guías Clínicas de la Sociedad Española de Diabetes. [Recommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes]. Aten Primaria 2011;43:202.e1-9. [PMID: 21382648 DOI: 10.1016/j.aprim.2010.07.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
578 Icks A, Chernyak N, Klein A, Brinks R, Genz J, Giani G. Kosteneffektivität der Primärprävention des Typ-2-Diabetes. Diabetologe 2011;7:92-98. [DOI: 10.1007/s11428-010-0638-z] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
579 Chiu CJ, Liu S, Willett WC, Wolever TM, Brand-Miller JC, Barclay AW, Taylor A. Informing food choices and health outcomes by use of the dietary glycemic index. Nutr Rev 2011;69:231-42. [PMID: 21457267 DOI: 10.1111/j.1753-4887.2011.00382.x] [Cited by in Crossref: 69] [Cited by in F6Publishing: 77] [Article Influence: 6.3] [Reference Citation Analysis]
580 Hsieh SH, Shih KC, Chou CW, Chu CH. Evaluation of the efficacy and tolerability of miglitol in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylureas. Acta Diabetol 2011;48:71-7. [PMID: 20963449 DOI: 10.1007/s00592-010-0220-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
581 Carnevale Schianca GP, Mella R, Scaglia E, Bigliocca M, Colli E, Fra GP, Bartoli E. Expanding the clinical use of standard OGTT: the percentage increment of 2 h with respect to fasting glucose as an index of β-cell dysfunction. Diabetes Metab Res Rev 2011;27:262-8. [PMID: 21309049 DOI: 10.1002/dmrr.1166] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
582 Sibal L, Agarwal SC, Home PD. Carotid intima-media thickness as a surrogate marker of cardiovascular disease in diabetes. Diabetes Metab Syndr Obes 2011;4:23-34. [PMID: 21448319 DOI: 10.2147/DMSO.S8540] [Cited by in Crossref: 43] [Cited by in F6Publishing: 52] [Article Influence: 3.9] [Reference Citation Analysis]
583 Øfjord E, Skag A, Helberg S, Aarskog D, Risberg K, Jacobsen T, Nasrala S, Bakken S, Syversen U, Jenssen T. Medikamentell forebygging ved prediabetes - ingen hensikt? Tidsskriftet 2011;131:1418-1419. [DOI: 10.4045/tidsskr.10.1459] [Reference Citation Analysis]
584 Van Buren P, Lewinter MM. Heart Failure as a Consequence of Diabetic Cardiomyopathy. Heart Failure: A Companion to Braunwald's Heart Disease 2011. [DOI: 10.1016/b978-1-4160-5895-3.10026-9] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
585 Menéndez Torre E, Lafita Tejedor FJ, Artola Menéndez S, Millán Núñez-cortés J, Alonso García Á, Puig Domingo M, García Solans JR, Álvarez Guisasola F, García Alegría J, Mediavilla Bravo J, Miranda Fernández-santos C, Romero González R. Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2. Clínica e Investigación en Arteriosclerosis 2011;23:40-48. [DOI: 10.1016/j.arteri.2011.01.007] [Reference Citation Analysis]
586 Sorrentino MJ. The Metabolic Syndrome. Hyperlipidemia in Primary Care 2011. [DOI: 10.1007/978-1-60327-502-6_2] [Reference Citation Analysis]
587 Mengel K. Antidiabetika. Arzneiverordnungs-Report 2011 2011. [DOI: 10.1007/978-3-642-21992-4_11] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
588 Reasner C. The Metabolic Syndrome: 2009. Comprehensive Cardiovascular Medicine in the Primary Care Setting 2011. [DOI: 10.1007/978-1-60327-963-5_7] [Reference Citation Analysis]
589 Graydon M. Diabetes in the Elderly. Canadian Journal of Diabetes 2011;35:13-16. [DOI: 10.1016/s1499-2671(11)51001-9] [Reference Citation Analysis]
590 Menéndez Torre E, Lafita Tejedor FJ, Artola Menéndez S, Núñez-cortés JM, Alonso García Á, Puig Domingo M, García Solans JR, Álvarez Guisasola F, García Alegría J, Mediavilla Bravo J, Fernández-santos CM, Romero González R. Recommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes. Endocrinología y Nutrición (English Edition) 2011;58:112-120. [DOI: 10.1016/s2173-5093(11)70022-8] [Reference Citation Analysis]
591 Gore MO, Inzucchi SE, Mcguire DK. Diabetes and Cardiovascular Disease. Preventive Cardiology: Companion to Braunwald's Heart Disease 2011. [DOI: 10.1016/b978-1-4377-1366-4.00021-4] [Reference Citation Analysis]
592 Hansel B, Bastard J, Bruckert E. Syndrome métabolique. EMC - Endocrinologie - Nutrition 2011;8:1-12. [DOI: 10.1016/s1155-1941(11)51209-0] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
593 Westerhaus B, Gosmanov AR, Umpierrez GE. Diabetes prevention: can insulin secretagogues do the job? Prim Care Diabetes 2011;5:73-80. [PMID: 21185798 DOI: 10.1016/j.pcd.2010.11.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
594 Jaber LA, Pinelli NR, Brown MB, Funnell MM, Anderson R, Hammad A, Herman WH. Feasibility of group lifestyle intervention for diabetes prevention in Arab Americans. Diabetes Res Clin Pract 2011;91:307-15. [PMID: 21168232 DOI: 10.1016/j.diabres.2010.11.032] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 3.7] [Reference Citation Analysis]
595 Youl E, Bardy G, Magous R, Cros G, Sejalon F, Virsolvy A, Richard S, Quignard JF, Gross R, Petit P, Bataille D, Oiry C. Quercetin potentiates insulin secretion and protects INS-1 pancreatic β-cells against oxidative damage via the ERK1/2 pathway. Br J Pharmacol 2010;161:799-814. [PMID: 20860660 DOI: 10.1111/j.1476-5381.2010.00910.x] [Cited by in Crossref: 157] [Cited by in F6Publishing: 137] [Article Influence: 13.1] [Reference Citation Analysis]
596 Ohta T, Miyajima K, Yamada T. Changes in Glycolipid Metabolism During A High-Sucrose Feeding in Spontaneously Diabetic Torii (SDT) Rats, A Genetic Model of Nonobese Type 2 Diabetes. J of Animal and Veterinary Advances 2010;9:2883-9. [DOI: 10.3923/javaa.2010.2883.2889] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
597 Volpe M, Borghi C, Cavallo Perin P, Chiariello M, Manzato E, Miccoli R, Modena MG, Riccardi G, Sesti G, Tiengo A, Trimarco B, Vanuzzo D, Verdecchia P, Zaninelli A, Del Prato S. 2009 SIPREC Consensus Document – Executive Summary. High Blood Pressure & Cardiovascular Prevention 2010;17:237-247. [DOI: 10.2165/11311990-000000000-00000] [Reference Citation Analysis]
598 DREAM On (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication Ongoing Follow-up) Investigators. Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes. Diabetologia 2011;54:487-95. [DOI: 10.1007/s00125-010-1985-4] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
599 Mayer-davis EJ, Dabelea D, Lawrence JM, Meigs JB, Teff K. Risk Factors for Type 2 and Gestational Diabetes. Diabetes Public Health 2010. [DOI: 10.1093/acprof:oso/9780195317060.003.0003] [Reference Citation Analysis]
600 Imperatore G, Linder B, Pettitt DJ. Diabetes in the Young. Diabetes Public Health 2010. [DOI: 10.1093/acprof:oso/9780195317060.003.0027] [Reference Citation Analysis]
601 Ramachandran A, Snehalatha C. Diabetes Prevention and Control Programs in Developing Countries. Diabetes Public Health 2010. [DOI: 10.1093/acprof:oso/9780195317060.003.0026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
602 Knowler WC, Hoskin M, Curtis JM, Nelson RG, Hanson RL. Prevention of Type 2 Diabetes. Diabetes Public Health 2010. [DOI: 10.1093/acprof:oso/9780195317060.003.0015] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
603 Pour OR, Dagogo-Jack S. Prediabetes as a therapeutic target. Clin Chem 2011;57:215-20. [PMID: 21062906 DOI: 10.1373/clinchem.2010.149096] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
604 Brand-Miller JC, Atkinson FS, Gahler RJ, Kacinik V, Lyon MR, Wood S. Effects of PGX, a novel functional fibre, on acute and delayed postprandial glycaemia. Eur J Clin Nutr 2010;64:1488-93. [PMID: 20924393 DOI: 10.1038/ejcn.2010.199] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
605 Stuebe A, Ecker J, Bates DW, Zera C, Bentley-Lewis R, Seely E. Barriers to follow-up for women with a history of gestational diabetes. Am J Perinatol 2010;27:705-10. [PMID: 20387186 DOI: 10.1055/s-0030-1253102] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 3.2] [Reference Citation Analysis]
606 Hunt KJ, Logan SL, Conway DL, Korte JE. Postpartum screening following GDM: how well are we doing? Curr Diab Rep 2010;10:235-41. [PMID: 20425588 DOI: 10.1007/s11892-010-0110-x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 4.0] [Reference Citation Analysis]
607 Uchida T, Kawai J, Fujitani Y, Kawamori R, Watada H, Hirose T. Efficacy and adverse effects of low-dose nateglinide in early type 2 diabetes: comparison with acarbose in a crossover study. Diabetol Int 2010;1:35-41. [DOI: 10.1007/s13340-010-0002-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
608 Hogan S, Zhang L, Li J, Sun S, Canning C, Zhou K. Antioxidant rich grape pomace extract suppresses postprandial hyperglycemia in diabetic mice by specifically inhibiting alpha-glucosidase. Nutr Metab (Lond) 2010;7:71. [PMID: 20799969 DOI: 10.1186/1743-7075-7-71] [Cited by in Crossref: 111] [Cited by in F6Publishing: 112] [Article Influence: 9.3] [Reference Citation Analysis]
609 References. Diabetic Neurology 2010. [DOI: 10.3109/9781420085549-19] [Reference Citation Analysis]
610 Saaristo T, Moilanen L, Korpi-Hyövälti E, Vanhala M, Saltevo J, Niskanen L, Jokelainen J, Peltonen M, Oksa H, Tuomilehto J. Lifestyle intervention for prevention of type 2 diabetes in primary health care: one-year follow-up of the Finnish National Diabetes Prevention Program (FIN-D2D). Diabetes Care. 2010;33:2146-2151. [PMID: 20664020 DOI: 10.2337/dc10-0410] [Cited by in Crossref: 219] [Cited by in F6Publishing: 236] [Article Influence: 18.3] [Reference Citation Analysis]
611 Mann DM, Carson AP, Shimbo D, Fonseca V, Fox CS, Muntner P. Impact of A1C screening criterion on the diagnosis of pre-diabetes among U.S. adults. Diabetes Care. 2010;33:2190-2195. [PMID: 20628087 DOI: 10.2337/dc10-0752] [Cited by in Crossref: 87] [Cited by in F6Publishing: 92] [Article Influence: 7.3] [Reference Citation Analysis]
612 Bailey CJ, Krentz AJ. Oral Antidiabetic Agents. Textbook of Diabetes 2010. [DOI: 10.1002/9781444324808.ch29] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
613 American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care. 2010;33 Suppl 1:S11-S61. [PMID: 20042772 DOI: 10.2337/dc10-s011] [Cited by in Crossref: 2086] [Cited by in F6Publishing: 2353] [Article Influence: 173.8] [Reference Citation Analysis]
614 Chrysant SG. Stopping the cardiovascular disease continuum: Focus on prevention. World J Cardiol 2010; 2(3): 43-49 [PMID: 21160754 DOI: 10.4330/wjc.v2.i3.43] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
615 Furman BL. Endocrine and Metabolic Agents. Pharmaceutical Sciences Encyclopedia 2010. [DOI: 10.1002/9780470571224.pse024] [Reference Citation Analysis]
616 Sena CM, Bento CF, Pereira P, Seiça R. Diabetes mellitus: new challenges and innovative therapies. EPMA J 2010;1:138-63. [PMID: 23199048 DOI: 10.1007/s13167-010-0010-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 2.9] [Reference Citation Analysis]
617 Schnell O, Standl E. Diabetes and cardiovascular disease: Current status of trials. Clin Res Cardiol Suppl 2010;5:27-34. [DOI: 10.1007/s11789-010-0009-8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
618 Sheehan JP. Bad medicine: there is a lot wrong with diabetes care in the United States. Cult Med Psychiatry 2010;34:2-12. [PMID: 20066481 DOI: 10.1007/s11013-009-9158-y] [Reference Citation Analysis]
619 Garber AJ. Combined pharmacologic/nonpharmacologic intervention in individuals at high risk of developing type 2 diabetes: pro pharmacologic therapy. Diabetes Care 2009;32 Suppl 2:S184-8. [PMID: 19875549 DOI: 10.2337/dc09-S307] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
620 Chiasson JL. Early insulin use in type 2 diabetes: what are the cons? Diabetes Care 2009;32 Suppl 2:S270-4. [PMID: 19875563 DOI: 10.2337/dc09-S321] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
621 Humpert PM. Oxidative stress and glucose metabolism--is there a need to revisit effects of insulin treatment? Diabetologia 2010;53:403-5. [PMID: 20052454 DOI: 10.1007/s00125-009-1652-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
622 Buyken AE, Mitchell P, Ceriello A, Brand-Miller J. Optimal dietary approaches for prevention of type 2 diabetes: a life-course perspective. Diabetologia 2010;53:406-18. [PMID: 20049415 DOI: 10.1007/s00125-009-1629-8] [Cited by in Crossref: 79] [Cited by in F6Publishing: 58] [Article Influence: 6.6] [Reference Citation Analysis]
623 Horton ES. Prevention of Type 2 Diabetes Mellitus. Principles of Diabetes Mellitus 2010. [DOI: 10.1007/978-0-387-09841-8_50] [Reference Citation Analysis]
624 Lara-castro C, Garvey WT. Role of Nutrition in the Pathophysiology, Prevention, and Treatment of Type 2 Diabetes and the Spectrum of Cardiometabolic Disease. Preventive Nutrition 2010. [DOI: 10.1007/978-1-60327-542-2_15] [Reference Citation Analysis]
625 Dinneen SF, Rizza RA. Classification and Diagnosis of Diabetes Mellitus. Endocrinology 2010. [DOI: 10.1016/b978-1-4160-5583-9.00039-3] [Reference Citation Analysis]
626 Mengel K. Antidiabetika. Arzneiverordnungs-Report 2010 2010. [DOI: 10.1007/978-3-642-13380-0_11] [Reference Citation Analysis]
627 Wong JM, Josse AR, Augustin L, Saxena N, Chiavaroli L, Kendall CW, Jenkins DJ. Implications of the Glycemic Index in Obesity. Obesity Prevention 2010. [DOI: 10.1016/b978-0-12-374387-9.00017-9] [Reference Citation Analysis]
628 Monnier L, Colette C. Diététique des états diabétiques. EMC - Endocrinologie - Nutrition 2010;7:1-12. [DOI: 10.1016/s1155-1941(09)51220-6] [Reference Citation Analysis]
629 Mangyo R. The Role and Effect of Group Work in the Diabetes Prevention Classroom. Rigakuryoho kagaku 2010;25:451-455. [DOI: 10.1589/rika.25.451] [Reference Citation Analysis]
630 Colette C, Monnier L. Diététique des états diabétiques. Diabétologie 2010. [DOI: 10.1016/b978-2-294-70868-8.50006-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
631 Zaccardi F, Stefano PD, Busetto E, Federici MO, Manto A, Infusino F, Lanza GA, Pitocco D, Ghirlanda G. Group of signs: a new method to evaluate glycemic variability. J Diabetes Sci Technol 2008;2:1061-5. [PMID: 19885294 DOI: 10.1177/193229680800200614] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
632 DeFronzo RA, Banerji MA, Bray GA, Buchanan TA, Clement S, Henry RR, Kitabchi AE, Mudaliar S, Musi N, Ratner R, Reaven P, Schwenke DC, Stentz FD, Tripathy D; ACT NOW Study Group. Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study. Diabetologia 2010;53:435-45. [PMID: 20012012 DOI: 10.1007/s00125-009-1614-2] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 3.8] [Reference Citation Analysis]
633 Bray GA. Preventing Diabetes: Lessons Learned from the Diabetes Prevention Program and Its Follow-Up. Obesity and Weight Management 2009;5:273-276. [DOI: 10.1089/obe.2009.0603] [Reference Citation Analysis]
634 Bang H, Edwards AM, Bomback AS, Ballantyne CM, Brillon D, Callahan MA, Teutsch SM, Mushlin AI, Kern LM. Development and validation of a patient self-assessment score for diabetes risk. Ann Intern Med 2009;151:775-83. [PMID: 19949143 DOI: 10.7326/0003-4819-151-11-200912010-00005] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
635 Nicholas AS, Nadeau DA, Johnson ACL. Treatment Considerations for Diabetes: A Pharmacist’s Guide to Improving Care in the Elderly. Journal of Pharmacy Practice 2009;22:575-587. [DOI: 10.1177/0897190009333160] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
636 Bang H, Edwards AM, Bomback AS, Ballantyne CM, Brillon D, Callahan MA, Teutsch SM, Mushlin AI, Kern LM. Development and validation of a patient self-assessment score for diabetes risk. Ann Intern Med 2009;151:775-83. [PMID: 19949143 DOI: 10.7326/0003-4819-151-11-200912010-00005] [Cited by in Crossref: 186] [Cited by in F6Publishing: 203] [Article Influence: 14.3] [Reference Citation Analysis]
637 Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM; Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009;374:1677-86. [PMID: 19878986 DOI: 10.1016/S0140-6736(09)61457-4] [Cited by in Crossref: 1908] [Cited by in F6Publishing: 2056] [Article Influence: 146.8] [Reference Citation Analysis]
638 Rhee MK, Herrick K, Ziemer DC, Vaccarino V, Weintraub WS, Narayan KM, Kolm P, Twombly JG, Phillips LS. Many Americans have pre-diabetes and should be considered for metformin therapy. Diabetes Care 2010;33:49-54. [PMID: 19808929 DOI: 10.2337/dc09-0341] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 4.1] [Reference Citation Analysis]
639 Schwarz P, Köhler D, Hoffmann R, Landgraf R. Prävention des Diabetes mellitus Typ 2. Diabetologe 2009;5:471-486. [DOI: 10.1007/s11428-008-0354-0] [Reference Citation Analysis]
640 O'Keefe JH, Carter MD, Lavie CJ. Primary and secondary prevention of cardiovascular diseases: a practical evidence-based approach. Mayo Clin Proc 2009;84:741-57. [PMID: 19648392 DOI: 10.1016/S0025-6196(11)60525-9] [Cited by in F6Publishing: 47] [Reference Citation Analysis]
641 Cosentino F, Rydén L, Francia P, Mellbin LG. Diabetes Mellitus and Metabolic Syndrome. The ESC Textbook of Cardiovascular Medicine 2009. [DOI: 10.1093/med/9780199566990.003.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
642 Stefan N, Fritsche A, Häring HU. [Individualized prevention of type 2 diabetes]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2009;52:677-82. [PMID: 19626284 DOI: 10.1007/s00103-009-0868-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
643 Fisman EZ, Tenenbaum A. A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. Cardiovasc Diabetol 2009;8:38. [PMID: 19619327 DOI: 10.1186/1475-2840-8-38] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 2.5] [Reference Citation Analysis]
644 Perreault L, Kahn SE, Christophi CA, Knowler WC, Hamman RF;  Diabetes Prevention Program Research Group. Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program. Diabetes Care. 2009;32:1583-1588. [PMID: 19587364 DOI: 10.2337/dc09-0523] [Cited by in Crossref: 121] [Cited by in F6Publishing: 128] [Article Influence: 9.3] [Reference Citation Analysis]
645 González Sarmiento E, Fernández Galante I, Fernández Martínez I, Hinojosa Mena-bernal M, Jabary N. Resistencia a la insulina, síndrome metabólico y metabolismo de la glucosa en pacientes con hipertensión arterial esencial. Hipertensión y Riesgo Vascular 2009;26:145-150. [DOI: 10.1016/s1889-1837(09)72174-9] [Reference Citation Analysis]
646 Florez JC. Genetic susceptibility to type 2 diabetes and implications for therapy. J Diabetes Sci Technol 2009;3:690-6. [PMID: 20144315 DOI: 10.1177/193229680900300413] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
647 Tabák AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimäki M, Witte DR. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 2009;373:2215-21. [PMID: 19515410 DOI: 10.1016/S0140-6736(09)60619-X] [Cited by in Crossref: 552] [Cited by in F6Publishing: 576] [Article Influence: 42.5] [Reference Citation Analysis]
648 Hill AN, Roche C, Appel SJ. Signs of improvement: Diabetes update 2009. The Nurse Practitioner 2009;34:12-22. [DOI: 10.1097/01.npr.0000352283.97228.10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
649 Uusitupa M, Peltonen M, Lindström J, Aunola S, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Valle TT, Eriksson JG, Tuomilehto J; Finnish Diabetes Prevention Study Group. Ten-year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study--secondary analysis of the randomized trial. PLoS One 2009;4:e5656. [PMID: 19479072 DOI: 10.1371/journal.pone.0005656] [Cited by in Crossref: 124] [Cited by in F6Publishing: 135] [Article Influence: 9.5] [Reference Citation Analysis]
650 American Diabetes Association. Standards of medical care in diabetes--2009. Diabetes Care 2009;32 Suppl 1:S13-61. [PMID: 19118286 DOI: 10.2337/dc09-S013] [Cited by in Crossref: 1159] [Cited by in F6Publishing: 1311] [Article Influence: 89.2] [Reference Citation Analysis]
651 van de Laar FA. Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes. Vasc Health Risk Manag 2008;4:1189-95. [PMID: 19337532 DOI: 10.2147/vhrm.s3119] [Cited by in Crossref: 189] [Cited by in F6Publishing: 196] [Article Influence: 14.5] [Reference Citation Analysis]
652 Hunte S, Tulloch-reid M. Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Curr Cardio Risk Rep 2009;3:157-8. [DOI: 10.1007/s12170-009-0025-8] [Reference Citation Analysis]
653 Seebauer W. Krebs, Diabetes und Ernährung – Ergebnisse der EPIC-Studie. Komplementäre und Integrative Medizin 2009;50:19-26. [DOI: 10.1016/j.kim.2009.02.014] [Reference Citation Analysis]
654 Hippisley-Cox J, Coupland C, Robson J, Sheikh A, Brindle P. Predicting risk of type 2 diabetes in England and Wales: prospective derivation and validation of QDScore. BMJ 2009;338:b880. [PMID: 19297312 DOI: 10.1136/bmj.b880] [Cited by in Crossref: 219] [Cited by in F6Publishing: 250] [Article Influence: 16.8] [Reference Citation Analysis]
655 Shlyakhto EV, Grineva EN, Babenko AY, Dronova AV. Features of treatment of type 2 diabetes mellitus in patients with concomitant pathology. Arter gipertenz 2009;15:31-41. [DOI: 10.18705/1607-419x-2009-15-1-31-41] [Reference Citation Analysis]
656 Hayashino Y, Hennekens CH, Kurth T. Aspirin use and risk of type 2 diabetes in apparently healthy men. Am J Med 2009;122:374-9. [PMID: 19233341 DOI: 10.1016/j.amjmed.2008.09.044] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
657 Basile JN. Antihypertensive therapy, new-onset diabetes, and cardiovascular disease. Int J Clin Pract 2009;63:656-66. [PMID: 19220522 DOI: 10.1111/j.1742-1241.2009.02009.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
658 Zeitler P, Pinhas-Hamiel O. Prevention and screening for type 2 diabetes in youth. Endocr Res 2008;33:73-91. [PMID: 19156575 DOI: 10.1080/07435800802080369] [Reference Citation Analysis]
659 Shimazu T, Inami N, Satoh D, Kajiura T, Yamada K, Iwasaka T, Nomura S. Effect of acarbose on platelet-derived microparticles, soluble selectins, and adiponectin in diabetic patients. J Thromb Thrombolysis. 2009;28:429-435. [PMID: 19137265 DOI: 10.1007/s11239-008-0301-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 2.4] [Reference Citation Analysis]
660 Bottomley JM, Raymond FD. Pharmaco-economic issues for diabetes therapy. Insulin 2009;4:32-60. [DOI: 10.1016/s1557-0843(09)80005-5] [Reference Citation Analysis]
661 Sadikot SM. The Epidemiology of Diabetes in Women and the Looming Epidemic of GDM in the Third World. Diabetes in Women 2009. [DOI: 10.1007/978-1-60327-250-6_12] [Reference Citation Analysis]
662 Shaw JE, Simpson RW. Prevention of Type 2 Diabetes. Diabetes and Exercise 2009. [DOI: 10.1007/978-1-59745-260-1_2] [Reference Citation Analysis]
663 Kaplan RM. Diabetes, Obesity, and the Metabolic Syndrome. Disease, Diagnoses, and Dollars 2009. [DOI: 10.1007/978-0-387-74045-4_8] [Reference Citation Analysis]
664 Florez HJ, Sanchez AA, Marks JB. Type 2 Diabetes. Diabetes and the Brain 2009. [DOI: 10.1007/978-1-60327-850-8_2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
665 Hu FB. Diet and Physical Activity in the Prevention of Obesity. Nutrition and Metabolism 2009. [DOI: 10.1007/978-1-60327-453-1_7] [Reference Citation Analysis]
666 Yannakoulia M, Fappa E, Hwang JJ, Mantzoros CS. Diet and Exercise in the Prevention and Management of the Metabolic Syndrome. Nutrition and Metabolism 2009. [DOI: 10.1007/978-1-60327-453-1_8] [Reference Citation Analysis]
667 Blake EW, Sease JM. Effect of Diabetes Medications on Cardiovascular Risk and Surrogate Markers in Patients with Type 2 Diabetes. Journal of Pharmacy Technology 2009;25:24-36. [DOI: 10.1177/875512250902500105] [Reference Citation Analysis]
668 Westman EC, Yancy WS Jr, Mavropoulos JC, Marquart M, McDuffie JR. The effect of a low-carbohydrate, ketogenic diet versus a low-glycemic index diet on glycemic control in type 2 diabetes mellitus. Nutr Metab (Lond) 2008;5:36. [PMID: 19099589 DOI: 10.1186/1743-7075-5-36] [Cited by in Crossref: 240] [Cited by in F6Publishing: 266] [Article Influence: 17.1] [Reference Citation Analysis]
669 Britov AN. Lechenie sakharnogo diabeta 2-go tipa tiaglitazonami; vliyanie na sostoyanie serdechno-sosudistoy sistemy. Obes metabol 2008;5:11-17. [DOI: 10.14341/2071-8713-5221] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
670 Mirhashemi F, Kluth O, Scherneck S, Vogel H, Kluge R, Schurmann A, Joost HG, Neschen S. High-fat, carbohydrate-free diet markedly aggravates obesity but prevents beta-cell loss and diabetes in the obese, diabetes-susceptible db/db strain. Obes Facts 2008;1:292-7. [PMID: 20054191 DOI: 10.1159/000176064] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
671 Bloomgarden ZT. American College Of Endocrinology Pre-Diabetes Consensus Conference: part one. Diabetes Care. 2008;31:2062-2069. [PMID: 18820229 DOI: 10.2337/dc08-zb10] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
672 Schwarz PEH, Schwarz J, Bergmann A, Hühmer U, Bornstein SR. Perspectives and challenges to undertake diabetes prevention in clinical practice. Diabetes & Vascular Disease 2008;8:295-298. [DOI: 10.1177/1474651408098986] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
673 Bloomgarden ZT. American College of Endocrinology Pre-Diabetes Consensus Conference: part two. Diabetes Care 2008;31:2222-9. [PMID: 18955719 DOI: 10.2337/dc08-zb11] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
674 Duffy H, Brown-friday JO, Walker EA. Prevention: Educating Those at Risk for Diabetes. Educating Your Patient with Diabetes. [DOI: 10.1007/978-1-60327-208-7_19] [Reference Citation Analysis]
675 Mühlhauser I. Diabetes experts' reasoning about diabetes prevention studies: a questionnaire survey. BMC Res Notes 2008;1:90. [PMID: 18854022 DOI: 10.1186/1756-0500-1-90] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
676 Mateos Polo L, Hernndez Criado J, Cubino Bveda N, Garca Mingo A. Antidiab?ticos orales. Medicine - Programa de Formaci?n M?dica Continuada Acreditado 2008;10:1188-1194. [DOI: 10.1016/s0211-3449(08)73226-0] [Reference Citation Analysis]
677 Gmez Marcos M, Garca Ortiz L. Manejo general y extrahospitalario del paciente con diabetes. Valoraci?n de la sintomatolog?a. Procesos intercurrentes. Medicine - Programa de Formaci?n M?dica Continuada Acreditado 2008;10:1138-1148. [DOI: 10.1016/s0211-3449(08)73217-x] [Reference Citation Analysis]
678 Feig DS, Zinman B, Wang X, Hux JE. Risk of development of diabetes mellitus after diagnosis of gestational diabetes. CMAJ. 2008;179:229-234. [PMID: 18663202 DOI: 10.1503/cmaj.080012] [Cited by in Crossref: 284] [Cited by in F6Publishing: 303] [Article Influence: 20.3] [Reference Citation Analysis]
679 Mengel K. Antidiabetika. Arzneiverordnungs-Report 2007. [DOI: 10.1007/978-3-540-72548-0_12] [Reference Citation Analysis]
680 Huang JF, Yu ML, Dai CY, Hsieh MY, Hwang SJ, Hsiao PJ, Lee LP, Lin ZY, Chen SC, Hsieh MY, Wang LY, Shin SJ, Chang WY, Chuang WL. Reappraisal of the characteristics of glucose abnormalities in patients with chronic hepatitis C infection. Am J Gastroenterol 2008;103:1933-40. [PMID: 18637090 DOI: 10.1111/j.1572-0241.2008.01996.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 2.9] [Reference Citation Analysis]
681 Doyle A, Desilva P, Koduah D, Birdi J, Sabah M, King R. An insight into undiagnosed impaired glucose regulation. Prim Care Diabetes 2007;1:155-8. [PMID: 18632037 DOI: 10.1016/j.pcd.2007.07.001] [Reference Citation Analysis]
682 Giugliano D, Ceriello A, Razzoli E, Esposito K. Defining the role of insulin lispro in the management of postprandial hyperglycaemia in patients with type 2 diabetes mellitus. Clin Drug Investig 2008;28:199-210. [PMID: 18345710 DOI: 10.2165/00044011-200828040-00001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
683 Joshi P, Joshi S. Type 2 diabetes: Primary prevention, screening and health care approach for diagnosis in South Africa. South African Family Practice 2008;50:14-20. [DOI: 10.1080/20786204.2008.10873733] [Reference Citation Analysis]
684 Hsueh WA, Handelsman Y. Pharmacologic treatment options for prediabetes. Nat Rev Endocrinol 2008;4:380-381. [DOI: 10.1038/ncpendmet0842] [Reference Citation Analysis]
685 Devers M, Fisher M. Glycaemic control and metabolic risk: getting the extra mile from diabetes control. Pract Diab Int 2008;25:233-6. [DOI: 10.1002/pdi.1260] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
686 Kawahara T, Takahashi K, Inazu T, Arao T, Kawahara C, Tabata T, Moriyama H, Okada Y, Morita E, Tanaka Y. Reduced progression to type 2 diabetes from impaired glucose tolerance after a 2-day in-hospital diabetes educational program: the Joetsu Diabetes Prevention Trial. Diabetes Care 2008;31:1949-54. [PMID: 18591401 DOI: 10.2337/dc07-2272] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
687 Joost HG. Pathogenesis, risk assessment and prevention of type 2 diabetes mellitus. Obes Facts. 2008;1:128-137. [PMID: 20054172 DOI: 10.1159/000137673] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
688 Ballesteros-pomar MD, León-sanz M. Nutrition in the metabolic syndrome: Pharmacological treatment. e-SPEN, the European e-Journal of Clinical Nutrition and Metabolism 2008;3:e108-e116. [DOI: 10.1016/j.eclnm.2008.02.001] [Reference Citation Analysis]
689 Rotella CM, Pala L. Time to insulin in type-2 diabetes: high hurdles or Santiago way? Acta Diabetol 2008;45:67-74. [PMID: 18408882 DOI: 10.1007/s00592-008-0027-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
690 Rendell MS. Insulin treatment of post-prandial hyperglycemia. Drug Dev Res 2008;69:124-129. [DOI: 10.1002/ddr.20237] [Reference Citation Analysis]
691 Bethel MA. Therapies for Delay or Prevention of Type 2 Diabetes. Type 2 Diabetes Mellitus. [DOI: 10.1007/978-1-60327-043-4_6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
692 Gillies CL, Lambert PC, Abrams KR, Sutton AJ, Cooper NJ, Hsu RT, Davies MJ, Khunti K. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ. 2008;336:1180-1185. [PMID: 18426840 DOI: 10.1136/bmj.39545.585289.25] [Cited by in Crossref: 181] [Cited by in F6Publishing: 201] [Article Influence: 12.9] [Reference Citation Analysis]
693 Godbout A, Chiasson JL. Who should benefit from the use of alpha-glucosidase inhibitors? Curr Diab Rep 2007;7:333-9. [PMID: 18173965 DOI: 10.1007/s11892-007-0055-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
694 Schwarz PE, Li J, Lindström J, Bergmann A, Gruhl U, Saaristo T, Tuomilehto J. How should the clinician most effectively prevent type 2 diabetes in the obese person at high risk? Curr Diab Rep 2007;7:353-62. [PMID: 18173968 DOI: 10.1007/s11892-007-0058-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
695 Fonseca VA, Bratcher C, Thethi T. Pharmacological treatment of the insulin resistance syndrome in people without diabetes. Metab Syndr Relat Disord 2005;3:332-8. [PMID: 18370733 DOI: 10.1089/met.2005.3.332] [Reference Citation Analysis]
696 Wyne KL. Management of type 2 diabetes mellitus: is it time for a paradigm shift? Metab Syndr Relat Disord 2004;2:251-62. [PMID: 18370694 DOI: 10.1089/met.2004.2.251] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
697 émile C. Nouvelles stratégies thérapeutiques du diabète de type 2. Option/Bio 2008;19:8-9. [DOI: 10.1016/s0992-5945(08)70078-3] [Reference Citation Analysis]
698 Everitt AV, Hilmer SN, Brand-Miller JC, Jamieson HA, Truswell AS, Sharma AP, Mason RS, Morris BJ, Le Couteur DG. Dietary approaches that delay age-related diseases. Clin Interv Aging 2006;1:11-31. [PMID: 18047254 DOI: 10.2147/ciia.2006.1.1.11] [Cited by in Crossref: 113] [Cited by in F6Publishing: 85] [Article Influence: 8.1] [Reference Citation Analysis]
699 Lingvay I, Rhee C, Raskin P. Type 2 Diabetes Mellitus: An Evidence-Based Approach to Practical Management. Type 2 Diabetes Mellitus 2008. [DOI: 10.1007/978-1-60327-043-4_10] [Reference Citation Analysis]
700 Soto A, Iglesias M, Buño M, Bellido D. Metformina. Endocrinología y Nutrición 2008;55:39-52. [DOI: 10.1016/s1575-0922(08)76262-4] [Reference Citation Analysis]
701 Mengel K. Antidiabetika. Arzneiverordnungs-Report 2008 2008. [DOI: 10.1007/978-3-540-69219-5_11] [Reference Citation Analysis]
702 Clinical Management of the Metabolic Syndrome. The Metabolic Syndrome in Clinical Practice 2008. [DOI: 10.1007/978-1-84628-911-8_6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
703 Aiello LP, Cavallerano J, Prakash M, Aiello LM. Diagnosis, Management, and Treatment of Nonproliferative Diabetic Retinopathy. Albert &amp;amp Jakobiec's Principles &amp;amp Practice of Ophthalmology 2008. [DOI: 10.1016/b978-1-4160-0016-7.50136-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
704 Gomis R. Inhibidores de las disacaridasas. Endocrinología y Nutrición 2008;55:13-16. [DOI: 10.1016/s1575-0922(08)76258-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
705 Peter R, Rees A. Review: Postprandial glycaemia and cardiovascular risk. Diabetes & Vascular Disease 2008;8:8-14. [DOI: 10.1177/14746514080080010401] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
706 Émile C. Traitement médicamenteux du diabète de type 2, actualités et nouveautés. Actualités Pharmaceutiques 2008;47:29-30. [DOI: 10.1016/s0515-3700(08)70306-9] [Reference Citation Analysis]
707 Meigs JB. Metabolic Syndrome. Controversies in Treating Diabetes 2008. [DOI: 10.1007/978-1-59745-572-5_3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
708 Demidova TY, Galieva OR. Profilaktika i upravlenie prediabeticheskimi narusheniyami uglevodnogo obmena u bol'nykhs metabolicheskim sindromom. Obes metabol 2007;4:19-24. [DOI: 10.14341/2071-8713-5001] [Reference Citation Analysis]
709 Rasmussen SS, Glümer C, Sandbaek A, Lauritzen T, Borch-Johnsen K. Determinants of progression from impaired fasting glucose and impaired glucose tolerance to diabetes in a high-risk screened population: 3 year follow-up in the ADDITION study, Denmark. Diabetologia 2008;51:249-57. [PMID: 18060659 DOI: 10.1007/s00125-007-0893-8] [Cited by in Crossref: 70] [Cited by in F6Publishing: 71] [Article Influence: 4.7] [Reference Citation Analysis]
710 Nichols GA, Koro CE, Kolatkar NS. The epidemiology of congestive heart failure in hyperglycemia below the threshold for diabetes: A critical review. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2007;1:273-8. [DOI: 10.1016/j.dsx.2007.09.004] [Reference Citation Analysis]
711 Tan AS, Brietzke SA, Gardner DW, Sowers JR. Obesity, Diabetes, and Hypertension. Contemporary Diabetes. [DOI: 10.1007/978-1-59259-985-1_10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
712 Blackburn GL. Diet, Exercise, and Behavioral Treatment of Obesity. Contemporary Diabetes. [DOI: 10.1007/978-1-59259-985-1_25] [Reference Citation Analysis]
713 Crandall J. Type 2 Diabetes. Type 2 Diabetes 2007. [DOI: 10.3109/9780849379581-33] [Reference Citation Analysis]
714 Capes SE. The Patient at Risk for Diabetes Considering Prevention. Evidence-Based Endocrinology. [DOI: 10.1007/978-1-59745-008-9_19] [Reference Citation Analysis]
715 Hoogwerf BJ. Diabetes Mellitus, Hyperinsulinemia, and Coronary Artery Disease. Contemporary Cardiology. [DOI: 10.1007/978-1-59745-096-6_7] [Reference Citation Analysis]
716 Ülgen MS, Soylu A, Düzenli MA. Antidiabetic Treatment In Diabetic Patients With Coronary Artery Disease. ELECTRON J GEN MED 2007;4:190-198. [DOI: 10.29333/ejgm/82528] [Reference Citation Analysis]
717 Zeitler P. Type 2 Diabetes in Children and Adolescents: Treatment. Obesity Management 2007;3:216-221. [DOI: 10.1089/obe.2007.0066] [Reference Citation Analysis]
718 Lau DC, Yan H, Dhillon B. Metabolic syndrome: a marker of patients at high cardiovascular risk. Can J Cardiol 2006;22 Suppl B:85B-90B. [PMID: 16498518 DOI: 10.1016/s0828-282x(06)70992-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 2.0] [Reference Citation Analysis]
719 Hunt KJ, Schuller KL. The increasing prevalence of diabetes in pregnancy. Obstet Gynecol Clin North Am. 2007;34:173-199, vii. [PMID: 17572266 DOI: 10.16/j.ogc.2007.03.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
720 Hunt KJ, Schuller KL. The increasing prevalence of diabetes in pregnancy. Obstet Gynecol Clin North Am. 2007;34:173-199, vii. [PMID: 17572266 DOI: 10.1016/j.ogc.2007.03.002] [Cited by in Crossref: 319] [Cited by in F6Publishing: 339] [Article Influence: 21.3] [Reference Citation Analysis]
721 Chapter 1: Introduction. European Journal of Cardiovascular Prevention & Rehabilitation 2007;14:S2-S113. [DOI: 10.1097/01.hjr.0000277985.25720.16] [Reference Citation Analysis]
722 Hayashino Y, Fukuhara S, Suzukamo Y, Okamura T, Tanaka T, Ueshima H. Normal fasting plasma glucose levels and type 2 diabetes: the high-risk and population strategy for occupational health promotion (HIPOP-OHP) [corrected] study. Acta Diabetol 2007;44:164-6. [PMID: 17721756 DOI: 10.1007/s00592-007-0258-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
723 Schwarz PEH, Gruhl U, Bornstein SR, Landgraf R, Hall M, Tuomilehto J. Development and Implementation of A European Guideline and Training Standards for Diabetes Prevention-The IMAGE project. J Public Health 2007;15:353-60. [DOI: 10.1007/s10389-007-0145-x] [Reference Citation Analysis]
724 Srikanth S, Deedwania P. Management of coronary artery disease in patients with type 2 diabetes mellitus. Curr Cardiol Rep 2007;9:264-71. [PMID: 17601392 DOI: 10.1007/BF02938374] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
725 Hanefeld M. Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes. Cardiovasc Diabetol 2007;6:20. [PMID: 17697384 DOI: 10.1186/1475-2840-6-20] [Cited by in Crossref: 61] [Cited by in F6Publishing: 66] [Article Influence: 4.1] [Reference Citation Analysis]
726 Pfützner A, Forst T. A Diabetes Outcome and Progression Trial – Die ADOPT Studie. Diabetologe 2007;3:261-269. [DOI: 10.1007/s11428-007-0138-y] [Reference Citation Analysis]
727 Miyazaki Y, Kawano H, Yoshida T, Miyamoto S, Hokamaki J, Nagayoshi Y, Yamabe H, Nakamura H, Yodoi J, Ogawa H. Pancreatic B-cell function is altered by oxidative stress induced by acute hyperglycaemia. Diabet Med 2007;24:154-60. [PMID: 17257277 DOI: 10.1111/j.1464-5491.2007.02058.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 44] [Article Influence: 2.5] [Reference Citation Analysis]
728 Nichols GA, Hillier TA, Brown JB. Progression from newly acquired impaired fasting glusose to type 2 diabetes. Diabetes Care 2007;30:228-33. [PMID: 17259486 DOI: 10.2337/dc06-1392] [Cited by in Crossref: 170] [Cited by in F6Publishing: 181] [Article Influence: 11.3] [Reference Citation Analysis]
729 Wiegand S. Die Therapie des Typ-2-Diabetes-mellitus. Monatsschr Kinderheilkd 2007;155:M19-M28. [DOI: 10.1007/s00112-007-1535-4] [Reference Citation Analysis]
730 Barrios V, Escobar C, Calderón A. Beneficios adicionales del tratamiento con candesartán en la insuficiencia cardíaca. Programa CHARM. Hipertensión 2007;24:34-42. [DOI: 10.1016/s0212-8241(07)75767-5] [Reference Citation Analysis]
731 Vigil Medina L, López Jiménez M, García Carretero R. Recomendaciones específicas para el manejo del paciente con síndrome metabólico. Hipertensión 2007;24:101-109. [DOI: 10.1016/s0212-8241(07)72441-6] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
732 Joost H, Mengel K. Antidiabetika. Arzneiverordnungs-Report 2006. [DOI: 10.1007/978-3-540-34370-7_12] [Reference Citation Analysis]
733 Jürgens HS, Neschen S, Ortmann S, Scherneck S, Schmolz K, Schüler G, Schmidt S, Blüher M, Klaus S, Perez-Tilve D, Tschöp MH, Schürmann A, Joost HG. Development of diabetes in obese, insulin-resistant mice: essential role of dietary carbohydrate in beta cell destruction. Diabetologia 2007;50:1481-9. [PMID: 17437079 DOI: 10.1007/s00125-007-0662-8] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
734 Schwarz PE, Schwarz J, Schuppenies A, Bornstein SR, Schulze J. Development of a diabetes prevention management program for clinical practice. Public Health Rep 2007;122:258-63. [PMID: 17357369 DOI: 10.1177/003335490712200216] [Cited by in Crossref: 47] [Cited by in F6Publishing: 53] [Article Influence: 3.1] [Reference Citation Analysis]
735 Reinli K, Guggenbühl B. Diabetesprimärprävention. Diabetologe 2007;3:105-112. [DOI: 10.1007/s11428-007-0115-5] [Reference Citation Analysis]
736 Schwarz P, Gruhl U, Hoffmann R, Bornstein S, Schulze J, Landgraf R. Primärprävention des Diabetes mellitus. Diabetologe 2007;3:86-95. [DOI: 10.1007/s11428-006-0113-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
737 Kohl A, Pfeiffer A. Primärprävention. Diabetologe 2007;3:120-125. [DOI: 10.1007/s11428-006-0106-y] [Reference Citation Analysis]
738 Marks J. Overview of diabetes mellitus. Psychiatric Disorders and Diabetes Mellitus 2007. [DOI: 10.3109/9780203931592-2] [Reference Citation Analysis]
739 Shah V, Pratley RE. The DREAM trial: Using ramipril and rosiglitazone to prevent diabetes. Curr Diab Rep 2007;7:53-55. [DOI: 10.1007/s11892-007-0009-3] [Reference Citation Analysis]
740 Bouskela E, de Aguiar LGK, Nivoit P, Bahia LR, Villela NR, Bottino DA. Dysfonctionnement vasculaire dans les désordres métaboliques : evaluation de quelques essais thérapeutiques. Bulletin de l'Académie Nationale de Médecine 2007;191:475-493. [DOI: 10.1016/s0001-4079(19)33040-7] [Reference Citation Analysis]
741 Laubner K, Seufert J. Medikamentöse Therapie des Diabetes mellitus Typ 2. Internist 2007;48:297-310. [DOI: 10.1007/s00108-006-1789-2] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
742 Gallwitz B. The fate of Beta-cells in type 2 diabetes and the possible role of pharmacological interventions. Rev Diabet Stud 2006;3:208-16. [PMID: 17487346 DOI: 10.1900/RDS.2006.3.208] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
743 Pfeiffer A, Kohl A. Komplexe diätetische und Pharmakotherapie beim metabolischen Syndrom. Internist 2007;48:164-172. [DOI: 10.1007/s00108-006-1795-4] [Reference Citation Analysis]
744 Mariosa LSS, Ribeiro-filho FF, Ribeiro AB, Zanella MT. Diagnosing Abnormal Glucose Tolerance in Hypertensive Women: Are We Making the Best Choice? J CardioMetab Syndrome 2007;2:98-103. [DOI: 10.1111/j.1559-4564.2007.06482.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
745 Davidson MB. Clinical implications of the DREAM Study. Diabetes Care 2007;30:418-20. [PMID: 17259522 DOI: 10.2337/dc06-2051] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
746 Ascaso J, Gonzalez Santos P, Hernandez Mijares A, Mangas Rojas A, Masana L, Millan J, Pallardo LF, Pedro-Botet J, Perez Jimenez F, Pintó X, Plaza I, Rubiés J, Zúñiga M. Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum. Am J Cardiovasc Drugs 2007;7:39-58. [PMID: 17355165 DOI: 10.2165/00129784-200707010-00004] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 2.7] [Reference Citation Analysis]
747 Devers M, Fisher M. Type 2 diabetes: getting off to a good start. Pract Diab Int 2007;24:6-8. [DOI: 10.1002/pdi.1033] [Reference Citation Analysis]
748 Kaku K. 3. Progress in Chemotherapy of Type 2 Diabetes Mellitus. J Jpn Soc Intern Med 2007;96:505-509. [DOI: 10.2169/naika.96.505] [Reference Citation Analysis]
749 Kim S, Kim H, Han KA, Baek SH, Son HS, Cha BS, Min KW. Efficacy and Safety of Mitiglinide in Korean Type 2 Diabetic Patients: Prospective Randomised Multicenter Comparative Phase III Study. J Korean Diabetes Assoc 2007;31:163. [DOI: 10.4093/jkda.2007.31.2.163] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
750 Borch-johnsen K. New Definitions of Diabetes: Consequences. Pharmacotherapy of Diabetes: New Developments 2007. [DOI: 10.1007/978-0-387-69737-6_2] [Reference Citation Analysis]
751 Vinik A. Too Many Notes: Up and Down the Scales of Diabetes Therapy. Clinical Therapeutics 2007;29:1227-35. [DOI: 10.1016/j.clinthera.2007.07.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
752 Pignone M. Rosiglitazone Reduced the Incidence of Diabetes in Patients With Impaired Glucose Tolerance. Clinical Diabetes 2007;25:23-24. [DOI: 10.2337/diaclin.25.1.23] [Reference Citation Analysis]
753 Vigil Medina L, López Jiménez M, García Carretero R. Recomendaciones específicas para el manejo del paciente con síndrome metabólico. Hipertensión y Riesgo Vascular 2007;24:101-109. [DOI: 10.1016/s1889-1837(07)71859-7] [Reference Citation Analysis]
754 Referencias. Bioestadística Para no Estadísticos 2007. [DOI: 10.1016/b978-84-458-1782-7.50018-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
755 Traitement médicamenteux du diabète de type 2recommandation de bonne pratique. Diabetes & Metabolism 2007;33:S26-S105. [DOI: 10.1016/s1262-3636(07)80038-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
756 American Diabetes Association. Standards of medical care in diabetes--2007. Diabetes Care 2007;30 Suppl 1:S4-S41. [PMID: 17192377 DOI: 10.2337/dc07-S004] [Cited by in Crossref: 1032] [Cited by in F6Publishing: 1146] [Article Influence: 64.5] [Reference Citation Analysis]
757 Aguilar D, Solomon SD. ACE inhibitors and angiotensin receptor antagonists and the incidence of new-onset diabetes mellitus: an emerging theme. Drugs 2006;66:1169-77. [PMID: 16827595 DOI: 10.2165/00003495-200666090-00001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
758 Crandall J, Schade D, Ma Y, Fujimoto WY, Barrett-Connor E, Fowler S, Dagogo-Jack S, Andres R; Diabetes Prevention Program Research Group. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J Gerontol A Biol Sci Med Sci 2006;61:1075-81. [PMID: 17077202 DOI: 10.1093/gerona/61.10.1075] [Cited by in Crossref: 161] [Cited by in F6Publishing: 188] [Article Influence: 10.1] [Reference Citation Analysis]
759 Rasmussen SS, Glümer C, Sandbaek A, Lauritzen T, Borch-Johnsen K. Progression from impaired fasting glucose and impaired glucose tolerance to diabetes in a high-risk screening programme in general practice: the ADDITION Study, Denmark. Diabetologia 2007;50:293-7. [PMID: 17143605 DOI: 10.1007/s00125-006-0530-y] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 1.8] [Reference Citation Analysis]
760 Arponen S, Surez Fernndez C. Aspectos actuales y perspectiva de futuro del tratamiento del s?ndrome metab?lico. Medicine - Programa de Formaci?n M?dica Continuada Acreditado 2006;9:4429-4435. [DOI: 10.1016/s0211-3449(06)74449-6] [Reference Citation Analysis]
761 Jawa A, Fonseca V. Metabolic Syndrome and Type 2 Diabetes Mellitus. Metabolic Syndrome and Cardiovascular Disease 2006. [DOI: 10.3109/9781420020601-4] [Reference Citation Analysis]
762 Drummond R, Fisher M. Thiazolidinediones: the answer to everyone's dreams? Pract Diab Int 2006;23:381-383. [DOI: 10.1002/pdi.1016] [Reference Citation Analysis]
763 Llanes de Torres R, Arrieta F, Mora Navarro G. [Pre-diabetes in primary care: diagnosis... and treatment?]. Aten Primaria 2006;37:400-6. [PMID: 16733022 DOI: 10.1157/13087385] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
764 Type 2 Diabetes. Wiley Handbook of Current and Emerging Drug Therapies 2006. [DOI: 10.1002/9780470041000.cedt029] [Reference Citation Analysis]
765 Yeo KK, Tai BC, Heng D, Lee JM, Ma S, Hughes K, Chew SK, Chia KS, Tai ES. Ethnicity modifies the association between diabetes mellitus and ischaemic heart disease in Chinese, Malays and Asian Indians living in Singapore. Diabetologia 2006;49:2866-73. [PMID: 17021918 DOI: 10.1007/s00125-006-0469-z] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 3.1] [Reference Citation Analysis]
766 Reasner C. The Metabolic Syndrome: Identification and Management of the Patient at High Risk for Cardiovascular Disease. Comprehensive Management of High Risk Cardiovascular Patients 2006. [DOI: 10.3109/9781420019667.011] [Reference Citation Analysis]
767 Goldberg R. Type 2 Diabetes. Comprehensive Management of High Risk Cardiovascular Patients 2006. [DOI: 10.3109/9781420019667.006] [Reference Citation Analysis]
768 Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest. 2006;116:1802-1812. [PMID: 16823478 DOI: 10.1172/jci29103] [Cited by in Crossref: 1222] [Cited by in F6Publishing: 1265] [Article Influence: 76.4] [Reference Citation Analysis]
769 Ng DS. Insulin Resistance, Diabetes and its Complications. Encyclopedia of Molecular Cell Biology and Molecular Medicine 2006. [DOI: 10.1002/3527600906.mcb.200400011] [Reference Citation Analysis]
770 Yoshizumi M, Ishizawa K, Izawa Y, Tamaki T. Folia Pharmacol Jpn 2006;128:147-151. [DOI: 10.1254/fpj.128.147] [Reference Citation Analysis]
771 Kellerer M. Differenzierter Einsatz oraler Antidiabetika bei Diabetes mellitus Typ 2. Diabetologe 2006;2:445-455. [DOI: 10.1007/s11428-006-0073-3] [Reference Citation Analysis]
772 Burnet DL, Elliott LD, Quinn MT, Plaut AJ, Schwartz MA, Chin MH. Preventing diabetes in the clinical setting. J Gen Intern Med 2006;21:84-93. [PMID: 16423130 DOI: 10.1111/j.1525-1497.2005.0277.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 24] [Article Influence: 1.1] [Reference Citation Analysis]
773 Colagiuri R, Colagiuri S, Yach D, Pramming S. The answer to diabetes prevention: science, surgery, service delivery, or social policy? Am J Public Health 2006;96:1562-9. [PMID: 16873751 DOI: 10.2105/AJPH.2005.067587] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.0] [Reference Citation Analysis]
774 Goldstein BJ. Closing the gap between clinical research and clinical practice: can outcome studies with thiazolidinediones improve our understanding of type 2 diabetes? Int J Clin Pract 2006;60:873-83. [PMID: 16846404 DOI: 10.1111/j.1742-1241.2006.01018.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
775 Andrulionyte L, Laukkanen O, Chiasson JL, Laakso M; STOP-NIDDM Study Group. Single nucleotide polymorphisms of the HNF4alpha gene are associated with the conversion to type 2 diabetes mellitus: the STOP-NIDDM trial. J Mol Med (Berl) 2006;84:701-8. [PMID: 16838170 DOI: 10.1007/s00109-006-0063-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
776 Dailey G. Rapid-acting insulin glulisine: a new tool for postprandial glucose control. Expert Rev Endocrinol Metab 2006;1:469-78. [PMID: 30290463 DOI: 10.1586/17446651.1.4.469] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
777 Rendell MS. Postprandial hyperglycemia: Why do we care about it? What should we do? Drug Dev Res 2006;67:582-586. [DOI: 10.1002/ddr.20127] [Reference Citation Analysis]
778 Onishi Y, Fujisawa T, Sakaguchi K, Maeda M. Effect of nateglinide on the size of LDL particles in patients with type 2 diabetes. Adv Ther 2006;23:549-55. [PMID: 17050498 DOI: 10.1007/BF02850044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
779 Blackburn DF, Wilson TW. Antihypertensive medications and blood sugar: theories and implications. Can J Cardiol 2006;22:229-33. [PMID: 16520854 DOI: 10.1016/s0828-282x(06)70902-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 1.4] [Reference Citation Analysis]
780 Caldwell SH, Al-osaimi A, Chang C, Davis C, Hespenheide EE, Krugner-higby L, Hylton AI, Iezzoni JC, Le TH, Nakamoto RK, Redick J, Peterson T. Nonalcoholic Fatty Liver (NAFL): Overview. NASH and Nutritional Therapy. [DOI: 10.1007/4-431-27172-4_1] [Reference Citation Analysis]
781 Wien M. A Review of Macronutrient Considerations for Persons With Prediabetes: . Topics in Clinical Nutrition 2006;21:64-75. [DOI: 10.1097/00008486-200604000-00002] [Reference Citation Analysis]
782 . 耐糖能異常と拡張機能障害(4.循環器疾患の成因としての糖尿病/耐糖能異常,<特集II>第69回日本循環器学会学術集会). Journal of JCS Cardiologists 2006;14:69-73. [DOI: 10.1253/jjcsc.14.1_69] [Reference Citation Analysis]
783 Pascual Fuster V, Meco López JF. [New concepts in dietary treatment of metabolic syndrome]. Rev Clin Esp 2006;206:100-2. [PMID: 16527170 DOI: 10.1157/13085362] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
784 Chiasson J, Rabasa-lhoret R, Srivastava AK. Oxidative Stress in the Development of Diabetes and its Complications. Developments in Cardiovascular Medicine. [DOI: 10.1007/0-387-29553-4_16] [Reference Citation Analysis]
785 Forouhi NG, Balkau B, Borch-Johnsen K, Dekker J, Glumer C, Qiao Q, Spijkerman A, Stolk R, Tabac A, Wareham NJ. The threshold for diagnosing impaired fasting glucose: a position statement by the European Diabetes Epidemiology Group. Diabetologia. 2006;49:822-827. [PMID: 16525842 DOI: 10.1007/s00125-006-0189-4] [Cited by in Crossref: 74] [Cited by in F6Publishing: 74] [Article Influence: 4.6] [Reference Citation Analysis]
786 Rinninger F, Standl E. Diabetes mellitus. Therapie innerer Krankheiten. [DOI: 10.1007/3-540-26504-x_50] [Reference Citation Analysis]
787 Yudkin JS. Postprandial hyperglycaemia and cardiovascular disease. Diabet Med 2006;23 Suppl 1:24-5; author reply 25-6. [PMID: 16483262 DOI: 10.1111/j.1464-5491.2006.01833g.x] [Reference Citation Analysis]
788 Marchesini G, Marzocchi R, Grave RD. Outcome research in obesity: lessons from the QUOVADIS study. Drug Dev Res 2006;67:260-270. [DOI: 10.1002/ddr.20084] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
789 Llisterri Caro J, Luque Otero M. Hipertensión arterial y síndrome metabólico. SEMERGEN - Medicina de Familia 2006;32:73-83. [DOI: 10.1016/s1138-3593(06)73224-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
790 Valentine M, Rayfield E. Pathophysiology and Clinical Management of Diabetes and Prediabetes. Nutrition and Disease Prevention 2006. [DOI: 10.1201/9781420014884.ch2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
791 Joost H, Mengel K. Antidiabetika. Arzneiverordnungs-Report 2005. [DOI: 10.1007/3-540-30505-x_12] [Reference Citation Analysis]
792 Lankisch M, Füth R, Schotes D, Rose B, Lapp H, Rathmann W, Haastert B, Gülker H, Scherbaum WA, Martin S. High prevalence of undiagnosed impaired glucose regulation and diabetes mellitus in patients scheduled for an elective coronary angiography. Clin Res Cardiol 2006;95:80-7. [PMID: 16598515 DOI: 10.1007/s00392-006-0328-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]
793 Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49:289-297. [PMID: 16391903 DOI: 10.1007/s00125-005-0097-z] [Cited by in Crossref: 1181] [Cited by in F6Publishing: 1270] [Article Influence: 73.8] [Reference Citation Analysis]
794 Diabetes Mellitus. Coronary Heart Disease in Clinical Practice. [DOI: 10.1007/1-84628-135-0_3] [Reference Citation Analysis]
795 Robb GH, Lawrenson R. Diabetes Mellitus. Brackenridge’s Medical Selection of Life Risks 2006. [DOI: 10.1007/978-1-349-72324-9_20] [Reference Citation Analysis]
796 Gómez Otero I, González-juanatey JR. Dislipemia diabética, síndrome metabólico y riesgo cardiovascular. Revista Española de Cardiología Suplementos 2006;6:13G-23G. [DOI: 10.1016/s1131-3587(06)75325-0] [Reference Citation Analysis]
797 American Diabetes Association. Standards of Medical Care in Diabetes–2006. Diabetes Care 2006;29:s4-s42. [DOI: 10.2337/diacare.29.s1.06.s4] [Cited by in Crossref: 289] [Cited by in F6Publishing: 288] [Article Influence: 18.1] [Reference Citation Analysis]
798 Robb GH, Lawrenson R. Diabetes Mellitus. Brackenridge’s Medical Selection of Life Risks 2006. [DOI: 10.1007/978-1-349-56632-7_20] [Reference Citation Analysis]
799 Ignacio Bernardino J, Ángeles Martínez M, García-puig J. Metabolismo glucídico en la hipertensión arterial: papel de la sobrecarga oral de la glucosa. Medicina Clínica 2006;126:116. [DOI: 10.1157/13083878] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
800 Uwaifo GI, Yanovski JA. Cardiovascular Risk Profile Improvement with Large-Volume Liposuction. Liposuction 2006. [DOI: 10.1007/3-540-28043-x_67] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
801 Schneider CA. Kardiovaskuläre Risikofaktoren und deren therapeutische Beeinflussung. Klinische Kardiologie. [DOI: 10.1007/3-540-29425-2_1] [Reference Citation Analysis]
802 Oldroyd J, Banerjee M, Heald A, Cruickshank K. Diabetes and ethnic minorities. Postgrad Med J. 2005;81:486-490. [PMID: 16085737 DOI: 10.1136/pgmj.2004.029124] [Cited by in Crossref: 92] [Cited by in F6Publishing: 101] [Article Influence: 5.4] [Reference Citation Analysis]
803 Fonseca VA, Bratcher C, Thethi T. Pharmacological Treatment of the Insulin Resistance Syndrome in People Without Diabetes. Metabolic Syndrome and Related Disorders 2005;3:260-6. [DOI: 10.1089/met.2005.3.260] [Reference Citation Analysis]
804 Nichols GA, Brown JB. Higher medical care costs accompany impaired fasting glucose. Diabetes Care 2005;28:2223-9. [PMID: 16123494 DOI: 10.2337/diacare.28.9.2223] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 2.3] [Reference Citation Analysis]
805 Bernardino de la Serna J, Garca Puig J. Factores metab?licos de riesgo cardiovascular. Relevancia epidemiol?gica. Tratamiento farmacol?gico. Situaciones de especial relevancia. Medicine - Programa de Formaci?n M?dica Continuada Acreditado 2005;9:3032-3043. [DOI: 10.1016/s0211-3449(05)73850-9] [Reference Citation Analysis]
806 Pontiroli AE, Folli F, Paganelli M, Micheletto G, Pizzocri P, Vedani P, Luisi F, Perego L, Morabito A, Bressani Doldi S. Laparoscopic gastric banding prevents type 2 diabetes and arterial hypertension and induces their remission in morbid obesity: a 4-year case-controlled study. Diabetes Care 2005;28:2703-9. [PMID: 16249543 DOI: 10.2337/diacare.28.11.2703] [Cited by in Crossref: 109] [Cited by in F6Publishing: 112] [Article Influence: 6.4] [Reference Citation Analysis]
807 Cheng D. Prevalence, predisposition and prevention of type II diabetes. Nutr Metab (Lond) 2005;2:29. [PMID: 16232315 DOI: 10.1186/1743-7075-2-29] [Cited by in Crossref: 79] [Cited by in F6Publishing: 85] [Article Influence: 4.6] [Reference Citation Analysis]
808 Wiegand S. Therapie des Diabetes mellitus Typ 2. Monatsschr Kinderheilkd 2005;153:936-44. [DOI: 10.1007/s00112-005-1234-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
809 Eckert S, Tschöpe D. Glukosestoffwechsel. ZS Kardiologie 2005;94:iii88-iii91. [DOI: 10.1007/s00392-005-1312-0] [Reference Citation Analysis]
810 del Cañizo-gómez F, Moreira-andrés M. Glucemia posprandial y riesgo cardiovascular. Endocrinología y Nutrición 2005;52:452-465. [DOI: 10.1016/s1575-0922(05)71043-3] [Reference Citation Analysis]
811 Díez Espino J. El cese del hábito de fumar y el tratamiento antihipertensivo con diuréticos pueden limitar el efecto beneficioso de la dieta y el ejercicio en la prevención de la diabetes mellitus tipo 2 en varones sin intolerancia a la glucosa. FMC - Formación Médica Continuada en Atención Primaria 2005;12:512. [DOI: 10.1016/s1134-2072(05)74619-3] [Reference Citation Analysis]
812 Dominguez LJ, Sowers JR. Metabolic syndrome therapy: prevention of vascular injury by antidiabetic agents. Curr Hypertens Rep 2005;7:110-6. [PMID: 15748534 DOI: 10.1007/s11906-005-0083-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
813 Hanefeld M, Temelkova-kurktschiev T. Lipide. Diabetes und Herz. [DOI: 10.1007/3-7985-1531-x_2] [Reference Citation Analysis]
814 Schernthaner G. Hypertonie. Diabetes und Herz. [DOI: 10.1007/3-7985-1531-x_23] [Reference Citation Analysis]
815 Schmidt MI, Duncan BB, Bang H, Pankow JS, Ballantyne CM, Golden SH, Folsom AR, Chambless LE; Atherosclerosis Risk in Communities Investigators. Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study. Diabetes Care 2005;28:2013-8. [PMID: 16043747 DOI: 10.2337/diacare.28.8.2013] [Cited by in Crossref: 308] [Cited by in F6Publishing: 334] [Article Influence: 18.1] [Reference Citation Analysis]
816 Arora SK, McFarlane SI. The case for low carbohydrate diets in diabetes management. Nutr Metab (Lond) 2005;2:16. [PMID: 16018812 DOI: 10.1186/1743-7075-2-16] [Cited by in Crossref: 50] [Cited by in F6Publishing: 58] [Article Influence: 2.9] [Reference Citation Analysis]
817 Assaloni R, Da Ros R, Quagliaro L, Piconi L, Maier A, Zuodar G, Motz E, Ceriello A. Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients. Diabetologia 2005;48:1919-24. [PMID: 16007412 DOI: 10.1007/s00125-005-1849-5] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 2.5] [Reference Citation Analysis]
818 de Tomás M, Beltrán S. Respuesta del autor. Endocrinología y Nutrición 2005;52:328. [DOI: 10.1016/s1575-0922(05)74806-3] [Reference Citation Analysis]
819 Hu G, Qiao Q, Tuomilehto J. Metabolic syndrome, diabetes, and coronary heart disease. Coronary Heart Disease Epidemiology 2005. [DOI: 10.1093/acprof:oso/9780198525738.003.0022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
820 Johnston DG, Alberti KGMM, Godsland IF, Pierce M, Shepperd S. Screening for type 2 diabetes. Coronary Heart Disease Epidemiology 2005. [DOI: 10.1093/acprof:oso/9780198525738.003.0043] [Reference Citation Analysis]
821 Mamedov MN. According to the proceedings of the First International Congress on Prediabetes and Metabolic Syndrome: Acarbose has been recognized as the drug of choice in preventing diabetes mellltus and myocardial infarction. Arter gipertenz 2005;11:173-176. [DOI: 10.18705/1607-419x-2005-11-3-173-176] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
822 Cheng AY, Fantus IG. Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ 2005;172:213-26. [PMID: 15655244 DOI: 10.1503/cmaj.1031414] [Cited by in Crossref: 270] [Cited by in F6Publishing: 280] [Article Influence: 15.9] [Reference Citation Analysis]
823 Feig DS, Palda VA, Lipscombe L; Canadian Task Force on Preventive Health Care. Screening for type 2 diabetes mellitus to prevent vascular complications: updated recommendations from the Canadian Task Force on Preventive Health Care. CMAJ 2005;172:177-80. [PMID: 15655234 DOI: 10.1503/cmaj.1041197] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 1.2] [Reference Citation Analysis]
824 Knowler WC, Hamman RF, Edelstein SL, Barrett-Connor E, Ehrmann DA, Walker EA, Fowler SE, Nathan DM, Kahn SE; Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005;54:1150-6. [PMID: 15793255 DOI: 10.2337/diabetes.54.4.1150] [Cited by in Crossref: 361] [Cited by in F6Publishing: 375] [Article Influence: 21.2] [Reference Citation Analysis]
825 Sabés-figuera R. Réplica. Gaceta Sanitaria 2005;19:265-266. [DOI: 10.1157/13075964] [Reference Citation Analysis]
826 Diabetes Prevention Program Research Group. Strategies to identify adults at high risk for type 2 diabetes: the Diabetes Prevention Program. Diabetes Care 2005;28:138-44. [PMID: 15616247 DOI: 10.2337/diacare.28.1.138] [Cited by in Crossref: 49] [Cited by in F6Publishing: 54] [Article Influence: 2.9] [Reference Citation Analysis]
827 Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005;65:385-411. [PMID: 15669880 DOI: 10.2165/00003495-200565030-00005] [Cited by in Crossref: 814] [Cited by in F6Publishing: 689] [Article Influence: 47.9] [Reference Citation Analysis]
828 González Pujol N, Briceño García H, Orozco Beltrán D, Sáez Fernández R. Prevalencia de alteraciones del metabolismo de los hidratos de carbono en atención primaria. Atención Primaria 2005;35:440-441. [DOI: 10.1157/13074806] [Reference Citation Analysis]
829 Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, Rutten GE, Van Weel C. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005;:CD003639. [PMID: 15846673 DOI: 10.1002/14651858.CD003639.pub2] [Cited by in Crossref: 84] [Cited by in F6Publishing: 130] [Article Influence: 4.9] [Reference Citation Analysis]
830 Halimi S. Place des glitazones dans de futures recommandations cliniques. Annales d'Endocrinologie 2005;66:59-70. [DOI: 10.1016/s0003-4266(05)81734-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
831 Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system. Drugs 2004;64:2537-65. [PMID: 15516153 DOI: 10.2165/00003495-200464220-00004] [Cited by in Crossref: 199] [Cited by in F6Publishing: 208] [Article Influence: 11.7] [Reference Citation Analysis]
832 Padwal R, Majumdar SR, Johnson JA, Varney J, McAlister FA. A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care 2005;28:736-44. [PMID: 15735219 DOI: 10.2337/diacare.28.3.736] [Cited by in Crossref: 108] [Cited by in F6Publishing: 120] [Article Influence: 6.4] [Reference Citation Analysis]
833 Krentz AJ. Adverse effects of new treatments for diabetes. Adverse Drug Reaction Bulletin 2005;&NA;:883-886. [DOI: 10.1097/00012995-200502000-00001] [Reference Citation Analysis]
834 Park SH, Park CK. Pathogenesis and Management of Non-alcoholic Steatohepatitis. J Korean Med Assoc 2005;48:169. [DOI: 10.5124/jkma.2005.48.2.169] [Reference Citation Analysis]
835 Cameron A, Shaw J, Zimmet P. The Metabolic Syndrome. The Metabolic Syndrome at the Beginning of the XXI Century 2005. [DOI: 10.1016/b978-84-8174-892-5.50028-0] [Reference Citation Analysis]
836 Singleton JR, Smith AG, Russell J, Feldman EL. Polyneuropathy with Impaired Glucose Tolerance: Implications for Diagnosis and Therapy. Curr Treat Options Neurol. 2005;7:33-42. [PMID: 15610705 DOI: 10.1007/s11940-005-0004-4] [Cited by in Crossref: 43] [Cited by in F6Publishing: 49] [Article Influence: 2.5] [Reference Citation Analysis]
837 Ahrén B. GLUCOSE | Glucose Tolerance. Encyclopedia of Human Nutrition 2005. [DOI: 10.1016/b0-12-226694-3/00154-x] [Reference Citation Analysis]
838 Karathanasis SK, Schiebinger RJ. Drug Treatment in the Metabolic Syndrome. The Metabolic Syndrome at the Beginning of the XXI Century 2005. [DOI: 10.1016/b978-84-8174-892-5.50027-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
839 Koh G, Woo J. Prevention of Metabolic Syndrome. J Korean Med Assoc 2005;48:1188. [DOI: 10.5124/jkma.2005.48.12.1188] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
840 Andrulionytè L, Zacharova J, Chiasson JL, Laakso M; STOP-NIDDM Study Group. Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial. Diabetologia 2004;47:2176-84. [PMID: 15592662 DOI: 10.1007/s00125-004-1577-2] [Cited by in Crossref: 91] [Cited by in F6Publishing: 81] [Article Influence: 5.1] [Reference Citation Analysis]
841 Tenenbaum A, Fisman EZ. Impaired glucose metabolism in patients with heart failure: pathophysiology and possible treatment strategies. Am J Cardiovasc Drugs 2004;4:269-80. [PMID: 15449970 DOI: 10.2165/00129784-200404050-00001] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 1.6] [Reference Citation Analysis]
842 Hermanns-Lê T, Scheen A, Piérard GE. Acanthosis nigricans associated with insulin resistance : pathophysiology and management. Am J Clin Dermatol 2004;5:199-203. [PMID: 15186199 DOI: 10.2165/00128071-200405030-00008] [Cited by in Crossref: 97] [Cited by in F6Publishing: 106] [Article Influence: 5.4] [Reference Citation Analysis]
843 Van de Laar F, Lucassen P, Akkermans R, Van de Lisdonk E, De Grauw W. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. The Cochrane Database of Systematic Reviews 2004. [DOI: 10.1002/14651858.cd005061] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
844 Cabezas-cerrato J, Cabezas Agrícola J. Tratamiento no farmacológico y farmacológico de la diabetes mellitus. Medicine - Programa de Formación Médica Continuada Acreditado 2004;9:1000-1007. [DOI: 10.1016/s0211-3449(04)70148-4] [Reference Citation Analysis]
845 Herrera Pombo J, Sánchez-vilar O. Diabetes mellitus tipo 2. Manifestaciones clínicas y seguimiento. Referencia a la medicina especializada. Medicine - Programa de Formación Médica Continuada Acreditado 2004;9:981-989. [DOI: 10.1016/s0211-3449(04)70146-0] [Reference Citation Analysis]
846 Sierra C, Ruilope LM. Novel antihypertensive agents. Expert Opinion on Investigational Drugs 2004;13:987-998. [DOI: 10.1517/13543784.13.8.987] [Reference Citation Analysis]
847 Maritz FJ. Insulin resistance and vascular disease. Journal of Endocrinology, Metabolism and Diabetes of South Africa 2004;9:54-61. [DOI: 10.1080/16089677.2004.11073590] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
848 Borch-Johnsen K, Colagiuri S, Balkau B, Glümer C, Carstensen B, Ramachandran A, Dong Y, Gao W. Creating a pandemic of prediabetes: the proposed new diagnostic criteria for impaired fasting glycaemia. D